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DNA methylation is an epigenetic mechanism that enables heritable changes in gene 
expression without changes in DNA sequence. Methyl groups are transferred from the methyl 
donor S-adenosyl methionine (SAM) to the 5-carbon of cytosine by DNA methyltransferases 
(DNMTs).  
The DNMT family comprises a set of DNA-modifying enzymes and uses a similar 
catalytic mechanism to form a covalent reaction intermediate between the substrate base and 
the enzyme. Food-derived bioactive compounds are among the exogenous factors that can 
modulate the DNA methylation patterns, either via generating SAM through one-carbon 
metabolism or by inhibiting the activity of DNMTs.  
In this study, cell lines with stable over-expression of each of 13 DNMTs isoform 
(DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, 
DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4, DNMT3L, and DNMT1) were 
generated by lentiviral transduction of human embryonic kidney cells (HEK293T). DNA 
methylation patterns in these 13 cell lines were analysed by Illumina Infinium Methylation 
EPIC BeadChip, which interrogates more than 850,000 CpG sites across the genome. The 
sensitivity and specificity of each DNMT isoform to selected food constituents (caffeic acid 
(CA), (-)-Epigallocatechin-3-gallate (EGCG), curcumin, vitamin C, and theaflavin) were 
investigated by quantification of DNA methylation at specific CpG sites targeted by the 
DNMTs, using pyrosequencing. DNA methylation patterns for each DNMT isoform were 
obtained and the potential underlying biological mechanisms for DNMT-target CpGs were 
explored.  
At the selected CpG sites, DNA methylation was decreased with CA and vitamin C in 
DNMT∆3B4 and DNMT3A2 cells, respectively. In addition, the enzymatic activity of 
DNMT∆3B4 decreased after CA treatment. In summary, despite similarity of their protein 
structures, DNMT isoforms show regional specificity in the maintenance of DNA methylation 
patterns. This study also revealed that the activity of DNMT∆3B4 and DNMT3A2 can be 
specifically modulated by CA and vitamin C, respectively, in a dose-response manner.  
These observations further understanding of nutrition-epigenetic mechanisms, especially 
interactions with enzymatic activity, could be applied to modulate DNA methylation profiles 
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1. Chapter 1: General Introduction 
 
1.1 Overview of epigenetics 
Epigenetics is a mechanism of modifications in gene expression without changing DNA 
sequences (1). Examples of epigenetic mechanisms are DNA methylations, RNA 
modifications, and histone modifications (Figure 1.1) (2). DNA methylations, particularly on 
cytosine residue that lie next to a guanine base, are commonly related to repressing gene 
expression. Histone modifications, however, can lead to either the activation or deactivation 
of gene expression. For example, di-methylation of histone3 (H3) at lysine 4 (H3K4) and 
acetylation of H3K9 play an active role in transcription, however tri-methylation of H3K9 
(H3K9me3) and H3K27me3 are inactive markers. Each of these epigenetic markers may 
induce independent modifications, but commonly interplay reciprocally in controlling gene 
expression during stem cell differentiation, embryonic development (3), and carcinogenesis 
(4). Those epigenetic markers are inherited between generations, but also the level of 
epigenetic markers at each successive generation is modifiable by internal and external 
stimuli, such as pro-inflammatory foods or antioxidant-rich diets. Later in this chapter, DNA 
methylations, which are amongst the well-studied epigenetic mechanisms, will be discussed 
with differential expression of DNA methyltransferases (DNMTs) and modulating its activity 





Figure 1.1 Epigenetic machinery. DNA methylations, histone tail modifications, and non-
coding RNAs (ncRNAs). Transcriptional factor, TF; Methylation, Me. (taken from Sayyed 
K.Z. et al.) (2). 
 
Histone modification  
Lysine (K) and arginine (R) residues are the main amino acids in histone tails that are subject 
to post-translational modifications such as acetylation and methylation. Histone octamers are 
wrapped by DNA and each contains two copies of the histone variants: H2A, H2B, H3, and 
H4. There are numerous histone methyltransferases and demethylases, including histone 
acetyltransferases (HAT) and histone deacetylases (HDACs) (5). Which particular lysine 
residues on each of the histones are methylated under particular circumstances is determined 
by the actions of epigenetic writers (methyltransferases) and erasers (demethylases) (5). 
Histone H3 methylation at lysine 9 and lysine 27 (H3K9 and H3K27), as well as Histone H4 
methylation at lysine 20 (H4K20) are well known markers of inactivation, since, these are 
associated with heterochromatin formation; in contrast, H3K36 and H3K4 methylation are 
known activation markers (6). Concomitant tri-methylations of H3K4 and H3K27 (bivalent 
domains) modulate lineage-specific gene expression from a poised state in embryonic stem 
cells (7). Also, a genome-wide study of histone methylation patterns showed that gene 
3 
 
expression was positively correlated with levels of H3K4 methylation and negatively 
correlated with H3K27 methylation (8). 
 
RNA modifications 
Non-coding RNAs are not translated into protein and they can be separated into regulatory 
non-coding RNAs and housekeeping non-coding RNAs. The regulatory role of RNA is 
mainly based on size; short chain non-coding RNAs (miRNAs, siRNAs, and piRNAs) and 
long non-coding RNAs (IncRNAs) (9-11). Non-coding RNAs play an important role in 
regulating gene expression (12, 13). Among non-coding RNAs, miRNAs act as post-
transcriptional regulators via base-pairing with complementary sequences within messenger 
RNA (mRNA) targets resulting in mRNA degradation or translational repression (14) 
resulting in regulated gene expression. These noncoding RNAs generally work with 
components of DNA methylations and chromatin (DNMT, H3K27 methylation, histone 
deacetylase 4) (6), to sustain or establish silencing that contribute to transformation, tumour 
development, and tumour progression (15).  
 
DNA methylation 
DNA methylation may also inhibit the binding of transcription factors and, therefore, repress 
gene expression to modify cellular phenotype (16, 17). All the known DNMTs use S-adenosyl 
methionine (SAM), derived from methionine, as the methyl donor. Although epigenetic 
maintenance requires the interplay of many epigenetic components (e.g. chromatin and 
histone modifications) as well as proteins to control gene expression and cellular function, the 
availability of methyl donors for DNMTs and the activity of DNMT enzymes are critical to 
maintain normal DNA methylation patterns (18). Further detail of the key players in DNA 
methylations is discussed in the DNA methylations and DNMT sections (see section 1.2 and 
1.4). 
 Patterns of histone modifications, DNA methylations, and expression of noncoding 
RNA act together to establish the epigenetic signatures that convey regulatory information 
and so control the phenotype by activating or suppressing of gene expression. Information 
given by epigenetic signatures may be considered to be as important as sequence information 
because these signatures are proven useful biomarkers to predict the pathological conditions 
and biological outcome (19). In contrast with genetic information, epigenetic information 




1.2 Mechanisms of DNA methylation and demethylation 
 
1.2.1 DNA methylation 
DNA methylation is an epigenetic modification in which a DNMT catalyses the transfer of a 
methyl group from SAM to the 5-carbon of cytosine to form 5-methylcytosine (5-mC), and in 
which SAM is converted to S-adenosylhomocysteine (SAH) (Figure 1.2) (21). 
 
 
Figure 1.2 DNMTs catalyse the covalent addition of -CH3 to 5-carbon of cytosine (22). 
 
In mammals, the majority of DNA methylation occurs on cytosines preceding 
guanines (CpG dinucleotides) (23). Approximately 3x107 residues of 5-methylcytosine (5-
mC) are located within CpG dinucleotides 5’-m5CG-3’ in mammalian genomes (24, 25). Over 
60% of human genes at promoters have CpG islands (CGIs) (26) which are short interspersed 
sequences. CGI is defined as a location with at least 200 bp, which have CG content greater 
than 50% and CpG ratio greater than 0.6 (27). Most CpGs in CGI regions are in a non-
methylated state and permit transcription initiation, leading to stable activation of the 
associated promoter (28). The cytosines in CpG dinucleotides within CpG islands tend to be 
hypomethylated compared with those in non-island CpGs. The regions surrounding CGIs are 
known as “Shores” (North and South), followed by “Shelves” (North and South) and “Open 
sea” (Figure 1.3) (29). Transcription factors containing a CXXC zinc finger domain bind to 
unmethylated CpGs via a CXXC binding domain motif, contributing to generation of a 
transcriptionally competent chromatin configuration that prevents DNA methylation (30). 
Closer investigation of DNA methylation has revealed that exons show markedly higher 






Figure 1.3 The distribution of DNA methylation levels by CpG density (adapted from Edgar 
R et al. (29)). 
 
DNA methylation also functions to repress retrotransposons, long interspersed nuclear 
element (LINE-1) and Alu elements, which are highly methylated to keep them quiet in the 
human genome (32, 33). DNA methylation is also involved in genomic imprinting, silencing 
of repetitive elements and X chromosome inactivation (34).  
DNA methylation has dual roles, both permissive and inhibitory, depending on the 
genomic location. DNA methylation of intragenic or distal regulatory elements with different 
degrees of CpG density are involved in the gene regulation (35). Gene body methylation have 
been found in Arabidopsis and this methylation was associated with active genes. In mammal, 
gene body methylation has been found in the active human X chromosome compared to the 
inactive X chromosome (36). The hypomethylated sites in the gene body have been correlated 
with low expression genes in cancer cell lines, also methylated of CpG-rich regions in gene 
bodies have been correlated with higher gene expression in human B cells (37). DNA 
methylation in a promoter is also an important epigenetic mechanism for the suppression of 
gene expression especially of tumour suppressor genes at early stage of carcinogenesis and 
occurs with various frequencies (38).  
Enhancers are important roles in gene regulation as the enhancer-promoter interaction 
can increase the gene expression of downstream (39). The alteration of enhancer methylation 
plays an important role in cancer progression (40). Additionally, enhancer methylation 
accounts for a significant portion of intertumour expression heterogeneity (41). Moreover, 
enhancer methylation can be used to distinct breast cancer lineages (42). 
 
Gene regulation by methylation  
All housekeeping genes contain CpG islands in the proximal transcription start sites. These 
genes are frequently correlated with CpG islands in intronic regions downstream of the first 
exon, which tends to be smaller than the promoter-related CpG islands (43) and are often 
methylated (44). In mammals, the methylation of region 2 at CpG island in the second intron 
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of insulin like growth factor 2 receptor gene is the imprinting signal, which maintains 
expression of the maternal allele (45). In cancer, aberrant methylation at the transcription start 
sites leads to the silencing of tumour suppressor genes, namely p16, VHL, and Rb (46-48). It 
has been postulated that tumour suppressor genes might be overexpressed during tumour 
development and triggered hypermethylation of downstream CpG islands. Next, the 
methylation would spread from these sites to the CpG islands at the transcription start sites, 
therefore silencing the tumour suppressor genes (49). Moreover, methylation is used to 
silence one X chromosome in female by showing low DNA methylation on inactive X-
chromosome than active X at intragenic and intergenic regions for genes subject to X-
chromosome inactivation, but not at genes, which escape from inactivation (50). 
 
1.2.2 DNA demethylation 
DNA demethylation can be accomplished passively (in the new copy of DNA after 
replication) or actively (in a replication-independent enzymatic process) (22). Active DNA 
demethylation refers to an enzymatic mechanism for removal of the methyl group from 5mC. 
However, passive DNA demethylation refers to the lack of DNA methylation maintenance, 
which could be due to the absence of DNMT1 or the presence of DNMT inhibitors during 
DNA replication (23). Ten-eleven translocation (TET) methylcytosine dioxygenases are a 
family of enzymes that catalyses the conversion of 5-mC to 5-hydroxymethylcytosine (5-
hmC) through oxidation (Figure 1.4) (51, 52). 5-formylcytosine (5-fC) and 5-
carboxylcytosine (5-caC) are produced subsequently from 5-mC during further consecutive 
oxidation steps (53). 5-caC is present at extremely low levels in DNA and can be excised by 
either a base excision repair enzyme or by thymine DNA glycosylase (TDG) to regenerate 
unmodified cytosine (54). 5-fC and 5-caC are much less abundant in the mammalian genome 
than 5-hmC is because TDG is more efficient at selection and excision of 5-fc and 5-caC, 




Figure 1.4 The cycle of active DNA demethylation and chemical structure of 5-
methylcytosine (5-mC) and its oxidation products 5-hydroxymethylcytosine (5-hmC), 5-
formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). DNA methyltransferases (DNMTs) 
covert unmodified cytosine to 5-mC. 5-mC can be converted back to cytosine by ten-eleven 
translocations (TETs) to 5-hmC, 5-fC, and 5-caC followed by excision of 5-fC or 5-caC 
mediated by thymine DNA glycosylase (TDG) coupled with base excision repair (BER) (the 
process of active modification-active removal (AM-AR) or replication-dependent dilution of 
5-hmC, 5-fC or 5-caC (the process of active modification-passive dilution (AM-PD) (taken 
from Xioaoji W. and Yi Z.) (55). 
 
Demethylation occurs during early gametogenesis especially during development of 
primordial germ cells and also occurs postnatal (56). Aberrant demethylation has been 
observed in cancer. The active DNA demethylation is required for differentiation through 
modulation the enhancer’s activities and promoters (55). Also, active DNA demethylation 
regulates cell reprogramming (57, 58) and cell fate transitions (59, 60). 
 
1.3 DNA methylation in human diseases 
When epigenetic information is not properly maintained or established, epigenetic 
abnormalities may arise. This section provides an insight into the pathological consequences 




There are two types of epigenetic abnormalities: hypomethylation or hypermethylation. 
Hypermethylation in cancer has been found most often at CGIs (61), while very often 
hypomethylation has been observed in both highly and moderately repeated DNA sequences 
in cancers (62). Aberrant patterns of DNA methylation have been discovered in various 
cancer types, e.g. colon, liver, breast, prostate, ovarian, bone, bladder, and oesophageal 
cancers. Typically, cancer cells show hypomethylation of intergenic regions where there is 
normally high methyl-cytosine content (63). This may activate transposable elements 
contributing to the genome instability observed in cancer cells (64). Hypermethylation was 




Autoimmune diseases are caused by over activity of the immune system leading to damage of 
own tissues. Genome-wide DNA methylation analysis of peripheral blood mononuclear cells 
(PBMCs) revealed that aberrant patterns of DNA methylation of human leukocyte antigen 
class II lead to high risk of developing rheumatoid arthritis (66). Hypermethylation of patched 
1 gene (PTCH1), accompanied by low expression of patched 1 protein, activated the 
Hedgehog signalling pathway, resulting in increased secretion of tumour necrosis factor alpha 
and interleukin 6 (IL6) in the arthritic rat (67). Expression of IL6 mRNA was significantly 
higher in systemic lupus erythematosus (SLE) patients than in healthy controls and this was 
associated with decreased DNA methylation of the IL6 promoter in SLE patients (68). 




Epigenome-wide association studies showed the disturbances in DNA methylation of genes 
involved in lipid and lipoprotein metabolism, and inflammatory pathways are predictors of 
future development of type 2 diabetes, cardiovascular disease (CVD), and other adverse 
clinical consequences of obesity (70, 71). Genome-wide analysis has identified loci at which 
DNA methylation is altered in obesity (72). For example, DNA hypermethylation on 
adiponectin (ADIPOQ)-associated promoter suppressed adiponectin expression in adipocytes 
of obese patients (73). Moreover, CpG sites within ATF-motifs on hepatic glycolysis and 
insulin resistance genes were hypomethylated in both, non-diabetic and type 2 diabetic obese 
patients (74). DNA methylation profiling, which is a high throughput technology, has been 
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performed to discover novel genes and markers for obesity. The DNA methylation profiles 
from the blood of obese and normal individuals analysed using the Illumina 
HumanMethylation27 BeadChip kit showed the different pattern of DNA methylation on the 
promoters of Tripartite Motif Containing3 (lower methylation levels in the obese cases) and 
Ubiquitin Associated and SH3 Domain Containing A (higher methylation levels in obese 
cases) (75). Additionally, the obesity-related cg07814318 methylation encoding Kruppel-like 
Factor-13 (KLF13) gene was found in the blood of childhood obesity (76). Aberrant DNA 
methylation patterns have been identified in the young obese generation compared to control 
individuals (77) and specific epigenetic marks have been identified in severely cases of child 
obesity (78). Recently, the study of DNA methylation between subcutaneous and omental 
adipose from obese individuals before and after gastric bypass showed 3,239 loci in 
subcutaneous and 7,722 in omental adipose that were significantly differentially methylated 
(79). DNA methylation on SLC19A1 in obesity could be an epigenetic biomarker for obesity-
related insulin resistance (80).  
 
1.4 DNA methyltransferases  
DNMT is responsible for the transfer of the methyl group to 5C-position of cytosine residues 
in DNA. DNMTs can either introduce new methylation marks or maintain them during 
genome replication (81). There are five mammalian DNMT families, which are DNMT1, 
DNMT2, DNMT3A, DNMT3B, and DNMT3L. DNMT3A, DNMT3B and DNMT1 are 
canonical cytosine-5 DNMTs, while DNMT2 and DNMT3L are non-canonical members as 
they are inactive forms. DNMT1 is responsible for the maintenance of DNA methylation 
patterns during DNA replication (Figure 1.5A), whereas DNMT3A and DNMT3B are known 
to be de novo methyltransferase which transfer the methyl groups onto unmethylated DNA 
elements (Figure 1.5B). Nevertheless, most DNMTs share similar domains with two 
functional parts: the N-terminal regulatory domain and the C-terminal catalytic domain (82). 
The N-terminal regulatory domain guides the nuclear translocation of the enzymes and 
mediates their interaction with the DNA and chromosome. The C-terminal catalytic part is 
conserved between eukaryotes and prokaryotes (83). Due to splicing and/or promotor usage, 







Figure 1.5 DNA methylation pathways. A) DNMT3A and DNMT3B are the de novo DNMTs 
which transfers -CH3 onto naked DNA B) DNMT1 is the maintenance DNMT which 






Figure 1.6 Structure of DNMT isoforms. Their proline-tryptophan-tryptophan-proline 
(PWWP), plant homology domain (PHD)-like and catalytic motifs (I, IV, VI, IX and X) and 




1.4.1 DNMT family members  
DNMT1 and DNMT2 
DNMT1 is a multimodular protein comprising 1,620 amino acids and it contains both the N-
terminal regulatory domain and C-terminal catalytic domain. At C-terminal domain, there are 
two sub-domains: the target recognition domain (TRD) and the methyltransferase domain 
(88). The N-terminal regulatory domain contains a DNA methyltransferase 1-associated 
protein 1 (DMAP1) binding domain, a CXXC zing finger domain, a replication foci targeting 
sequence (RFTS) domain, and a tandem bromo-adjacent homology (BAH1/2) domain (89).  
Human and mouse DNMT1 share approximately 80% of their sequence identity (89). Loss of 
DNMT1 function leads to neurological abnormality and genome-wide demethylation (23, 90). 
Disruption of DNMT1 in the human colorectal carcinoma cell line (HCT116) causes loss of 
cell proliferation and led to cell death (91). Consistent with this, knockout of DNMT1 leads to 
cell death and global hypomethylation (92). DNMT1 depletion in mice contributed to 
chromosome instability and tumour development (90, 93). Paradoxically, inhibition of 
DNMT1 by genetic knockdown or treatment with 5-aza 2’ deoxycytidine has reduced tumour 
formation of colon cancer in a mouse model (94, 95). Loss of DNMT1 disrupts imprinted X 
chromosome inactivation and associated phenotypic abnormalities (96). Also, loss of 
methylation by depletion of DNMT1 leads to demethylation of probes located in gene 
involved in neuroepithelial differentiation, fat homoeostasis/body mass, and olfactory receptor 
genes (97). 
The human DNMT2 located on chromosome 10p13 encodes a protein of 384 amino 
acids and it is homologous to yeast pmt1 (98). DNMT2 consists only in a catalytic domain 
and it lacks the DNA methyltransferase activity. However, DNMT2 was found to methylate 
cytosine 38 of transfer RNA at anticodon loop (99). DNMT2-family enzymes affect the 
metazoan development and are involved in RNA methylation in the cytoplasm. Knockdown 
of Dnmt2 resulted in defecting in differentiation of the retina, brain, and liver (100). 
 
DNMT 3A and 3B 
DNMT3A and DNMT3B are highly expressed in embryonic stem cells, early embryos, and 
developing germ cells, whereas low expression is observed in differentiated somatic cells (84, 
101). DNMT3A encodes at least two known isoforms, which are DNMT3A1 (about 130 kDa) 
and DNMT3A2 (100 kDa) (Figure 1.6). DNMT3A2 lacks the N-terminal region and is the 
major isoform in embryonic stem cells (84). In humans, DNMT3A2 is transcribed from an 
alternative promoter in intron 6 of DNMT3A. Unlike DNMT3A that was concentrated on 
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heterochromatin, DNMT3A2 showed a pattern suggestive of euchromatin association (84). 
Moreover, the specific de novo DNA methylation target sites of DNMT3A1 are correlated 
with H3K4me3 modification (transcriptionally active) (87). DNMT3A2 was detectable in 
breast/ovarian cancer cell lines and it also was expressed in testis, ovary, thymus and spleen 
(84). There are two subfamilies for DNMT3B; DNMT3B and DNMTΔ3B. DNMT3B has 
more than 30 isoforms as a result of alternative pre-mRNA splicing leading to various 
transcriptional variants (102-105). Only DNMT3B1 and DNMT3B2 are catalytically active, 
while DNMT3B3, DNMT3B4, and DNMT3B5 are not (Figure 1.6) (106). ΔDNMT3B lacks 
200 amino acids from the N-terminal area of DNMT3B and there are seven isoforms; 
ΔDNMT3B1-ΔDNMT4 are catalytically active, while ΔDNMT3B5-ΔDNMT7 lack the 
catalytic domain (107).  
Additionally, DNMT3B shows high homology with DNMT3A by conservation 
proline-tryptophan-tryptophan-proline (PWWP) domain, C-terminal catalytic domain, and 
cysteine-rich PHD zinc finger domain. DNMT3B is required by DNMT3A for restoration of 
methylation in somatic cells and DNMT3A and DNMT3B are essential for establishment of 
global DNA methylation patterns (108). Dnmt3a knockout significantly delayed the loss of 
gene expression driven by the CMV promoter which was highly methylated (109). 
 
DNMT3L 
The human DNMT3L located on chromosome 21q22.3 encodes a 387 amino acid containing a 
cystine-rich region with a novel-type zinc finger domain (110). DNMT3L is expressed only in 
embryonic stem cells and germ cells, and it regulates the expression of repetitive elements and 
imprinting genes in germ cells (111, 112). DNMT3L interacts with histone H3 tails and 
recruits or activates DNMT3A2 leading to de novo DNA methylation (113). Dnmt3L is a 
regulator of methylation in the gene body of housekeeping genes (114). Dnmt3L was also 
reported to cooperate with Dnmt3a and Dnmt3b to methylate the DNA (115, 116). Knockout 
DNMT3L in human embryonal carcinoma cells caused cell apoptosis and inhibited cell 
growth (117). Co-expression of DNMT3L and DNMT3A led to a stimulation of DNA 
methylation of imprinted genes by DNMT3A (118).  
 
The identity matrix of the previously mentioned 13 DNMT isoforms plus DNMT2 
was analysed by Fernanda I. et al. (Figure 1.7) (119). The amino acid sequences were 
identical at the catalytic site of DNMT3A1 and DNMT3A2 isoforms, and at that of 
DNMT3B1, DNMT3B2, DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4. 
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Although the majority of DNMTs was identical within subfamilies, the amino acid sequences 
at the catalytic site of DNMT1, DNMT2, and DNMT3L showed a significant difference with 
the rest of the isoforms. The DNMTs also differ by size, which is governed by alternative 
splicing events and chromosome location. These factors contribute to changes in preferential 
DNA binding sites of DNMTs leading to different biological function expressed from target 
genes. 
The roles of DNMTs in DNA methylation has been increased and partners of each 
DNMT have been reported. Numerous studies showed that DNMT1 and proliferative cell 
nuclear antigen (PCNA) interaction was important for DNMT1 activity (120). Also, the 
DNMT1/PCNA interaction could modify the structure of the replication focus targeting 
sequence domain and by a ricochet increase in both its activity and the DNMT1 affinity for 
DNA (121). Interaction of DNMT1 and CysxxCys finger protein1 presents a high affinity for 
unmethylated DNA. The inhibition of this interaction strongly decreased tumour growth of 
glioma cells in nude mice (122). Methyl-CpG-binding domain protein (MBD) interacts with 
DNMT1 and this interaction presents at methylated DNA and also involves in the recruitment 
of DNMT1 (123). Interaction of DNMT1 and DNMT-associated protein1 was involved in 
both early and late S phase of DNA replication and in the recruitment of PCNA (124). 
Recruitment of DNA methylation machineries by polycomb proteins has been found in highly 
methylated area to silence specific loci such as HOX genes (125). The recruitment of MBD 
and DNMT3A from the orphan nuclear receptor germ cell nuclear factor leads to Oct4 
repression (126). Moreover, double knockout of DNMT1 and DNMT3B resulted in 





Figure 1.7 Identity matrix of the catalytic site of 14 DNMT isoforms (taken from Fernanda I. 
et al.) (119). The degree of identity, from 0% to 100%, is represented by a colour gradient 
with dark red corresponding to 0% and dark blue to 100%. 
 
1.4.2 The role of DNMTs in cancers and other diseases 
Links between alterations in DNMT gene expression and protein activities are widely 
reported in multiple cancers (Table 1.1) (128). An increased DNMT activity is one 
mechanism that can lead to disease development through DNA hypermethylation. 
Hypermethylation can be found not only in the promoter region but also at the actively 
transcribed gene bodies and enhancer regions (129-131). Various studies show that aberrant 
DNA methylation contributes to cancer (62). Hypomethylation is a common characteristic of 
the cancer epigenome. Generally, hypomethylation of retrotransposon elements is found in 
tumour cells contributing to aberrant integrity of the genome (132). In a rat model, methyl 
donor deficiency promoted liver tumours and was associated with hypomethylation of 
oncogenes (133). Mice carrying a hypomorphic Dnmt1 allele developed aggressive T cell 




Table 1.1 Studies linked between DNMT alterations and various cancer types (adapted from 
Zhang and Xu) (128). 
Tumour type DNMT subtype Model studied Alteration 
AML 
DNMT3A Human Mutation 
DNMT3A Mouse tumour Mutation 
DNMT3A Mouse tumour Deletion 
DNMT3B Mouse tumour  Deletion 
DNMTs Human Overexpression 
MDS DNMT3A Human Mutation 
CMML DNMT3A Mouse Mutation 
CML DNMTs Human Overexpression 
ALL DNMT3A Human Mutation 
Lymphoma 
DNMT1 Mouse tumour  Deletion 
DNMT3A Mouse  Deletion 
DNMT3B Cell line Overexpression 
Breast 
DNMT1 Mouse tumour  Deletion 
DNMT1 Human Overexpression 
DNMT3B Human Overexpression 
Lung DNMT3A Mouse tumour  Deletion 
DNMT1 Cell line Overexpression 
Colon 
DNMT1 Human Mutation 
DNMT3B Human Overexpression 
DNMT3B Mouse tumour  Overexpression 
Liver 
DNMT1 Human Overexpression 
DNMT3A Human  Overexpression 
Melanoma DNMT3A Mouse tumour  Overexpression 
Pancreas DNMT1 Human Overexpression  
Prostate DNMT3B Human Overexpression 
Oesophagus DNMT1 Human Overexpression 
Acute myeloid leukaemia (AML), Myelodysplastic syndrome (MDS), Chronic 
myelomonocytic leukaemia (CMML), Chronic myeloid leukaemia (CML), Acute 




Hypermethylation of the oncogenes caused by the overexpression of DNMTs 
(DNMT3A, DNMT3B, and DNMT1) is displayed in a variety of tumours (134). The over-
expression of DNMT1 has been linked to the development of lung cancer (135). High activity 
of DNMT1 promotes tumour cell proliferation (136). DNMT1 deletion showed DNA 
demethylation and delayed lymphomagenesis and impairing tumour cell proliferation (137). 
DNMT1 and DNMT3B are over-expressed in T-cell acute lymphoblastic leukaemia and 
Burkitt’s lymphoma (138). Around 15% of acute myeloid leukaemia (AML) cases display a 
heterozygous somatic missense mutation in DNMT3A (139). This missense mutation affects 
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amino acid R882 and is highly recurrent in these AML patients (139). DNMT3A is also 
involved in hepatocellular carcinogenesis and the depletion of DNMT3A in hepatocellular 
carcinoma inhibits cell proliferation and colony formation (140). Transient transfection of 
DNMT3B1 and DNMT3B2 in primary prostate cells increased methylation of tumour specific 
CpG sites such as CpG island hypermethylation of Zinc Finger Protein 296 (141). Moreover, 
somatic mutations in DNMTs are one of the factors contributing to malignant transformation 
(142). The variation of DNMT3A is frequently mutated in myelodysplastic syndrome, AML 
and this has also been correlated with therapeutic resistance and increased disease 
aggressiveness (139, 143, 144). Dnmt3a-knockout mice led to increased proliferation of 
hematopoietic stem cells (145).  
Aberrant DNA methylation or aberrant DNMT expression have also been associated 
with autoimmune disease (146), type 1 diabetes (147), SLE (148), vitiligo (149), and 
rheumatoid arthritis (RA) (150). Global methylation was significantly decreased in RA 
patients compared with control subjects, despite higher DNMT1 expression in RA (150). Loss 
of Dnmt3a in the nervous system led to degeneration in adulthood and lethality (151). In 
another study, a tissue-specific Dnmt triple mutant (Dnmt1, Dnmt3a, aDnmt3b) mouse model 
demonstrated global genomic hypomethylation with reorganisation of the photoreceptor and 
synaptic layers within the retina (152). Mutations in the human DNMT3B gene have been 
shown to demethylate of classic satellite sequences and responsible for subsequent 
abnormalities such as multi-radiate chromosomes observed in immunodeficiency, 
chromosome abnormalities and facial anomalies (ICF) syndrome (153). Mutations in 
DNMT3A gene cause microcephalic dwarfism, a hypocellular disorder of extreme global 
growth failure (154). Additionally, multiple dominant germ line mutations clustered in a 
single small domain of DNMT1 result in a heterogeneous group of adults-onset neurological 
disorders including sensorineural deafness, ataxia, narcolepsy, dementia, and psychosis (155). 
 
1.5 DNMT inhibitors (DNMTi) and their function 
Several approaches have been investigated for inhibiting DNMT enzyme activity, with the 
goal of controlling aberrant DNA methylation. These can predominantly be divided into two 
categories: nucleoside and non-nucleoside compounds. 
 
1.5.1 Nucleoside hypomethylating agents 
Azacytidine and decitabine are cytidine analogues modified in position 5 of the pyrimidine 
ring in which a nitrogen replaces the carbon (Figure 1.8) (156). Azacytidine, a ribonucleoside, 
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is incorporated into both RNA and DNA, while decitabine, a deoxyribose analogue, is 
incorporated into only into DNA. DNMTs are incapable of performing methyl group transfer 
on incorporated cytidine analogues, so covalent enzyme-DNA adducts (DNMT-analogue 
complexes) remain blocked and are later destroyed by the proteasome complex, which 
recognises these complexes as sites of DNA damage (157, 158). Azanucleosides (azacytidine 
and decitabine) are the first hypomethylating agents approved by the US Food and Drug 
Administration. These medicines have functioned as the archetypal DNMT inhibitors and 
have been used for the treatment of patients with AML and myelodysplastic syndrome. Also, 
azacytidine has been approved by the European Medicines Agency for the treatment of 
patients with chronic myelomonocytic leukaemia (159). The therapeutic potential of DNMT 
inhibitors is not only limited to haematological malignancies, but have shown effectiveness in 
other cancers (160). Zebularine is the third novel nucleoside DNMT inhibitor family and it 
has been investigated in in vitro studies (161). Zebularine is metabolised in the same way as 
azacytidine and is activated after incorporation into a DNA stand (156). The demethylating 
effect of azacytidine and decitabine is stronger than zebularine but their mechanisms of action 
partially overlap. Collectively, these current nucleoside DNMT inhibitors are cytotoxic, 
mutagenic and show lack of specificity, which might limit the clinical application.  
  
 
Figure 1.8 Nucleoside analogues inhibitors of DNMT (taken from Gnyszka A. et al.) (156). 
 
1.5.2 Non-nucleoside inhibitor of DNMTs from nutritional compounds 
Due to the toxicity of nucleoside DNMTi, researchers have discovered non-nucleoside 
DNMTi with improved specificity and toxicity. Another benefit of non-nucleoside DNMTi is 
that they are not incorporated into the DNA. This characteristic welcomes the possibility of 
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selective inhibition of different DNMTs with minimal consequences of side effects. Naturally 
occurring substances and dietary compounds have been investigated for their ability to inhibit 
DNMT enzymes. Several studies show the effect of polyphenols as epigenetic modulators 
through binding to the catalytic site of DNMTs in cancer chemoprevention (162). 
Polyphenolic compounds gained intensive interest due to their anti-carcinogenic, anti-
oxidative, and anti-inflammatory activities (163, 164).  
 In this section, the inhibitory effects of five dietary constituents: (-)-epigallocatechin-
3-gallate (EGCG), caffeic acid (CA), curcumin, theaflavin, and vitamin C, will be introduced. 
Their respective DNMT inhibitory effects are summarised in Table 1.2. 
 
Table 1.2 Studies outline the interaction between bioactive dietary components and DNMT 









Lee, W.J., et 
al. (166) 
EGCG 7 µM (in vitro), 
20 µM (in 
vivo)  
DNMT1 EGCG inhibited human DNMT1 
activity by binding to the catalytic 
core region 




50 µM (in 
vivo) 
DNMT1 EGC and EGCG showed 
competitive inhibition of DNMT1 
in treatment of the KYSE 510 cell 
line. EGCG showed a dose and 
time-dependent reversal of 
hypermethylation and re-
expression of mRNA of 
p16INK4a, RARβ, MGMT, and 
hMLH1 genes 
Nandakumar, 




25 µM (in 
vivo) 
DNMTs EGCG reduced the activity of 
DNMTs by decreasing the mRNA 
levels and protein expression of 
DNMTs 
Zhang, B. K., 
et al. (169) 
EGCG 20 µM (in 
vivo) 
DNMT1 EGCG inhibited the mRNA and 
protein expression activity of 
DNMT1 and downregulated 
binding to the promoter of 
DDAH2. 
Shukla, S., et 
al. (170) 
EGCG 20 µM (in 
vivo) 
DNMT1 EGCG decreased the mRNA and 
protein expression activity of 
DNMT1 and increased the 
expression of unmethylation-
specific GSTP1 promoter. 
Morris J. et 
al. (171) 
EGCG 100 µM (in 
vitro), 150 µM 






EGCG treatment decreased 
promoter methylation of RXRα 









20 µM (in 
vivo) 
DNMT1 A dose and time-dependent 
inhibition of DNMT activity and 
protein expression was observed. 










The caffeic acid and chlorogenic 
acid inhibited the DNA 
methylation that was catalysed by 
prokaryotic M.Sssl DNMT and 
human DNMT1, and increased 
levels of SAH. 
Liu, Z., et al. 
(174) 
Curcumin 100 µM (in 
vivo) 
DNMT1 Curcumin blocked covalently the 
catalytic thiolate of DNMT1 to 
exert its inhibitory effect on DNA 
methylation. 
Arumugam 
R., et al. 
(175) 





Theaflavin showed inhibitory 
effect on DNMT3a-C with a 
physiologically and nutritionally 
relevant IC50 value. 
Venturelli S., 
et al. (176) 
Ascorbate 
(Vitamin C) 
8 mM (in vivo) DNMTs, 
 




The most abundant catechin in green tea is the EGCG, which is a competitive inhibitor 
of DNMTs through binding within the DNMT active site, leading to decreased global DNA 
methylation (167). EGCG has been found to promote vascular health through epigenetic 
reprogramming of endothelial-immune cell signalling and conversing systemic low-grade 
inflammation (177).   
CA (3, 4-dihydroxy-cinnamic acid) is an organic compound and a type of polyphenol. 
The consumption of CA-rich foods is protective against carcinogenesis through preventing 
the formation of nitrosamines and nitrosamides, which are the main inducers (178, 179). 
Curcumin is a bioactive compound and it is present in turmeric. Curcumin is also 
widely used in Asian countries as a yellow colour food additive. Curcumin has shown broad-
spectrum epigenetic modulation through manipulating the activity of DNMTs, HATs, and 
HDACs (180). Curcumin has antioxidant activity through its influence on acetylation and 
deacetylation (181).  
Theaflavin is another group of polyphenols and it is enriched in both black and oolong 
tea (182). Theaflavin have recently gained significant attention due to its biological and health 
promoting benefits. Research has shown that this compound might contribute to the positive 
benefits on diseases (183).  
Apart from polyphenols, vitamin C (L-ascorbate) is a water-soluble vitamin and 
antioxidant. Vitamin C has recently been implicated in epigenetic regulation through its 
contribution in the demethylation cycle as a cofactor of TET (184). Oral vitamin C 
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supplementation to patients with myeloid cancer resulted in an increase in the 5-hmC/5-mC 
ratio compared to placebos (185).  
The chemical structures of EGCG, curcumin, CA, theaflavin, and vitamin C are shown 
in the Figure 1.9. Several molecular modelling studies have demonstrated the interaction 
between some of these dietary compounds with DNMTs. For example, EGCG exerted its 
inhibitory effect on DNMT1 activity via blocking the entry of the key nucleotide cytosine into 
its active site (167). Curcumin has the potential to inhibit the DNMT1 activity by either 
blocking the catalytic domain, C1226 (174). 
 
 
Figure 1.9 Chemical structures of EGCG, curcumin, CA, theaflavin, and vitamin C. 
 
1.6 Nutrition and epigenetics 
It is now widely known that bioactive food compounds alter molecular and cellular processes 
with individual genetic variations, lifestyle, physiological conditions, or environment. The 
recognition of individual variations in response to nutrients is the result of advances in 
genome-wide analysis, which allows the whole genome to be queried. Also, epigenetics can 
be modulated by bioactive dietary compounds and metabolites without changes in DNA 
sequences (186). Additionally, most epigenetic modifications are dynamic and plastic, 
indicating that epigenetic modifications are sensitive to environmental factors. Here, the effect 




1.6.1 Epigenetics and lifestyle 
Lifestyle is used to explain the way of life or the manner of living, which comprises 
behavioural habits (e.g. diet, physical activity, smoking, and alcohol consumption) and other 
factors affecting well-being such as working environment and stress. Numerous studies have 
provided supporting evidence of the influence of lifestyle in epigenetic regulation. Table 1.3 
presents examples of lifestyle factors that are recognised influencers of epigenetics. 
 
Table 1.3 Lifestyle factors implicated in epigenetic modulation (taken from Jorge A. et al.) 
(187). 
Factors Example 
Nutrition  Folate, phytoestrogen, polyphenols, selenium 
Physical activity Exercise 
Tobacco smoke Cigarette smoke, cigarette smoke condensate 
Alcohol High alcohol intake 
Pollutants Arsenic, PM10, black carbon, benzene, PAHs, POPs 
Emotional Stressful experiences 
Shift work Working at night 
 
 
This section will focus on the impact of nutrition factors on epigenetics. Several 
dietary components are known to modify epigenetic marks. Folic acid and vitamin B12 play a 
vital role in DNA metabolism, and are found in a wide range of foods such as dairy products, 
meat, liver, and fruits. These vitamins are required for SAM production, which is a methyl 
donor for DNA methylation in the one-carbon metabolism (Figure 1.10) (188). Also, the 
SAM and S-adenosylhomocysteine (SAH) is generated from SAM by methionine 
adonosyltransferase, and this reaction is influenced by methylation events, making the Sam 
and SAH ratio a determinant of methylation efficiency. Folate and vitamin B12 are important 
cofactors in the regeneration of methionine by methylation of homocysteine (189). 5-Methyl 
tetrahydrofolate, the circulating form of folate, is depleted under the condition of folate 
deficiency, in which DNA methylation activity is reduced through lower availability of SAM. 
Folate depletion significantly increased plasma homocysteine and lymphocyte DNA 
hypomethylation in healthy postmenopausal women (190). High dose of oral choline (500 






Figure 1.10 One-carbon metabolism. DHF, dihydrofolate; DMG, dimethyl glycine; SAH, S-
adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate (taken from 
James A.C. et al.) (192). 
 
Selenium reactivates the pi-class glutathione-S-transferase through partial promoter 
DNA demethylation in prostate cancer cells (193). Selenium also decreases the activity of 
histone deacetylase and levels of DNMT1, while the levels of acetylated lysine 9 on histone 
H3 increase (193). However, methylation of the promoter of p53, a tumour oncogene, was 
decreased in a human colon cancer cell line treated with selenite (194). In addition to 
demethylating activity, polyphenols have also been shown to modify the activity of histone 
acetylases and histone deacetylases (195-197). 
 
1.6.2. Methyl donors and DNMTi diet 
Dietary factors can influence DNA methylation patterns through either, 1) donating a methyl 
group, known as a methyl donor or 2) inhibiting the activity of DNMT, known as a DNMTi 
(198). For example, folate, choline, betaine, vitamin B12, and methionine are the methyl 
donors involved in the one-carbon metabolism and DNA methylation (Figure 1. 10) (199). In 
contrast, polyphenols can interfere with DNA methylation levels through inhibition DNMT 
activity. 
 
Dietary factors as methyl donors - effects on phenotype  
As for most methylation reactions within mammalian cells, the key methyl donor for the 
epigenome is SAM, which is generated during the methionine cycle via the one-carbon 
23 
 
metabolism (Figure 1.10) (200). Folate, vitamin B12, choline, betaine and methionine act as 
methyl donors in this pathway while vitamin B2 and vitamin B6 are cofactors for one- carbon 
transfers (199). Folate is an essential vitamin for SAM generation. Folate can intervenes with 
global DNA methylation by impacting DNMT expression, or by providing more SAM (201). 
The ability of methyl donors to modify both the phenotype and/or the epigenetic status of the 
successive generations in animal models has led to a surge in increasing the knowledge 
surrounding methyl donors in human diets (202-205). A compelling example of folate on 
phenotype is its role in the study of the Avy mouse model, whereby maternal folate dietary 
deficiency correlated with reduced DNA methylation and yellow coat colour in offspring 
(206). The Agouti gene in the yellow Avy offspring is constitutively expressed due to 
hypomethylation of its upstream repetitive elements, giving rise to elevated yellow colour 
production, as well as increased obesity when compared with genetically identical brown 
mice (206). In another study, higher rates of brown wild type mice were observed in the 
offspring of pregnant mice fed with methyl donor rich diets compared with a control group 
fed with a standard diet (207). The impact of maternal dietary methyl donors on foetal growth 
was highlighted in a separate study whereby a methylating micronutrients-rich maternal diet 
containing methionine, folate choline, vitamin B6, and vitamin B12 increased foetal weight 
(208).  
Not only site-specific CpG but also global DNA methylation is modulated by methyl 
donor diets. The global DNA methylation level was increased by two year folic acid and 
vitamin B12 supplementation in elderly (209). Similarly, in randomised clinical trial, global 
DNA methylation was increased in post-polypectomy patients supplemented with 600 µg/day 
(210). Further studies regarding folate status have reinforced the necessity of folate inclusive 
diets. For instance, insufficient folate intake has been correlated with a reduction in the global 
DNA methylation in postmenopausal women (190). Similar findings of lower global DNA 
methylation were also observed in the offspring of female C57B16/J mice fed with low folate 
diets (211).  
Folate supplementation was associated with increased DNA methylation of Zinc finger 
protein 57 in maternal blood samples (212). Moreover, folate interferes with DNMTs in both 
RNA and protein expressions. For example, in the HCT116 cell line, DNMT3A expression 
was significantly reduced in high folate states (4 mg/L or 16 mg/L) compared with 0 mg/L 
folate, while DNMT1 expression significantly increased in 16 mg/L of folate treated cells 
(213). Pseudo-pregnant mice fed a folate depleted diet (0 mg/L) showed a significant 
upregulation of RNA expression and protein expression of both Dnmt3a and Dnmt1, but no 
effects were observed for Dnmt3b (214). In addition to folate, choline and betaine are 
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precursors for SAM and supplementation of these also modulate DNA methylation (215). In 
animal studies, global DNA hypomethylation or hypomethylation of site-specific CpGs of 
cyclin-dependent kinase 3, vascular endothelial growth factor-C, angiopoietin 2, and 
calbindin 1 genes were observed in the offspring to maternal choline deficient rodents (216-
218). Rats fed by a low choline and methionine diet were deficient in 5-methyldeoxycytidine 
content of hepatic DNA (219). Methionine serves as a precursor for SAM in the one-carbon 
metabolism (220). The effect of the short-term feeding of methionine-supplementation in 
mice demonstrated increased methylation patterning of LINE-1 transposable elements (221).  
 
Dietary factors that act as DNMT inhibitors (DNMTi) 
This section was discussed in 1.5.2 about the inhibitors of DNMTs from nutritional 
compounds. Briefly, several phenolic acids, stilbenes, and flavonoids can inhibit the activity 
of DNMT, either directly by interaction with active site of DNMTs or through indirect 
mechanisms such as inhibition of DNA methylation by increasing SAH (196, 222-224). 
EGCG is the major metabolite (59%) of catechin (225) and has been shown to inhibit DNMT 
activity and to downregulate hTERT expression (226). In vitro studies have shown that 
catechin inhibits the enzyme activity of DNMT3A and DNMT3B (167, 226); however the 
biological consequences of this effect have not yet been examined. Genistein showed a dose-
dependent inhibition of DNMT activity (227). Other phenolic compounds such as luteolin, 
apigenin, naringin, and hesperetin indirectly regulate DNMT activity via modulating the ratio 
of SAM and SAH (166, 228, 229). Although some nutrients are known to target a specific 
DNMT isoform (Table 1.2), there are no studies on the effects of potential DNMT inhibitors 
or methyl donors on specific DNMT sub-isoforms. 
 
1.6.3 Effect of nutrition on human diseases 
Nutrition is an important factor in health and diseases. Insufficient or excessive dietary intake 
results in a reduced state of health conditions. In a systemic analysis from the Global Burden 
of Disease Study in 2017, the proportion of disease-specific burden induced by dietary risk 
factors was estimated, detailing 11 million deaths and 255 million disability-adjusted life-
years attributed to dietary risk factors such as high sodium intake and low intake of whole 
grains and fruits (230). Undernutrition, or nutrition deficiency, and overnutrition were the 
prevailing diet induced disease states. It is important to consume a balanced diet to prevent 
disease or reduce disease risk. For example, concentrated sugars and refined flour products 
impair glucose metabolism leading to obesity or diabetes (231). Low fibre intake, imbalance 
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of omega 3 and omega 6 fatty acids, and consumption of red meat contribute to increased 
cancer risk (232-235). Vitamin deficiency is well known to increase disease likelihood: 
vitamin D deficiency contributes to osteopenia and osteoporosis (236); xerophthalmia is an 
ocular manifestation of vitamin A deficiency (237); low vitamin B12 has been known as a 
potential risk factor of neural tube defects (238), scurvy is a condition caused by vitamin C 
deficiency. Some evidence shows the protective effect of vitamins on cancer risk. Vitamin 
B12, for instance, is essential for DNA synthesis and cellular energy production (239). 
Methylcobalamin, a form of vitamin B12, inhibited tumour growth of oestrogen-sensitive 
malignant cells in mice (240).  
 Nutrition influences health through multiple molecular mechanisms including changes 
in DNA methylation patterns (241), which modulate biological functions that impact health 
and ageing. As mentioned in the section 1.6.2, higher intake or status of several 
micronutrients participate in the one-carbon metabolism, including folate, choline, betaine, 
methionine, vitamin B6, and vitamin B12; all of which contribute to SAM production and are 
associated with increased DNA methylation (242, 243). For example, dietary methyl donor 
restriction and polymorphisms in genes encoding key components of the one-carbon 
metabolism pathway have been associated with aberrant DNMT expression, decreased global 
DNA methylation, and increased cancer risk (244). In addition, mice fed a folate deficient diet 
showed chromosomal damage in nucleated erythrocyte precursors (245). Hypomethylated 
DNA and double DNA strand breaks were observed in the liver of rats that were fed a 
methionine, choline, and folic acid deficient diet (246). Protein restriction in pregnant 
C57BL/6J mice caused hypermethylation of the liver X-receptor alpha promoter in liver tissue 
of their offspring, which is a nuclear receptor controlling cholesterol and fatty acid 
metabolism (247). In a human study, the incorporation of [3H] methyl groups was found to be 
increased in postmenopausal women who consumed a moderately folate-depleted diet (118 
µg folate per day) for seven weeks, suggesting low methylation of DNA (248). Reduced DNA 
methylation contributes to carcinogenesis by altering the gene expression of tumour 
suppressor genes or proto-oncogenes (249). Folate depletion also leads to an increase in 
homocysteine, which is a risk factor of CVD (250). Concomitantly, increasing plasma 
homocysteine correlated with elevated plasma SAH as well as DNA hypomethylation in 
lymphocytes (251). Maternal folate deficiency caused global and LINE-1 hypomethylation 
resulting in increased retrotransposition in foetuses, which in turn increased the risk of 
intrauterine growth retardation (252). Mice fed a high methionine and low B vitamin diet 
showed hypermethylation of netrin-1 gene promoter leading to low gene expression of netrin-
1 and association with memory loss (253).  
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 Methionine adenosyltransferase converts methionine to adenosylmethionine (AdoMet) 
and adenosylhomocysteine (AdoHcy) is generated following methyl donation before forming 
homocysteine. The elevated AdoHcy concentration results in a lower AdoMet/AdoHcy ratio, 
thus inhibiting DNA methyltransferase in liver (254) and human fibroblasts cell lines (255). 
In a mice study, a folate/choline-deficient diet significantly decreased AdoMet concentration 
but there was a significant increase in AdoHcy, and this consequently decreased the 
AdoMet/AdoHcy ratio (256). The effect of homocysteine on AdoMet and AdoHcy 
concentrations has been found to be tissue type dependent leading to within-tissue gene-
specific hypermethylation, but low global DNA methylation, all of which might promote 
CVD risk through an altered gene expression profile (257, 258). 
 
1.7 Personalised nutrition 
Data on relationships between dietary intake and health outcomes are used to build public 
health dietary recommendations. However, individuals respond differently to the same dietary 
intake and/ or nutrients because of inter-individual variations in their genetic makeup and 
other phenotypic factors. This has led to the idea that it may be possible to use individual 
characteristics to personalise nutritional advice. 
The concept of personalised nutrition (PN) (259, 260) is based on the idea that the 
generic “one size fits all” notion may not be appropriate for everyone in the population and 
that tailoring advice for each individual may be more effective on health and disease 
outcomes. PN can be based on biological characteristics, on current eating behaviour and/or 
on psychosocial parameters of the individual (261). The potential benefits of PN in promoting 
health include improved efficacy and reduced costs of healthcare. Also, PN can be applied 
either in management of patients with specific diseases or in improving public health. The 
differential response of individuals to the same nutritional components provides the 
motivation and strategy development for PN.  
  A better understanding of how nutrients or diet plays an important role in health by 
using technology, e.g. Next-generation sequencing methods and mass-spectrophotometry 
enables biological differences between individuals to be observed for tailoring PN regimens, 
through genetic and epigenetic assessment. The concept of PN was proved by the Food4Me 
study to providing personalised dietary advice based on individual dietary intake, phenotypic 
and genotypic data (262, 263). In the Food4Me study after six months, those randomised to 
PN had bigger improvements in their diet than those randomised to the control (generic 
dietary advice) (262, 263). However, there was no evidence of added benefit of using 
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genotypic and/or phenotypic information in generating the PN advice (262). However, in a 
smaller Canadian intervention study, genotype-based dietary advice was more effective than 
general dietary advice in reducing salt intake in healthy young adults (264). Advances in data 
science, analytical technologies, molecular science and nutritional knowledge will allow 
researchers to refine PN. However, to be useful in improving public health, PN will also need 
to address the psychological, social, economic and cultural factors that influence eating 
patterns in order to ensure that advice is converted into action and that improved dietary 
habits are sustained in perpetuity (261). 
 
1.8 Research gap 
Since the discovery of epigenetic factors as drivers of diseases, tools and strategies have been 
developed to investigate the epigenome. This implementation of epigenetic tools has proven 
useful in designating treatment. Numerous DNMT isoforms were previously discovered (see 
section 1.4). High similarity of the catalytic domain among DNMT isoforms was found 
through the assembly of structures (119). To date, it remains a controversy over which DNMT 
isoform would be the best maker for diseases. Although preferential target sites for DNMTs 
have been identified, these target sites were limited only the cancer-related genes, due to the 
availability of an outdate version of the Illumina DNA methylation assay (87). Moreover, a 
cell model to assist with the unveiling of novel disease associated CpGs in DNMT genes is 
unavailable. Therefore, cell model systems that each overexpress one of 13 different DNMTs 
can be investigated to reveal preferential DNMT target CpG sites that are isoform-specific 
using Illumina Infinium Methylation EPIC BeadChip (EPIC arrays).  
 The role of DNMTs in human disease is important for therapeutic purposes. It is 
necessary to develop selective DNMTi toward a specific DNMT isoform, which could 
identify an appropriate DNMT isoform to target in specific diseases. However, this remains a 
grey area due to lack of materials and techniques. It will be valuable data for all potential 
DNMTi to be screened for their efficacy across a selection of conditions. Also, there remains 
controversy over which DNMTi can be inhibited through the action of a DNMTi. Although 
the catalytic pockets of DNMTs are conserved, amino acid residues are dissimilar. For 
example, Cys662 in DNMT3a is replaced by Trp1173 in DNMT1, Arg887 by Asn1580, and 
Trp889 by Val582. Additionally, the SAM cofactor can receive a different conformation in its 
binding pocket based on the type of methyltransferase (265).  
 Based on the studies discussed in this chapter, there is growing evidence that diet and 
bioactive food compounds play an important role in the epigenome through modulating DNA 
28 
 
methylation, DNMT activity, and DNMT expression. Assessment of these epigenetic 
determinants provides valuable information on how individuals respond to dietary factors. 
Therefore, nutrition and epigenetics collectively bring forward the prospect of dietary 
intervention for the health-promotion, disease prevention, and as a combatant therapy in diet-
related disorders. Epigenetic biomarkers to help govern PN remain largely unknown or very 
limited. Thus, the concept of a balanced diet between methyl donor and DNMTi diet can 
bring us closer to the goal of effective PN. 
 
1.9 Hypotheses, aims and objectives 
 
1.9.1 Hypotheses 
1. Overexpression of DNMTs leads to aberrant DNA methylation patterns. 
2. Each DNMT isoform characteristically targets different CpG sites. 
3. Certain micronutrients and other food constituents can alter global DNA 
methylation or methylation at specific CpG sites. 
4. Polyphenols and vitamin C inhibit specific DNMTs and, as a consequence, 
modulate patterns of DNA methylation. 
 
1.9.2 Aim 
• To test these hypotheses using short-term cultures of cells models. 
 
1.9.3 Objectives 
1. To generate 13 cell lines that each over-express a different DNMT isoforms. 
2. To identify the CpG sites that are methylated differentially by each DNMT 
isoform, I will undertake genome-wide DNA methylation analysis using the 
Illumina Infinium Methylation EPIC BeadChip.  
3. To assess CpG specific DNMTs in relation to biological mechanism by pathway 
analysis according to enrichment statistics of the difference of gene. 
4. To investigate interactions between selected food constituents, i.e. theaflavin, 
EGCG, CA, curcumin, and vitamin C, and specific DNMT isoforms in 




2. Chapter 2: Materials and methods 
 
 
2.1 Generation of cell lines with stable over-expression of specific DNMT isoforms 
 
2.1.1 Cell culture conditions 
MEG-01 cell line 
The megakaryoblast cell line (MEG-01) was purchased from Merck, UK. This cell was 
cultured in Roswell Park Memorial Institute (RPMI) medium (Sigma, UK) supplemented with 
10% foetal bovine serum (FBS) (Sigma, UK), and 2 µM glutamine, at 37 °C in a 5% CO2 
humidified atmosphere. 
 
HEK293T cell line 
The human embryonic kidney 293T cell line (HEK293T) (gifted from Dr Viktor Korolchuk, 
Newcastle University) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) - high 
glucose (Sigma, UK) supplemented with 10% FBS (Sigma, UK), and 2 mM glutamine, at 37 
°C in a 5% CO2 humidified atmosphere. 
 
HEK293FT cell line 
The human embryonic kidney 293FT cell line (HEK293FT), a fast growing HEK293T strain, 
(gifted from Dr Viktor Korolchuk, Newcastle University) was cultured in DMEM (Sigma, 
UK) supplemented with 10% FBS (Sigma, UK), 1% sodium pyruvate, 1% non-essential 
amino acid, and 1% G418, at 37 °C in a 5% CO2 humidified atmosphere. 
 
2.1.2 Retransformation of 13 DNMT-pIRES puro3 plasmids to E.coli DH5 
E.coli DH5α cell (Bioline, UK) (25 μL) was thawed on ice, then 2.5 μL of pIRES puro3 
plasmids (gifted from Dr Si Ho Choi) were added, followed by gentle swirling of the tube for 
a few seconds to mix and then kept on ice for 30 minutes. The tube containing the mixture 
was then placed in a 42 °C water bath for 45 seconds without shaking, then replaced on ice 
for 2 minutes. The mixture was diluted by addition 1 mL of pre-warmed LB medium and 
incubated at 37 °C for 1 hour with shaking. 100 μL of the transformed cells were plated out 





2.1.3 Plasmid construction for viral system 
Plasmid preparation 
The pLenti7.3/V5 DEST gateway vector (gifted from Dr Viktor Korolchuk, Newcastle 
University) (Figure 2.1A) was modified to add more restriction cloning sites using oligo 
nucleotide sequences (containing XbaI, NheI, ClaI, EcoRI, SwaI, PspOMI, and MluI sites) 
(IDT DNA, UK) (Figure 2.1B).  
The pLenti7.3/V5 DEST gateway vector was cut by XbaI and MluI restriction 





Figure 2.1 Cloning sites within pLenti7.3/V5-DEST. A) Plasmid map of pLenti7.3/V5-DEST. 
B) Diagrammatic representation of new multiple cloning sites: NheI, ClaI, EcoRI, SwaI, and 








Table 2.1 Volume of reagents for restriction enzyme reaction. 
Reagent Volume per reaction 
10x Fast digest green buffer (Thermo Fisher Scientific, UK) 2 µL 
XbaI (Thermo Fisher Scientific, UK)  1 µL 
MluI (Thermo Fisher Scientific, UK)  1 µL 
Nuclease-free water (QIAGEN, USA) Up to the total volume 
pLenti7.3/V5 DEST gateway vector  1 µg 
Total  20 µL 
 
Mixture of vectors and restriction enzymes was incubated at 37 °C for 3 hours. These 
mixture solutions underwent gel electrophoresis on a 1% agarose gel at 90 volts for 1 hour. 
Then, all target vectors’ bands were cut out of the gel by hand under UV light and then 
purified using QIAquick gel extraction kit (QIAGEN, USA). Firstly, gel slices were weighed 
in a 1.5 mL microcentrifuge tube and 3 volumes of buffer QG were added per volume of gel. 
Then, this tube was incubated at 50 °C for 10 minutes until the gel slice had dissolved 
completely. After that, 1 gel volume of isopropanol was added and mixed by vortexing. The 
mixture was applied to the QIAquick column and this column was centrifuged at 12,000g for 
1 minute. The filtrate was discarded from the collection tube. 0.5 mL of buffer QG was added 
into the column and this column was centrifuged at 12,000g for 1 minute. For the washing 
step, 0.75 mL of PE buffer was added into the column and this column was centrifuged at 
12,000g for 1 minute. The filtrate was discarded from the collection tube and then the empty 
QIAquick column was centrifuged at 12,000g for 2 minutes. For the elution step, 50 µL of 
buffer EB (10 mM Tris-Cl, pH 8.5) were added into the column which was centrifuged at 
12,000g for 1 minute. 
 
Annealing oligonucleotide 
Two oligonucleotides for new multiple cloning sites: NheI, ClaI, EcoRI, SwaI, and PspOMI 






Table 2.2 Volume of each oligonucleotide. 
Reagent Volume per reaction 
Oligonucleotide forward sequence (10 µM) 
5’CTAGAGCTAGCATCGATGAATTCATTTAAATGGGCCCA3’ 10 µL 
Oligonucleotide Reverse sequence (10 µM) 
5’TCGATCGTAGCTACTTAAGTAAATTTACCCGGGTGCGC3’ 10 µL 
Total  20 µL 
  
Table 2.3 Temperatures and times for annealing condition. 
Temperature Time 
95 °C 30 seconds 
72 °C 2 minutes 
37 °C 2 minutes 
25 °C 2 minutes 
4 °C Hold 
  
 After incubation, annealing products were diluted by 1 µL of annealing product and 99 
µL of Nuclease-free water. 
 
Ligation between target DNA or oligomers and target plasmid 
The annealing product or target DNA was ligated into the pLenti7.3/V5 DEST gateway vector 
using the protocol outlined below (Table 2.4). 
 
Table 2.4 Volume of reagents for ligation reaction. 
Reagent Volume per reaction 
5x ligase reaction buffer (Thermofisher Scientific, UK)  2 µL 
Insert (diluted annealing product) Up to the total volume 
T4 ligase (5U/µL) 0.3 µL 
pLenti7.3/V5 DEST gateway vector  1 µg 




  The components detailed in Table 2.4 were added to the mixture which was incubated 
at 22 °C for 3 hours and them transformed into E.coli DH5α using the heat shock protocol 
described in 2.1.2. 
 
Plasmid DNA extraction 
A single colony was cultured in 7 mL and 100 mL of LB containing 100 µg/mL of ampicillin 
at 37 °C overnight with vigorous shaking (220 rpm). After incubation, positive bacteria were 
extracted using E.Z.N.A.® Endo-free Plasmid DNA Mini KitII (VWR, USA) and PureYieldTM 
Plasmid Midiprep System (Promega, UK). 
Use of the E.Z.N.A.® Endo-free Plasmid DNA Mini KitII 
Plasmid was extracted from bacteria using E.Z.N.A.® Endo-free Plasmid DNA Mini KitII, 
(VWR, USA) according to manufacturers’ instruction. Briefly, 7 mL of suspension containing 
bacteria were centrifuged at 5,000g for 10 minutes at room temperature and the medium was 
discarded. 500 µL of solution I/RNase A were added to the cell pellet which was resuspended 
by vortexing and then this mixture was transferred into a new 2 mL microcentrifuge tube. 500 
µL of solution II were added to the mixture in this microcentrifuge tube and mixed by 
inverting and gentle rotation of the tube 6 times. Next, for protein precipitation, 250 µL of N3 
buffer were added and the mixture was mixed gently by inverting until a flocculent white 
precipitate formed. This mixture was centrifuged at 12,000g for 10 minutes. A compact white 
pellet was formed and the clear lysate (supernatant) was transferred to a new 1.5 mL 
microcentrifuge tube. Then, one volume ETR binding buffer was added and this tube was 
inverted 10 times to mix thoroughly. A HiBind DNA mini column II was prepared by adding 
100 µL of 3M NaOH into this column and the column was centrifuged at 12,000g for 60 
seconds. The filtrate was discarded from the collection tube. The clear supernatant (described 
above) was transferred into the HiBind DNA mini column II carefully (not to disturb the 
pellet). This column was centrifuged at 12,000g for 1 minute and the filtrate was discarded. 
This step was repeated until all of the clear lysate (supernatant) had been transferred. Next, 
500 µL of ETR wash buffer were added into the column and the column was centrifuged at 
12,000g for 1 minute. Then, the filtrate was discarded, 500 µL of HBC buffer were added, the 
column was centrifuged at 12,000g for 1 minute and the filtrate was discarded. In the washing 
step, 700 µL DNA wash buffer were added into the column, which was centrifuged at 
12,000g for 1 minute. Then, the filtrate was discarded, and this step was repeated. After 
washing, the column was dried by centrifugation of the empty HiBind DNA Mini Column II 
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matrix at 12,000g for 2 minutes. For the elution step, 50 µL of elution buffer were added into 
the column and incubated at room temperature for 10 minutes. Then, this column was 
centrifuged at 12,000g for 1 minute. The plasmid DNA was stored at -20 °C. 
 
Use of the PureYieldTM Plasmid Midiprep System 
Plasmid was extracted from bacteria using PureYieldTM Plasmid Midiprep System (Promega, 
UK) according to manufacturers’ instruction. Briefly, 100 mL of suspension containing 
bacteria were transferred to 50 mL centrifuged tube and centrifuged at 5,000g for 10 minutes 
at room temperature and the medium was discarded. 3 mL of resuspension solution were 
added to the cell pellet which was resuspended by vortexing and then added 3 mL of lysis 
solution and mixed by inverting and gentle rotation of the tube five times. Next, for protein 
precipitation, 5 mL of neutralization solution were added, and the mixture was mixed gently 
by inverting and gentle rotation of the tube ten times. This mixture tube was centrifuged at 
10,000g for 30 minutes. Next, Column stack was prepared by placing a blue PureYieldTM 
clearing column on top of a white PureYieldTM binding column and placed onto a vacuum 
manifold. The clear lysate (supernatant) was transferred carefully into column stack and then 
all liquid was passed through both the clearing and binding columns after applying vacuum. 
The blue clearing column was removed while the binding column was left on the manifold. 
Next, 5 mL of endotoxin removal wash buffer were added into the binding column and 
allowed to pass through the binding column after applying vacuum. Then, 20 mL of column 
wash solution were added into the binding column and allowed to pass through the binding 
column after applying vacuum. After this, binding column was dried by applying a vacuum 
for 1 minute and removed from manifold. For the elution step, 450 µL nuclease-free water 
were added into the binding column which was placed into a new 50 mL centrifuged tube. 
This tube was centrifuged at 2,000g for 5 minutes. The plasmid DNA was stored at -20 °C. 
 
Colony screening by PCR and cutting by restriction fragment length polymorphism (RFLP) 
E. coli colony containing a positive vector was screened by PCR and RFLP using the mixture 







The mixture tube was incubated at 37 °C for 1 hour and run gel electrophoresis on a 
1% agarose gel at 90 volts for 1 hour. To confirm the positive colony by PCR, each colony 
was picked up separately and diluted in 20 µL of water. PCR master mix was prepared as 
shown below (Table 2.6). 
 
Table 2.5 Volume of the reagents for RFLP. 
Reagent Volume per reaction 
10x Fast digest green buffer (Thermofisher Scientific, UK)  2 µL 
EcoRI (Thermofisher Scientific, UK) 1 µL 
KpnI (Thermofisher Scientific, UK)  1 µL 
Nuclease-free water (QIAGEN, USA) Up to the total volume 
pLenti7.3/V5 DEST gateway vector  1 µg 
Total  20 µL 
 
 
Table 2.6 Volumes of the reagents for colony PCR. 
Reagent Volume per reaction 
2x GoTaq® Green Master Mix (Promega, UK)   12 µL 
CMV forward primer (10 μM) 
: 5’ CGCAAATGGGCGGTAGGCGTG 3’ 
1 µL 
Myc reverse primer (10 μM) 
: 5’ CTGAGATCAGCTTCTGCTC 3’ 
1 µL 
Nuclease-free water (QIAGEN, USA) 9 µL 
Diluted colony 1 µL 
Total  24 µL 
 
Table 2.7 Condition of colony PCR using thermocycler PCR. 
Procedure Temperature Time Number of cycles 
Pre-denaturation 95 °C 10 minutes 1 
Denaturation  95 °C 40 seconds 
35 
Annealing  58 °C 40 seconds 
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Extension 72 °C 30 seconds 
Final extension 72 °C 5 minutes 1 
 4 °C Hold  
 
Confirmation the insert’s sequences by Sanger sequencing 
All positive colonies were cultured and extracted using PureYieldTM Plasmid Midiprep 
System (see page 33). These plasmids were cut by PvuI to confirm the target vectors. These 
plasmids were sent to MRC PPU DNA Sequencing and Services at Dundee University for 
sequence analysis. 
  
2.1.4 Virus production 
HEK293FT cells were seeded into 6-well plate by one million cells per well and incubated at 
37 °C in a 5% CO2 humidified atmosphere for 24 hours. After 24 hours, the confluence of 
HEK293FT cells were around 60-70%. All plasmids were prepared as the following protocol. 
REV PLP2, GAG PLP1, and VSV PLP1 plasmids were prepared with 600 ng of final 
concentration and mixed with 600 ng of plenti7.3/V5-DEST gateway-DNMTs or 
plenti7.3/V5-DEST gateway-Myc. The mixed solution volume was then adjusted to be 250 
μL using Opti-MEM® Medium (Sigma, UK). Diluted Lipofectamine® 2000 (Thermo Fisher 
Scientific, UK) was prepared using 7.2 μL Lipofectamine® 2000, and 242.8 μL Opti-MEM® 
Medium and mixed by vortexing and incubated at room temperature for 5 minutes. Diluted 
plasmids and diluted Lipofectamine® 2000 were combined and incubated at room temperature 
for 20 minutes. 500 μL DNA-lipid complex were added into MEG-01 or HEK293T cells 
without changing media and incubated at 37 °C in a 5% CO2 humidified atmosphere for 16-
18 hours. After incubation, all media were removed and replaced with fresh media. 
MEG-01 or HEK293T cells were seeded by 300,000 cells per well in 12-well plate for 
MEG-01 cells and 400,000 cells per well in 6-well plate for HEK293T cells, then all cells 
were incubated at 37 °C in a 5% CO2 humidified atmosphere for 16-18 hours. After 48 hours 
of virus production in HEK293FT cells, 1.5 mL of cultured media were harvested and filtered 
through a 0.45 μm filter. 500 μL of filtered media containing virus were mixed with 500 μL of 
fresh media and polybrene (final concentration: 5 μg/mL) and transferred into the target cells. 
After that, the target cells were incubated at 37 °C in a 5% CO2 humidified atmosphere for 




2.1.5 Confirmation of positive cells using fluorescent microscopy 
Positive cells were observed under fluorescent microscopy, Leica DMi8 (Leica microsystems, 
UK), as the positive cells can express green fluorescent protein (GFP) due to a GFP sequence 
in the pLenti7.3/V5 DEST gateway vector.  
 
2.1.6 Single cell selection by Fluorescence-activated cell sorting (FACS) 
All transfected cells were harvested and centrifuged at 800g for 5 minutes and filtered through 
a 30 μm filter into FACS tubes. Each cell was sorted and dispensed in a single drop into each 
well of a 96-well plate using a FACS Fusion Sorter.  
 
2.1.7 Confirmation the positive cells by qPCR and western blot assays 
Identification of housekeeping (HK) genes  
Eleven HK genes (Table 2.8) (266, 267) were used to identify the most stable HK genes for 
from cell lines overexpressing individual DNMT isoforms in MEG-01 or HEK293T cells. A 
set of tested candidate HK genes was performed, and a gene expression normalization factor 
was calculated using geNorm (268). Two most stable HK genes of each experimental were set 
for normalisation of gene expression based on geNorm analysis. Briefly, the cycle threshold 
(Ct) values were transformed to quantities by the comparative Ct method. The highest relative 
quantities for each gene were set to 1. These raw HK gene quantities were the required data 
input for geNorm to generate normalised factor (NF). In example (Figure 2.2), geNorm 
analysis would indicate that HK1 and HK2 were the most stable gene. Thus, after calculation 
of NF, the normalised gene of interest (GOI) expression levels can be calculated by dividing 





Figure 2.2 Normalisation flow chart. Cycle threshold: Ct, Gene of interest: GOI, 
Housekeeping gene: HK, Normalisation factor: NF. 
 
Table 2.8 Primer lists of housekeeping genes. 
Genes Primer sequence 
Ribosomal Protein S13 
(RPS13) 
Forward: 5’ GCTTTACCCTATCGACGCA 3’ 
Reverse: 5’ TTGTGCAACACCATGTGAATC 3’ 
Transferrin Receptor (TFRC) Forward: 5’ AACTGGACAGCACAGACTTC 3’ 




Forward: 5’ GGACTAATTATGGACAGGA 3’ 
Reverse: 5’ TTTGATGTAATCCAGCAGG 3’ 
Ribosomal Protein Lateral Stalk 
Subunit P0 (RPLP0). 
Forward: 5’ CATGTTGCTGGCCAATAAGG 3’ 
Reverse: 5’ TAGTGGTGATACCTAAAGCCT 3’ 
Ribosomal Protein L13A 
(RPL13A), 
Forward: 5’ GTACGCTGTGAAGGCATCAA 3’ 
Reverse: 5’ ACGGTCCGCCAGAAGATG 3’ 
Peptidylprolyl Isomerase A 
(PPIA) 
Forward: 5’ ATGGACAAGATGCCAGGAC 3’ 
Reverse: 5’ TCCAGGGTTTATGTGTCAGG 3’ 
Beta-2-Microglobulin (B2M) Forward: 5’ TACTCTCTCTTTCTGGCCTG 3’ 
Reverse: 5’ GGATGGATGAAACCCAGACA 3’ 
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Actin Beta (ACTB) Forward: 5’ GAGGCACTCTTCCAGCCTT 3’ 
Reverse: 5’ CGCCAGACAGCACTGTGTT 3’ 
Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) 
Forward: 5’ CATGTTCGTCATGGGTGTGA 3’ 
Reverse: 5’ GAGTCCTTCCACGATACCAA 3’ 
Glucuronidase Beta (GUSB) Forward: 5’ CCATTCCTATGCCATCGTGT 3’ 
Reverse: 5’ GATGGCGATAGTGATTCGGA 3’ 
18sRNA Forward: 5’ CCATTCCTATGCCATCGTGT 3’ 
Reverse: 5’ TAGTAGCGACGGGCGGTGTG 3’ 
 
RNA extraction 
All DNMT cell types were cultured by 1,000,000 cells per well in a 6-well plate for MEG-01 
and 400,000 cells per well in a 6-well plate for HEK293T cells, at 37 °C in a 5% CO2 
humidified atmosphere for 16-18 hours. Total RNA was extracted by E.Z.N.A.® Total RNA 
kit I. 
 
Use of the E.Z.N.A.® Total RNA kit I:  
Cell culture media were aspirated and discarded. Cells were then washed with 1% PBS and 
0.1-0.25% trypsin were added to allow cells to detach. After detachment, DMEM was added 
as the same volume as trypsin to inactivate the trypsin. All mixture solution was transferred to 
15 mL tubes and centrifuged at 800g for 5 minutes. The number of cells per sample was 
estimated (5 x 106 – 1 x 107 cells) and the appropriate volume of TRK lysis buffer (700 μL) 
was added to each pellet followed by vortexing for 20 seconds. 700 μL of 70% ethanol were 
added and followed by vortexing. The sample was loaded onto a Hibind RNA mini column 
inserted into a collection tube and centrifuged at 10,000g for 1 minute. The eluate was 
discarded and this step was repeated until all samples had been transferred to the column. 500 
μL of RNA wash buffer I were added to the Hibind RNA mini column and centrifuged at 
10,000g for 30 seconds. The eluate was discarded and 500 μL of RNA wash buffer II were 
added to the Hibind RNA mini column and centrifuged at 10,000g for 1 minute. The washing 
step was repeated and the empty column centrifuged at 13,000g for 2 minutes to completely 
dry the Hibind RNA mini column. The columns were transferred to new microcentrifuge 
tubes and the total RNA was eluted by centrifuging at 13,000g for 2 minutes with 50 μL of 
diethyl pyrocarbonate (DEPC) water. Total RNA quantity and purity were assessed by 
Nanodrop1000 (Thermo Fisher Scientific, UK). Total RNA was kept at -80 °C. 




Reverse transcription (RT) was carried out using the Omniscript RT kit (QIAGEN, USA) 
according to manufacturers’ instruction. The reaction volume was 20 μL, adjusted with 
molecular grade water. The remaining components were 2 μL 10x buffer RT, 2 μL dNTP mix 
(5 mM each dNTP), 2 μL random hexamer primer, 1 μL Omniscript reverse transcriptase, and 
2 μL (1.5 μg) sample total RNA. The reaction was incubated at 37 °C for 1 hour.  
  
Quantitative polymerase chain reaction (qPCR) 
PCR was used to amplify the target genes (DNMT isoforms), GFP gene, and HK genes using 
primer oligonucleotide (0.01 μmol) (Tables 2.8 and 2.9). Only primer sets of hDNMT1, 
hDNMT3A1, hDNMT3A2, hDNMT1, and hDNMT3L were specific to their respective genes, 
while hDNMT3B1-3B5, hDNMTΔ3B1- Δ3B2, and hDNMTΔ3B3- Δ3B4 were able to 
amplify the multiple DNMT isoforms of their respective genes. For primer sets of exogenous 
DNMTs, they were able to bind to Myc sequence introduced as marker of exogenous 
sequence. 10 µL 2x QuantiTect SYBR green PCR master mix (QIAGEN, USA), 0.4 µL 
forward and reverse primers (final concentration 10 µM), 8.2 µL nuclease-free water 
(QIAGEN, USA), and 1 µL cDNA was prepared and PCR condition was carried out as 
following (Table 2.10).  
 
Table 2.9 Primer lists of the total and exogenous DNMT isoforms. 
Genes Primer sequence 
Total DNMTs 
hDNMT1 Forward: 5’ AGGCGGCTCAAAGATTTGGA 3’ 
Reverse: 5’ GGGATTTGACTTTAGCCAGG 3’ 
hDNMT3A1 Forward: 5’ AGCGGTGACACGCCAAAGGA 3’ 
Reverse: 5’ CTTCAGGCAGGGTCTCAGCTG 3’ 
hDNMT3A2 Forward: 5’ AATGCTGTGGAAGAAAACCAG 3’ 
Reverse: 5’ ATCGCCTGCTTTGGTGGCAT 3’ 
hDNMT3B1-3B5 Forward: 5’ AAGACTCGATCCTCGTCAAC 3’ 
Reverse: 5’ ATGACTGGGGTGTCAGAGCC 3’ 
hDNMTΔ3B1- Δ3B2 Forward: 5’ TATCAGGATGGGAAGGAGTTT 3’ 
Reverse: 5’ CACCAGTTTGTCTGCAGAGA 3’ 
hDNMTΔ3B3- Δ3B4 Forward: 5’ TCTCTGCAGACAAACTGGTG 3’ 
Reverse: 5’ GCTGGTCCTCCAATGAGTC 3’ 
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hDNMT3L Forward: 5’ TGAGCTCTCAAGCTCCGTTT 3’ 
Reverse: 5’ GTAGGATTGGTACCCGTCAT 3’ 
Target genes (Exogenous DNMTs) 
Myc Forward: 5’ AGAAGCTGATCTCAGAGGAG 3’ 
Myc-DNMT1 Reverse: 5’ ATCGTCGGGCAGCGAGAT 3’ 
Myc-DNMT3A1 Reverse: 5’ CGCTCCGCAGCAGAGCT 3’ 
Myc-DNMT3A2 Reverse: 5’ ATCGTCGGGCAGCGAGAT 3’ 
Myc-DNMT3B1-3B5 Reverse: 5’ GTTGACGAGGATCGAGTCTT 3’ 
Myc-DNMTΔ3B1- Δ3B2 Reverse: 5’ CTTCCCATCCTGATACTCTG 3’ 
Myc-DNMTΔ3B3- Δ3B4 Reverse: 5’ TGCAGAGACCTGATACTCTG 3’ 
Myc-DNMT3L Reverse: 5’ CACTGGATCCCACCAAAATC 3’ 
 
 
Table 2.10 qPCR condition. 
Procedure Temperature Time Number of cycles 
PCR initial activation step 95 °C 15 minutes 1 
Denaturation  95 °C 15 seconds 
40 Annealing  (acquisition of fluorescence) 60 °C 30 seconds 
Extension 72 °C 30 seconds 
Melting curve step 72 - 95 °C 15 seconds 1 
 
Protein extraction 
The cell pellets were re-suspended in ice-cold Radioimmunoprecipitation assay (RIPA) buffer 
(1 mL per 100 mm dish) (Thermo Fisher Scientific, UK) and centrifuged at 13,000g for 20 
minutes in a 4 °C precooled centrifuge. A clear supernatant was transferred into a fresh 
centrifuge tube and kept on ice. 
 
Western blot using c-Myc antibody 
Protein concentration was established using a Biorad protein assay kit (BIORAD, USA). 
Standards were prepared from bovine serum albumin (BSA) prepared as 1 mg/mL stock 
solution in deionised water (DW). 5 μL of standards or samples were pipetted into microplate. 
Reagent A was mixed with reagent S and pipetted 25 μL per well into microplate. Reagent B, 
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then, was added into microplate by 195 μL per well and incubated at room temperature for 15 
minutes. Microplate was read for absorbance at 750 nm. Standard protein was plotted, and the 
unknown protein concentration of the samples was determined from the standard curve. 
To cast 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 2.4 mL 30% 
acrylamide, 2.4 mL 1.5M Tris, pH 8.8, 90 μL 10% SDS, 90 μL 10% ammonium persulfate, 
3.6 μL TEMED, and 4.6 mL DW were prepared, poured and left for 45 minutes at room 
temperature under DW until polymerisation was completed. The water was discarded, and the 
top of the gel washed with DW. A 5% PAGE (0.43 mL 30% acrylamide, 0.33 mL 1m Tris, 
pH 6.8, 26.5 μL 10% SDS, 26.5 μL 10% ammonium persulfate, 2.65 μL TEMED, and 1.4 mL 
DW) was prepared and poured into the resolving gel and a comb inserted and left for 30 
minutes at room temperature until polymerisation was completed. 25-70 μg of protein was 
mixed with 4x LaemmLi sample buffer to make 48 μL final volume. Each sample was boiled 
at 95 °C for 5 minutes and loaded into the gel. The gel was run at 150 volts for 1 hour. 
 Gel was placed in 1x transfer buffer for 10 minutes and blotting pads were soaked in 
1x transfer buffer. The membrane was soaked in methanol until no more bubbles were visible 
and washed in 1x transfer buffer. The transfer sandwich was assembled by gel and membrane 
in the middle of the sandwich without any bubbles and placed on the Trans-Blot SD semi-dry 
transfer cell and run at 17 volts for 1 hour. 
 Membrane was washed by DW and stained with Ponceau S solution for 5 minutes and 
washed by DW to check the transfer quality. Proteins were observed on the membrane. 
Membrane was washed by 1x PBS for 10 minutes, PBS-Tween (1x PBS mixed with 0.05% 
Tween 20) for 10 minutes, and the last with 1x PBS for 10 minutes. After that, the membrane 
blot was placed in 100 mL of blocking solution (5% non-fat dry milk) and incubated at room 
temperature for 1 hour with gentle shaking. Blocking solution was removed and added 
primary antibody, which was c-Myc antibody diluted (1:10000) in 5% milk and incubated at 4 
°C overnight with gentle shaking. The blot was washed in 1x PBS for 10 minutes, PBS-
Tween (1x PBS mixed with 0.05% Tween 20) for 10 minutes, and the last with 1x PBS for 10 
minutes. The second antibody, then, was added and incubated at room temperature for 1 hour 
with gentle shaking followed by washing. The chemiluminescent substrate (Bio-rad, USA) 
was applied to the blot and captured the chemiluminescent signals using a Fujifilm LAS4000 





2.2 DNA methylation microarray with DNMT overexpressing cells 
 
2.2.1 DNA extraction and the Illumina Methylation EPIC array 
Total and exogenous expression levels of DNMT isoforms were determined for all single cells 
from step 2.1.6. Each duplicated DNMT overexpressing cell was selected from the exogenous 
DNMT expression, which showed the similar levels of exogenous DNMT and DNA 
methylation levels were measured using Infinium Methylation EPIC arrays (Illumina, USA). 
Firstly, DNA was isolated from DNMT overexpressing cells using QIAamp® DNA 
mini and blood mini kit (QIAGEN, USA). Cells were harvested and the number of cells per 
sample was estimated (5 x 106 – 1 x 107 cells). 20 μL QIAGEN protease were added into a 
tube containing the cells. 200 μL AL were added to sample tube and mixed, then it was 
incubated at 56 °C for 10 minutes. 200 μL ethanol (100%) were added and mixed, then 
transferred to a QiAamp Mini Spin column with collection tube. The column was centrifuged 
at 6,000g for 1 minute and the eluate was discarded. 500 μL buffer AW1 were added into the 
column and centrifuged at 6,000g for 1 minute. Then, 500 μL buffer AW2 were added into 
the column and centrifuged at 13,000g for 3 minutes. The columns were transferred to new 
centrifuge tubes and the DNA was eluted by centrifuging at 13,000g for 1 minute with 50 μL 
of AE. DNA quantity and purity were assessed by Nanodrop1000. DNA was kept at -20 °C. 
Bisulphite converted DNA was hybridised to Infinium Methylation EPIC arrays 
(Illumina, USA) to measure DNA methylation in more than 850,000 CpG sites across the 
genome. All DNA methylation array processing was conducted at the Eurofins Genomics.  
 
2.2.2 Data analysis for Infinium Methylation EPIC data 
Unlike the Illumina Infinium Human Methylation27 BeadChip, in which only one probe type 
is measured, the Illumina Infinium Methylation EPIC BeadChip includes two probe types, 
Infinium I (n = 142,262) and Infinium II (n = 721,642) (269). EPIC microarray still contains 
93.3% of loci contained on the Illumina Infinium Human Methylation450 BeadChip (269). 
The direct output from Illumina iScan system is an IDAT file which contained BeadArray 






Figure 2.3 A framework of Illumina Methylation EPIC array data analysis. 
 
All IDAT files were imported and analysed in R studio using the Bioconductor 
package. The quality of data was evaluated by filtering out a high-detected p-value (p-value > 
0.01). Normalisation concern the removal of experimental artefact, technical and systematic 
variation, and random noise caused by microarray technology. PreprocessNoob was utilised 
for normalisation and 866,091 probes was left after this process. This step assesses and 
accounts for variation that is not caused by biological differences but by external variation. 
EPIC BeadChips use two fluorescent dyes that are linked to the nucleotides used in the single-
base extension step. A and T nucleotides are linked with a red dye (the red color channel), G 
and C nucleotides are linked with a green dye (green color channel). Uncorrected data usually 
feature higher intensities in the red color channel was called dye bias. For probes of Infinium 
type II design, which use separate color channels to measure the methylated and unmethylated 
signal, this results in a shifted distribution of β-values but probes of Infinium design type I are 
not affected, as they measure both signals in the same color channel. Dye-bias correction 
normalizes the red and green color channel. The 866,091 probes were adjusted for probe-type 
bias Infinium I (type I) and Infinium II (type II) (270). The cross-reactive probes (43,254 loci) 
were also removed from this data (271). Moreover, EPIC microarray contained 59 explicit 
SNP probes (“rs” probes) (272) and these probes were removed from the dataset. Finally, 
814,341 probes remained after quality control and filtering.  
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Bland Altman plot (install.Packages (“BlandAltmanLeh”)) was used to identify the 
mean difference between biologically duplicate samples. The 95% limits of agreement were 
calculated (mean ± 1.96 standard deviation) to select only those CpG sites showing high 
correlation of DNA methylation between biological duplicate samples. The ∆β was calculated 
by subtracting the DNA methylation levels at each CpG site in the cell over-expressing each 
DNMT isoform from the corresponding DNA methylation of the control cell (Myc cell). 
Hypo/hypermethylated probes were identified in each DNMT overexpressing cell. 
Differentially Methylated Positions (DMPs) were explored across DNMT isoform dataset. 
The cut-offs of ∆β were set at ∆β ≥ 0.4, or ≥ 0.3 or ≥ 0.2 and ∆β ≤ -0.4, or ≤ -0.3, or ≤ -0.2 
with FDR-adjusted p-value ≤ 0.05. FDR can be calculated by generating the empirical null 
distribution of test statistics, it is most commonly applied using the approach introduced by 
Benjamini and Hochberg. However, ∆β ≥ 0.4 and ≤ -0.4, and FDR-adjusted p-value ≤ 0.05 
were used to select the target CpG sites of each DNMT as these cut-offs were higher than 
usual cut-offs in coronary heart disease (273) and cancer study (274). DNA methylation 
patterns by genomic location and CpG density were examined in DNMT overexpressing 
dataset. All hypo/hypermethylation of DMPs were analysed using pathway analysis known as 
functional enrichment analysis by Ingenuity Pathway Analysis (IPA) (QIAGEN, USA) and 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.8 
(275). Canonical pathway analysis identified from IPA Knowledge Base that were most 
significant to the data set gene that met the FDR ≤ 0.001 and post hoc p-value < 0.001 cut-off 
and were correlated to a canonical pathway in IPA, was considered for the analysis. KEGG 
pathway was analysed using DAVID. 
 
2.3 Assessing specificity and sensitivity between dietary factors and DNMT isoform 
using in vitro model with measuring DNA methylation changes by pyrosequencing 
 
2.3.1 Cell viability and dietary compound dose selection 
Cells overexpressing each DNMT separately were seeded on opaque-walled multi-well plates, 
6 well plates, in culture medium (DMEM- high glucose (Sigma, UK) supplemented with 10% 
FBS (Sigma, UK), and 2 mM glutamine, at 37 °C in a 5% CO2 humidified atmosphere). 
Aqueous solution of vitamin C and dietary polyphenols (curcumin, theaflavin, CA, and 
EGCG) were prepared in several concentrations, i.e. 10, 25, 50, 100, and 200 µM. 
Cytotoxicity was measured using CellTiter- Glo® 2.0 assay (Promega, USA), according to 
manufacturers’ instruction. Briefly, 70,000 cells were subjected to selected concentration of 
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vitamin C, curcumin, theaflavin, CA, or EGCG and cells were incubated at 37 °C in a 5% 
CO2 humidified atmosphere for several incubation times, i.e. 12, 24, 48, and 72 hours. This 
reaction between cells and each concentration of compounds was equilibrated at room 
temperature for 30 minutes, then; a volume of CellTiter-Glo® Reagent was added equal to the 
volume of cell culture medium in each well. The plate was shaken to induce cell lysis and 
incubated at room temperature for 10 minutes to stabilise the luminescent signal. The plate 
was read, and luminescence was recorded. The half-maximal inhibitory concentration (IC50) 
was calculated for each compound. 
 
2.3.2 Treatment of cells, overexpressing specific DNMTs, with vitamin C and 
dietary polyphenols 
The optimum concentrations of each dietary compound were selected based on percentage of 
cell viability, which was higher than IC50: vitamin C (100 and 200 µM), curcumin (10 and 25 
µM), CA (100 and 200 µM), EGCG (50 and 100 µM), and theaflavin (80.5 and 161 µM). 
Cells overexpressing DNMTs were cultured with the specific concentration of each dietary 
compound for 48 hours at 37 °C in a 5% CO2 humidified atmosphere. 
 
2.3.3 Quantification of DNA methylation specific CpG sites by pyrosequencing     
                                    
2.3.3.1 DNA extraction and bisulphite conversion 
DNA was isolated using QIAamp® DNA mini and blood mini kit (QIAGEN, USA) described 
in 2.1.2. DNA samples were treated with bisulphite under alkaline conditions using the EZ 
DNA methylation-GoldTM kit (Zymo research, USA) which coverts unmethylated cytosine 
residues in DNA into uracil. 500 ng of DNA were prepared and the volume was adjusted to 
20 μL with nuclease-free water. 130 μL of CT conversion reagent solution were added into 
the DNA samples in PCR tube. The mixture was mixed and centrifuged briefly to ensure no 
droplets were in the cap or on the sides of the tube. The PCR tube was incubated in a 
thermocycler at 98 °C for 10 minutes, 64 °C for 2.5 hours, and 4 °C for storage up to 20 
hours. 600 μL of M-Binding buffer were added into a Zymo-spin IC column fitted with a 
collection tube. The bisulphite-treated samples were loaded into the Zymo-spin IC column 
containing M-Binding buffer, which was mixed by inverting the column several times 
following by centrifugation at 13,500g for 30 seconds. The flow-through was discarded. 100 
μL of M-Wash buffer were added into the column and the column was centrifuged at 13,500g 
for 30 seconds. 200 μL of M-Desulphonation buffer were added into the column and let stand 
47 
 
at room temperature for 15-20 minutes. After incubation, the column was centrifuged at 
13,500g for 30 seconds. 200 μL of M-Wash buffer were added into the column and the 
column was centrifuged at full speed for 30 seconds and this step was repeated once more. 
The column was placed into a 1.5 mL microcentrifuge tube and 20 μL of M-Elution buffer 
were added directly to the column matrix. The column was centrifuged at full speed for 30 
seconds to elute the DNA. 
 
2.3.3.2 Pyrosequencing 
PCR master mix was prepared as the following protocol (Table 2.11 and 2.12). All primers 
used in this experiment, were designed using MethPrimer and the original design was showed 
in Appendix C. 
 
Table 2.11 Volumes of the reagents for PCR. 
Reagent Volume per reaction 
2x GoTaq® Green Master Mix (Promega, UK)   12 µL 
Forward primer (10 μM) (Table 2.13) 1 µL 
Biotinylated reverse primer (10 μM) (Table 2.13) 
(This primer will be captured by streptavidin-sepharose beads) 
1 µL 
Nuclease-free water (QIAGEN, USA) 9 µL 
Bisulphite-treated DNA 1 µL 
Total  24 µL 
 
Table 2.12 PCR condition. 
Procedure Temperature Time Number of cycles 
Pre-denaturation 95 °C 10 minutes 1 
Denaturation  95 °C 40 seconds 
40 Annealing  56 °C 40 seconds 
Extension 72 °C 30 seconds 
Final extension 72 °C 5 minutes 1 




DNA methylation levels were quantified for all PCR products by pyrosequencing, 
which detects and calculates the percentage of methylation at individual CpG as a ratio of 
cytosine:thymine. 10 µL of PCR were mixed with 2 µL of streptavidin-sepharose beads, 40 
µL of 1x binding buffer, and 28 µL of water, in a PCR plate. The PCR plate was sealed with 
polyester PCR sealing (Starlab, UK) and shaken at room temperature at 1,400 rpm for 10 
minutes. 11.64 µL of annealing buffer was mixed with 10 μM sequencing primer into a white 
PSQ-HS plate (QIAGEN, USA). This plate was transferred to the vacuum prep station and the 
beads with PCR products were captured by slowly lowering the vacuum prep tool into the 
wells allowing the solution to flush through the probe tips for 10 seconds. The vacuum prep 
tool was transferred into 70% ethanol, denaturing solution, and wash buffer, then, the vacuum 
prep tool was disconnected from the station. The vacuum prep tool was placed into the PSQ-
HS plate to release the PCR products from the probe tips by gentle shaking the vacuum prep 
tool for 30 seconds. The PSQ-HS plate was sealed and placed on the 80 °C heat block for 2 
minutes and allowed it to cool at room temperature for 10 minutes. Pyrosequencing was 
performed by PyroMark Q96 MD (QIAGEN, USA). 
 
 
Table 2.13 Primer lists of potential CpG targets of DNMT3A2, DNMT3B4, DNMTΔ3B2, 






cg02732111 DNMT3A2 Forward:  
5’ TTGTTTAGGTTTATTATAGTTTG 3’ 
Reverse:  
biotin-5’ TCAATAACACATTTCAACAAATAC 3’ 
Sequencing:  
5’ TTGTTTAGGTTTATTATAGTTTG 3’ 
cg16204524 DNMT3A2 Forward:  
5’ ATTTTGTTATTAAGTGATGTATGATTGTAT 3’ 
Reverse:  
biotin-5’ ACCTCCTAAAATAAAATTTAAAAAC 3’ 
Sequencing:  
5’ ATTTTGTGAATTTTAAATT 3’ 
cg02788195 DNMT3B4 Forward:  
5’ GGTTATTGTAAAAATAGATTTAGTTAGATT 3’ 
Reverse: 
biotin-5’ AATCTCCTTCCCATTACCTTTTATTAA 3’ 
Sequencing:  
5’ AAGTTTTATTTAGTAGATA 3’ 
cg26286826 DNMT3B4 Forward:  
5’ TTTTTTAAAGTGTTGGGATTATAGG 3’ 
Reverse:  




5’ GGTTAGAGTATGAATTA 3’ 
cg25533247 DNMTΔ3B2 Forward:  
5’ AGAGATTTTGTAATAGTGTAGT 3’ 
Reverse:  
biotin-5’ ATACAACTCTATCATCTCTAAA 3’ 
Sequencing:  
5’ AGAGATTTTGTAATAGTGTAGT 3’ 
cg21808287 DNMTΔ3B2 Forward:  
5’ TTTTATGTTATGATTTTTTAATTTG 3’ 
Reverse:  
biotin-5’ CTAAAAACAACCCTTAAACTACA 3’ 
Sequencing:  
5’ TATATTTGTGAAATAAGGTGG 3’ 
cg20364776 DNMTΔ3B3 Forward: 
5’ TGAAAATTATTTTTATTTATAAGTTAGAA 3’ 
Reverse: 
biotin-5’ ACTTAAAAAAACACTTTCCCATCTC 3’ 
Sequencing:  
5’ TGAAAATTATTTTTATTTATAAGTTAGAA 3’ 
cg08927738 DNMTΔ3B3 Forward:  
5’ AGGTGGTGTTTTGAAGTTAGTAGATAGA 3’ 
Reverse:  
biotin-5’ CTTCCTAATATAAAACTACCCTCCCA 3’ 
Sequencing:  
5’ ATTATAAAATTTTATAGAA 3’ 
cg01065960 DNMT1 Forward:  
5’ AGGTTAGGTTTTTGGAAGGAG 3’ 
Reverse:  
biotin-5’ CCTCCTTTACAAACCCTCTAA 3’ 
Sequencing:  
5’ AGGTTAGGTTTTTGGAAGGAG 3’ 
cg20540357 DNMT3L Forward:  
5’ ATTGATTATTAGGATTATGTTTGG 3’ 
Reverse:  
biotin-5’ AAACCACCACCCACACTCAT 3’ 
Sequencing:  
5’ ATTGATTATTAGGATTATGTTTGG 3’ 
cg12150401 DNMT3L Forward:  
5’ TGGGTAGAGAATGGTTGTAAG 3’ 
Reverse: 
biotin-5’ CCCAAATAATTATTAAATTACAAAAT 3’ 
Sequencing:  







5’ TTTGTTTAGTGTTTTTAAGGGTTTT 3’ 
Reverse: 
biotin-5’ ACTATCTTATATCACCATTTCCCTC 3’ 
Sequencing:  
5’ GGTTTTGTTGTTATTTTTAT 3’ 








5’ TTTTTGAGTGATAATTTAAGAGAAGTAAGA 3’ 
Reverse:  
biotin-5’ ATAAACCAAAATCACACCACTACAC 3’ 
Sequencing:  
5’ TTTTTGAGTGATAATTTAAGAGAAGTAAGA 3’ 
 
 
2.4 DNMT activity/inhibitor assay 
 
2.4.1 Protein extraction 
Cells overexpressing DNMTΔ3B4 were cultured in 100 mm dish for 20 dishes until reaching 
80% confluence. Cells were lysed using Mammalian protein extraction reagent (M-PER) 
(Thermo Fisher Scientific, UK). Lysate was collected and transferred into a microcentrifuge 
tube. The lysate was then centrifuged at 14,000g for 10 minutes. The clear supernatant was 
transferred to a new tube and kept at -80 °C. 
 
2.4.2 Immunoprecipitation/Co-immunoprecipitation (IP/Co-IP) 
The exogenous DNMT protein tagged with c-Myc was isolated using Pierce c-Myc-Tag 
IP/Co-IP kit (Thermo Fisher Scientific, UK) according to manufacturers’ instruction. The 
bottom plug was placed on the Pierce Spin Column and 200 µL of protein lysate were added 
to the spin column. The anti-c-Myc agarose was thoroughly resuspended by inverting the vial 
several times immediately before dispensing. 10 µL of anti-c-Myc agarose slurry (5 µg anti-c-
Myc antibody) were dispensed into each labelled spin column using a wide-bore pipette tip. 
The vial mixture was incubated with gentle end-over-end mixing for overnight at 4 oC. A 
wash solution of Tris Buffered Saline plus 0.05% Tween 20 (TBS-T) was prepared. The top 
cap on the column was loosened and then the bottom plug was removed. A collection tube 
was put under the column and centrifuged for 10 seconds. The flow-through was discarded. 
0.5 mL of TBS-T was added to column and the cap was screwed following by gently 
inverting the column with collection tube 2-3 times. The column was centrifuged for 10 
seconds. The flow-through was discarded and this step was repeated 2 times. 500 µL of 1x 
conditioning buffer were added into column to wash the resin. The spin column was placed in 
the new collection tube and 10 µL of Elution buffer were added into the anti-c-Myc agarose 
with loose screwing on the cap and mixing. The column was centrifuged for 10 seconds and 




2.4.3 DNMT inhibition assay 
Inhibition of DNMTΔ3B4 was quantified using DNMT activity assay (Abcam, UK) 
according to manufacturers’ instruction. Briefly, the blank wells were prepared by adding 50 
µL of AdoMet working buffer per well. The positive control wells were prepared by adding 
50 µL of AdoMet working buffer and 1 µL of DNMT Enzyme Control per well. The sample 
wells without inhibitor were prepared by adding 45 µL of AdoMet working buffer and 5 µL 
of purified DNMT enzymes per well. The sample wells with CA were prepared by adding 40 
µL of AdoMet working buffer, 5 µL of purified DNMT enzyme, and 5 µL of inhibitor 
solution per well. The strip-well microplate was tightly covered with the adhesive covering 
film to avoid evaporation and incubated at 37 oC for 90 minutes. After incubation, the reaction 
solution was removed from each well and washed with 150 µL of 1x wash buffer each time; 
this process was repeated 3 times. 50 µL of the diluted capture antibody were added into each 
well, then the plate was covered with Parafilm M and incubated at room temperature for 1 
hour. The diluted capture antibody solution was removed from each well and 150 µL of the 
1x wash buffer solution were added to wash each well for 3 times. 50 µL of the diluted 
detection antibody were added to each well and the plate was covered with Parafilm M and 
incubated at room temperature for 30 minutes. The diluted detection antibody solution was 
removed from each well and 150 µL of the 1x wash buffer solution were added to wash each 
well 4 times. 50 µL of the diluted enhancer solution were added to each well and the plate 
was covered with Parafilm M and incubated for 30 minutes. The diluted enhancer solution 
was removed from each well. 150 µL of 1x wash buffer solution were added to wash each 
well for 5 times. 100 µL of developer solution were added to each well and incubated at room 
temperature for 10 minutes away from direct light. The developer solution then turned to blue 
colour in the presence of enough methylated DNA. 100 µL of stop solution were added to 
each well to stop enzyme reaction. The colour changed to yellow after adding the stop 
solution and the absorbance was read on a Thermo Scientific Muliskan GO microplate 
spectrophotometer (Thermo Fisher Scientific, UK) within 2 to 10 minutes at 450 nm with an 
optimal reference wavelength of 655 nm. 
 
2.5 Statistical analysis 
All statistical analyses were performed in IBM® SPSS statistical software programme 
(version 24) and R studio (version 1.1.442). Data were presented as mean ± standard 
deviation (SD) from three independent experiments for RT-PCR, cell viability, 
pyrosequencing, and DNMT inhibitory assay, and two biological duplicates for DMPs. A p-
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value ≤ 0.05 was considered statistically significant. Also, the p-values were adjusted for 
multiple hypothesis testing by the Benjamini-Hochberg method, with PFDR ≤ 0.05 considered 
significant. Paired-sample t-tests were used to identify DMPs. Two-sample Kolmogorov-
Smirnov test was used to identify significant changes of DNA methylation, global 
methylation and DNMT inhibition of selected cells overexpressing DNMTs after treatment 
with dietary constituents. Additionally, ANOVA test was applied to test the difference β 




3. Chapter 3: Generation of stable overexpressing DNMT cell lines 
 
3.1 Introduction 
DNMT1, DNMT3A, and DNMT3B are enzymatically active DNA methyltransferases, while 
DNMT3L is an enzymatically inactive regulatory factor (87). Additionally, DNMT1, 
DNMT3A, and DNMT3B are essential for survival, for example, knockout alleles of Dnmt1 
and Dnmt3b in mice leads to embryonic lethality (101, 276). Alternative splicing and/or 
promoter usage are the main factors for different isoforms of DNMT3A (84) and DNMT3B 
(85). More than 30 isoforms of DNMT3B were discovered in human and mouse cells (105-
107, 277) and some isoforms (DNMT3B3, DNMT3B4, and DNMT3B5) were found in cancer 
cells rather than normal cells (85, 106, 278). The structures of the most common DNMT 
isoforms are shown in Figure 1.6 (see Introduction section). DNMT1 is a multi-domain 
enzyme composed of a C-terminal catalytic domain and a N-terminal regulatory domain that 
consists of DNMT1-associated protein (DMAP) binding, replication foci, zing binding, and 
bromo-adjacent homology (BAH) (279, 280). DNMT3A consists of PWWP domain, ATRX-
DNMT3-DNMT3L (ADD) domain, and C-terminal catalytic domain but the DNMT3A2 
lacks of 200 amino acids at the N-terminal regulatory domain of DNMT3A1 (279, 280). 
DNMT3B also contains C-terminal catalytic domain and the N-terminal regulatory domain 
with alternative splicing in both domains (279). 
 In mouse cells, overexpression of Dnmt1 resulted in increased methylation of the 
imprinted regions of Insulin-like growth factor 2 and H19 and, more generally, genomic 
hypermethylation (281). DNMT1 overexpression occurs frequently in older cancer (breast and 
lung) patients with advanced clinical stages as well as unfavourable prognosis (282). 
DNMT3B overexpression also contributes to hypermethylation in breast cancer (283). 
Overexpression of DNMT3A and DNMT3B increased DNA methylation levels at CpG island 
and non-CpG islands, while overexpression of DNMT3B3, DNMT3B4, and DNMT3B5 did not 
change DNA methylation in those regions (87). In ApcMin/+ mice, overexpression of Dnmt3b1 
enhanced the number of colon tumours and increased the size of colonic microadenomas with 
loss of imprinting (284). Overexpression of the DNMT3B4 isoform is correlated with DNA 
hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis 
(285). DNA methylation of Long Interspersed Nuclear Element 1 (LINE-1) is increased by 
the overexpression of DNMT3B1, DNMT3B2, and DNMT∆3B isoforms, but not by 
overexpression of DNMT3A isoforms (87).  
Choi SH. et al. unveiled that the 13 most common DNMT isoforms have both 
specificity and overlap in their DNA methylation target profiles (87). They found that each 
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DNMT isoform changed methylation of a different number of CpG sites, and that DNMT3A1 
and DNMT3B1 showed the most distinct DNA methylation patterns. In contrast, DNMT3B3, 
DNMT3B4, and DNMT3B5 induced no methylation changes and these isoforms seemed to 
be inactive DNMTs. Furthermore, Choi SH. et al. (2011) found the specific target genes of 
DNMT3A1 were correlated with H3K4me3 modification, while the specific target genes of 
DNMT3B1 were correlated with H3K27me3 modification. However, their study investigated 
DNA methylation patterns in cells that over-expressed each DNMT isoform using the 
Illumina GoldenGate Methylation Cancer Panel I, which detects the DNA methylation of 
1,505 CpG sites only. Therefore, given that there are 28 million CpG sites in the human 
genome (286), the information available on target CpG sites of each DNMT isoform by using 
this technique is limited. High-throughput sequencing is a cutting-edge method that offers 
more extensive interrogation of methylation across the human genome. The Illumina Infinium 
Methylation EPIC BeadChip is the latest version of this array-based approach and measures 
methylation at more than 850,000 CpG sites. Use of such EPIC arrays allows investigation of 
more potential CpG sites that are targets of specific DNMT isoforms.  
The locus-specific methylation by individual DNMT isoforms is important 
information that might be applied to manipulate patterns of DNA methylation. This data can 
be applied to reveal the interaction of nutrients and individual DNMTs by measuring the 
DNA methylation changes on the locus-specific CpGs of each individual DNMT. Moreover, 
the locus-specific loci of DNMTs suggests a possibility of a mechanism of cancer or other 
diseases by which DNA methylation patterns are measured. From Choi’s study (87), EYA 
Transcriptional Coactivator And Phosphatase 4 (EYA4) and Homeobox A11 (HOXA11) were 
reported as the target genes of the DNMT3A1, and IGF2 Antisense RNA (IGF2AS) and 
Cadherin 11 (CDH11) were reported as the target genes of the DNMT3B1. Although, the 
aberration of DNA methylation patterns in each DNMT was revealed, the target sites of 
individual DNMT sub-isoforms are poorly understood.  
In the present study, I investigated the locus-specific target CpGs of each DNMT 
isoform by using molecular cloning to generate cell lines that over-expressed each of 
individual DNMT isoform. The efficacy of the overexpression was investigated by 








The hypotheses for this study were: 
1. The mRNA of DNMT isoform can be integrated into MEG-01 and HEK293T 
genomes using transient transfection or viral system. 




• To generate the stable transduced single-cell derived clonal lines in order to identify 
de novo DNA methylation target sites of specific DNMT isoforms. 
 
3.4 Objectives 
The objectives of this study were: 
1. To transport the mRNA of each of the DNMT isoforms into MEG-01 and 
HEK293T cells using transfection reagents and viral system. 
2. To select the cells that over-expressed each DNMT using a GFP marker. 
3. To generate single cell clones that over-expressed each DNMT isoform and to 
quantify expression of each specific DNMT in the selected clone at the mRNA and 
protein levels. 
 
3.5 Overview of the methods 
A detail description of the experimental procedures and methods for molecular cloning (2.1.3 
Plasmid construction for viral system, page 30), generating stable cell lines overexpressing 
individual DNMT isoforms (2.1.4 Viral production, page 36), quantifying exogenous mRNA 
and protein of each DNMT (2.1.7 Confirmation the positive cells by qPCR and western blot 
assays, page 37) can be found in the Method chapters.  
 In brief, DNMT-pIRES puro3 plasmids were retransformed and extracted from E.coli 
DH5α cells (see section 2.1.2 in Methods section, page 29). All plasmids were sub-cloned into 
the pLenti7.3/V5 DEST gateway vector with modifying at multiple cloning sites (see section 
2.1.3 in Methods section, page 30). DNMT-pIRES puro3 plasmids were transported into 
MEG-01 cells using transfection reagents. Lentivirus was produced using the modified 
pLenti7.3/V5 DEST gateway vector (see section 2.1.4 in Methods section, page 36). This 
virus incorporated the specific DNMT into MEG-01 and HEK293T genomes. GFP and Myc-
tag were identified as a marker for the successful transfection or transduction. Positive cell 
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lines, which overexpress each of the DNMTs individually, were detected using fluorescent 
microscopy and sorted using FACS (see section 2.1.5 (page 37) and 2.1.6 (page 37) in 
Methods section). Single clone of each DNMT was generated by a single cell after cell 
sorting. Expression of the DNMT isoform was quantified at the mRNA level using qPCR and 
at the protein level using western blotting in all GFP positive cells (see section 2.1.7 in 




3.6.1 Molecular cloning of DNMT isoforms 
3.6.1.1 Retransformation and confirmation of DNMT sequences  
All 14 DNMT-pIRES puro3 plasmids containing DNMT3A1, DNMT3A2, DNMT3B1, 
DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, 
DNMTΔ3B4, DNMT3L, DNMT1, or Myc sequence only (control), were re-transformed into 
E.coli DH5α. These plasmids were extracted from the bacteria clones grown on an ampicillin 
selective agar. To confirm the sequence of each isoform, these plasmids were sent to MRC 
PPU DNA Sequencing and Services at Dundee University. All sequences were aligned with 
the relevant DNA sequence templates from the commercial vectors for each DNMT isoform 
using the DNASTAR Lasergene bioinformatics software. Example results are shown in 




Figure 3.1 Sequence analysis and alignment analysis. A) The sequence of DNMT3A1 from 
Sanger sequencing and B) the alignment among DNMT3B1, DNMT3B2, and Myc; majority 
is a method to sum the weights of a base in DNA sequences, yellow highlights represent 
100% similar sequences with majority, number indicates the number of base pair. 
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3.6.1.2 Sub-clone DNMT isoform into virus system 
pLenti7.3V5-DEST was modified to add the restriction sites for NheI, ClaI, EcoRI, SwaI, and 
PspOMI. pLenti7.3V5-DEST was cut by XbaI and MluI, and the digest was run on gel 
electrophoresis. Three bands from original plasmid (sizes: 61bp, 1,781bp, and 7,788 bp) were 
separated on the gel and the largest band was extracted from the gel to be used as new 
backbone (Figure 3.2). 
 
Figure 3.2 pLenti7.3/V5-DEST backbone after being cut by XbaI and MluI. Three bands (61, 
1781, and 7,788 bp) were separated on the gel electrophoresis (four replicate samples). 
 
The pLenti7.3V5-DEST backbone was ligated with oligonucleotides containing the 
new restriction sites (NheI, ClaI, EcoRI, SwaI, and PspOMI). Plasmids were extracted from 
bacteria grown on an ampicillin selective agar. For screening for positive clones, these 
plasmids were cut by EcoRI and KpnI, which resulted in three bands on the gel 
electrophoresis (sizes: 647, 1,093, and 6,086 bp), whereas the negative plasmid was cut into 






Figure 3.3 Screening new backbone of pLenti7.3/V5-DEST with new restriction sites by 
restriction enzymes; EcoRI and KpnI. Lane 1 and 2 showed positive clones (there were three 
bands: 674, 1,093, and 6,086 bp). Lane 3 and 4 showed negative clones. 
 
The modified pLenti7.3/V5-DEST (positive clone) bacteria were grown and plasmids 
were extracted using the E.Z.N.A.® Endo-free Plasmid DNA Mini KitII. These plasmids were 
cut by NheI and PspOMI, which produce compatible cohesive ends with NotI, to make a new 
backbone. After running on the gel electrophoresis, there was only one band on the gel 
(Figure 3.4A). All pIRESpuro3-DNMTs were also cut by NheI and NotI to generate the sticky 
ends of DNMT sequences. Each of the different inserts gave a different size on the gel 
electrophoresis and these were separated completely from the starting plasmid (pIRESpuro3) 
(Figure 3.4B) apart from DNMT1 which could not be separated from the backbone. DNMT1 
was repeated and run on a low percentage (0.7%) gel electrophoresis. Although, there were 
non-specific bands, this showed that the DNMT1 product was separated into three bands 
(Figure 3.4C). Both backbone and target inserts were cut from the gel and DNA were purified 




Figure 3.4 Gel electrophoresis for backbone plasmid and target inserts. A) the single band of 
the modified pLenti7.3/V5-DEST was linearised by NheI and PspOMI (5 replicate samples), 
B) the insert targets of each DNMT isoform were cut by NheI and NotI (3 replicate samples); 
1-14 represent DNMT∆3B4, DNMT3B3, DNMT∆3B3, DNMT3A1, DNMT1, Myc, 
DNMT3L, DNMT3B5, DNMT3A2, DNMT3B2, DNMT3B4, DNMT∆3B2, DNMT3B1, and 
DNMT∆3B1, respectively and, C) DNMT1 band was run on a low percentage (0.7%) gel 
electrophoresis (four replicate samples). 
 
After ligation and incubation, the bacteria were screened by colony PCR to select the 
positive clones containing each target DNMT and Myc sequence. The PCR product was 
amplified using CMV forward primer and Myc reverse primer; the sizes of PCR product were 







Figure 3.5 Gel electrophoresis of PCR products from colony PCR. Lanes 1, 4, 7 showed the 
negative clone, while lanes 2, 3, 5, 6, 8 showed the positive clone. 
 
All positive plasmids were then sent to MRC PPU DNA Sequencing and Services at 
Dundee University to confirm the sequences. All sequences had been analysed and aligned 
with DNA sequence templates for each DNMT isoform using the DNASTAR Lasergene 




Figure 3.6 Sequence alignment. A) The sequence of DNMT3A1 from Sanger sequencing and 
B) the alignment between DNMT3A2 and commercial pcDNA-DNMT3A2; majority is a 
method to sum the weights of a base in DNA sequences, yellow highlights represent 100% 
similar sequences with majority, number indicates the number of base pair. 
 
3.6.1.3. Optimising transfection conditions between transient transfection 
and a virus system 
Firstly, MEG-01 cells were transfected with GFP plasmids using a range of transfection 
reagents; Hiperfect, GeneCellin, Lipofectamine2000, and Lipofectamine3000. After 48 hours, 
the GFP fluorescence was observed and recorded by photography (Figure 3.7). This showed 
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that both doses Lipofectamin2000 were effective in transferring the plasmids into the MEG-
01 cells, while Dharmafect, Hiperfect, GeneCellin, and Lipofectamine3000 were not effective 
when used for this transfection due to toxicity. 
 
 
Figure 3.7 Green fluorescent protein signal of transfected MEG-01 cells. MEG-01 cells were 
transfected with different transfection reagents: Dharmafect, Hiperfect, GeneCellin, 







 For the viral system, lentivirus with target DNMTs and GFP were applied to MEG-01 
cells for 24 hours with or without 5 µg/mL Hexadimethrine bromide (polybrene), which can 
enhance the efficiency of infection. The GFP signal was determined using inverted Leica 
Dmi8 wide field fluorescent microscopy. The MEG-01 cells’ morphology was normal, 
showing a round shape with a clearly defined (healthy) cell membrane (Figure 3.8A). This 
cell was incubated for 10 and 17 days with/without polybrene, and which the GFP signal was 
captured and compared with the non-transduced MEG-01 cells (Figure 3.8B). 
 
 
Figure 3.8 Cell morphology and green fluorescent protein (GFP) signal after MEG-01 cell 
transduction with a lentivirus system for 48 hours, 7 days, and 10 days. A) MEG-01 cell 
morphology after transduction with/without 5 µg/mL polybrene for 48 hours and B) the bright 
field (BF) and GFP channel images of transduced MEG-01 cells after 48 hours, 7 days, and 
10 days with/without 5 µg/mL polybrene compared with non-transduced MEG-01 cell. 
 
3.6.2 Using transient transfection to generate cell lines that over-expressed each 
DNMT isoform separately 
MEG-01 cells were transiently transfected with pIRESpuro3 contained individually DNMT 
sequences and c-Myc: DNMT3A1, DNMT3A2, DNMT∆3B1, and DNMT∆3B2. 
Lipofectamine2000 was used to transfer these plasmids into the MEG-01 cells. After 
transfection, cells were selected using puromycin treatment. However, there were a large 
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proportion of dead cells after puromycin treatment so the plan for generating cell lines that 
overexpress each of the DNMTs individually was changed to that using the virus system. 
 
3.6.3 Using lentiviral system to generate cell lines that over-expressed each 
DNMT isoform separately 
MEG-01 and HEK239T cells were transduced using lentivirus for 48 hours and images of 
GFP expression in the cells were captured using fluorescent microscopy. There was a few 
positive GFP cells in transduced MEG-01 cells (Figure 3.9) compared with HEK293T cells 
(Figure 3.10).  
 
 
Figure 3.9 Bright field (BF) and green fluorescent protein (GFP) signals from cells 




Figure 3.10 Bright field (BF) and green fluorescent protein (GFP) signals from cells 
overexpressing DNMTs in HEK293T cells after 48 hours transduction. 
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Transduced MEG-01 and HEK293T cells were grown for 17 days and then sorted 
using FACS, which selected for the positive GFP cells (Figure 3.11). Cells with a high GFP 
signal were sorted into a 96-well plate adding a single cell per well for HEK293T cells and 
into a flask adding a mix population for MEG-01 cells.     
 
 
Figure 3.11 Scatter plots of green fluorescent protein (GFP) signal from transduced cells. A) 
non-transduced cells (negative cells) and B) positive-GFP cells; blue colour represents non-
GFP cells or low GFP signal, pink colour represents high GFP signal. 
 
 Each single cell of DNMT-overexpressing HEK293T cells was cultured for 14 days, 
then the morphology of the cells and the number of live cells was observed. In 96-well plate 
of each DNMT cell, there were 7 clones for DNMT3A1, 8 clones for DNMT3A2, 14 clones 
for DNMT3B1, 14 clones for DNMT3B2, 29 clones for DNMT3B3, 31 clones for 
DNMT3B4, 22 clones for DNMT3B5, 10 clones for DNMT∆3B1, 11 clones for 
DNMT∆3B2, 15 clones for DNMT∆3B3, 40 clones for DNMT∆3B4, 31 clones for 
DNMT3L, 21 clones for DNMT1, and 30 clones for Myc. The example of morphology of 
stably transduced single cell-derived clonal lines was showed in Figure 3.12. 
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Figure 3.12 Morphology of single cell colonies from overexpression of DNMT∆3B4 in 
HEK293T cells in four different wells of 96-well plate. 
 
 After expansion of single cell clones, overexpression of the DNMTs in MEG-01 and 
HEK293T cells was confirmed by GFP signal. Mixed cell population of the DNMT-
overexpressing MEG-01 cells showed GFP signal (Figure 3.13). In addition, the stably 
transduced single cell-derived clonal lines of DNMT-overexpressing HEK293 cells showed 





Figure 3.13 Bright field (BF) and green fluorescent protein (GFP) signals from DNMT-




Figure 3.14 Bright field (BF) and green fluorescent protein (GFP) signals from DNMT-






Use of the InvitrogenTM TaliTM Image-based Cytometer showed that all DNMT-
overexpressing HEK293T cells were 100% GFP positive (Table 3.1).  
 
Table 3.1 Numbers of green fluorescent protein (GFP) and non-GFP cells in the clones 









Live cells Dead cells 




DNMT3A2 7.75x106 ± 7.23x102 0 7.75x106 ± 7.23x102 0 
DNMT3B1 1.16x107 ± 5.34x103 0 1.16x107 ± 5.34x103 0 








DNMT3B4 1.13x107 ± 4.76x103 0 1.13x107 ± 4.76x103 0 
DNMT3B5 8.49x106 ± 5.67x102 0 8.49x106 ± 5.67x102 0 




DNMT∆3B2 1.5x107 ± 7.23x103 0 1.5x107 ± 7.23x103 0 




DNMT∆3B4 1.35x107 ± 7.21x103 0 1.35x107 ± 7.21x103 0 
DNMT1 1.01x107 ± 7.42x103 0 1.01x107 ± 7.42x103 0 
DNMT3L 1.32x107 ± 2.34x103 0 1.32x107 ± 2.34x103 0 
















3.6.4 Confirmation of total and exogenous DNMTs expression at the RNA levels 
in the overexpressing cells 
To confirm the expression of exogenous DNMTs and understand the endogenous levels of 
DNMTs in overexpressing cells, RNA was extracted from all cell lines that overexpress each 
of the DNMTs individually for measurement of total and exogenous DNMTs. Firstly, 
expression of eleven housekeeping (HK) genes (ACTB, GUBS, RPL13A, RPS13, TFRC, 
HPRT1, 18sRNA, B2M, GAPDH, PPIA, and RPLP10) was determined to find the most stable 
HK genes for each experimental setting to be used for normalisation of gene expression based 
on geNorm analysis (see Methods section 2.1.7). The PCR products of HK genes for MEG-01 
cells were run on the 1% gel electrophoresis (Figure 3.15). The HK genes 18sRNA and 
RPL13A for MEG-01 cells, and PPIA and GAPDH for HEK293T cells were used in further 
quantification of DNMT expression at the RNA level. 
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Figure 3.15 PCR products of housekeeping genes and green fluorescent protein (GFP). Actin 
Beta (ACTB), Glucuronidase Beta (GUSB), Ribosomal Protein L13A (RPL13A), Ribosomal 
Protein S13 (RPS13), Transferrin Receptor (TFRC), Hypoxanthine Phosphoribosyltransferase 
1 (HPRT1), 18sRNA, Beta-2-Microglobulin (B2M), Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH), Peptidylprolyl Isomerase A (PPIA), Ribosomal Protein Lateral 
Stalk Subunit P0 (RPLP0). 
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Total DNMT (endo + exogenous) and exogenous DNMT expression were measured in 
all cell lines that over-expressed each of the DNMTs individual ly including the Myc-
expressing control cell. The total expression of DNMT was analysed using the specific primer 
pairs to DNMT3A1, DNMT3A2, DNMT3B (captured DNMT3B1, DNMT3B2, DNMT3B3, 
DNMT3B4, and DNMT3B5), DNMT∆3B1-2 (captured DNMT∆3B1 and DNMT∆3B2), 
DNMT∆3B3-4 (captured DNMT∆3B3 and DNMT∆3B4), DNMT1, and DNMT3L. Each set of 
primers was designed to amplify unique mRNA transcripts avoiding non-specific target from 
other DNMT isoforms. Exogenous expression of DNMTs was analysed using the Myc primer 
as the forward primer and the DNMT isoform specific primers as the reverse primer. There 
was a signal of exogenous DNMTs in each DNMT cell but not in the Myc control cell. The 
total expression (endo + exogenous) of DNMT∆3B1, DNMT∆3B2, and DNMT1 was lower 
than the endogenous expression in the MEG-01 cells (Figure 3.16), whereas, total expression 
of DNMT3A2 in HEK293T cells showed low amount compared with a basal expression in 
Myc control cell (Figure 3.17). However, other total expressions of DNMTs expressed higher 
than endogenous DNMTs of Myc control cell (Figure 3.17). As expected, DNMT3L was 
expressed in both transgenic MEG-01 and HEK293T cells as this isoform did not express in 




Figure 3.16 Total DNMT expression in the mixed cell population of overexpressing-DNMT 
MEG-01 cells. The relative expression of each DNMT isoform was compared between 
overexpressing-DNMT MEG-01 cells and Myc control cell. Error bars represent standard 




Figure 3.17 Total DNMT expression in the mixed cell population of overexpressing-DNMT 
HEK293T cells. The relative expression of each DNMT isoform was compared between 
overexpressing-DNMT HEK293T cells and Myc control cell. Error bars represent standard 
deviation from triplicates and * represents p-value ≤ 0.05 compared with Myc cell. 
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3.6.5 Confirmation of the expression of DNMT isoforms at the protein levels in 
the DNMT-overexpressing MEG-01 and HEK293T cells 
In order to confirm the protein expression of DNMT isoform in overexpressing cells, the 
exogenous protein expression of each DNMT were measured in both MEG-01 and HEK293T 
cells using the c-Myc antibody. It was difficult to detect the expression of any DNMT 
proteins in MEG-01 cells even if the input of protein concentration was increased (data not 
availablen). However, except for DNMT∆3B3 (where the protein was not detected), 
expression of the other DNMT proteins was detected in DNMT-overexpressing HEK293T 
cells. HEK293T cells transfected stably with DNMT3L expressed relatively large amounts of 
DNMT3L (Figure 3.18A). DNMT3B2 and DNMT1, DNMT3A1, DNMT3B4, DNMT3B5, 
DNMT∆3B2, DNMT∆3B4 proteins were expressed at relatively low levels, while 
DNMT∆3B3 protein expressed very low levels (Figure 3.18B-D). 
 
 
Figure 3.18 Expression of DNMT isoforms at the protein levels in DNMT-overexpressing 
HEK293T cells. A) DNMT3L protein (25 µg of total protein) in DNMT3L cells compared 
with Myc control cell; B) DNMT3B1 (50 µg of total protein), DNMT3B2 (70 µg of total 
protein), DNMT3B3 (50 µg of total protein), and DNMT1 proteins (50 µg of total protein); C) 
DNMT3A1 (50 µg of total protein), DNMT3A2 (50 µg of total protein), DNMT3B4 (50 µg 
of total protein), and DNMT3B5 proteins (50 µg of total protein); and D) DNMT∆3B1 (70 µg 
of total protein), DNMT∆3B2 (70 µg of total protein), DNMT∆3B3 (70 µg of total protein), 






3.7.1 Main findings 
The chosen viral system was an effective approach for creating cell lines that over-expressed 
each of the DNMT isoforms in MEG-01 and HEK293T cells. However, single clones of cells 
that over-expressed each of the DNMT isoforms were generated successfully only for the 
HEK293T cells. Each of these clones expressed the specific exogenous DNMT isoform at 
both RNA and protein levels. 
 
3.7.2 Overexpression of DNMT isoforms in MEG-01 cells 
MEG-01 cells, which can be differentiated to platelets that play a critical role in diseases such 
as cardiovascular disease (287), were over-expressed individually DNMT isoforms using both 
transient transfection and viral system. Using transient transfection of pIRESpuro3 contained 
individually DNMT sequences was unsuccessful to generate the stable transgenic cells 
overexpressing DNMTs in MEG-01 cells because transfected MEG-01 cells no longer 
expressed the puromycin resistance gene leading to the large number of dead cells mixing 
with a few live cells. Also, it was difficult to harvest the positive cells containing target 
DNMTs from this mixed population, as MEG-01 cells being suspension cells, dead and live 
cells were not separated. However, the transduction of DNMTs into MEG-01 cells was 
successful using lentivirus. Lentivirus depends on an active transport of the viral pre-
integration complex into the cell nucleus through the nucleopore (288). This ability allows 
lentiviruses to infect both non-dividing and diving cells.  
The exogenous DNMTs expression was lower than endogenous in the transduced 
MEG-01 cells, especially DNMTΔ3B1, DNMTΔ3B2, and DNMT1 possibly due to polyclones. 
Polyclones would include the major cell population of transgenic cells expressed those 
DNMTs at low levels. Furthermore, the number of GFP-positive cells was lower than that of 
HEK293T cells. This shows the low efficiency of transduction system in MEG-01 cells. 
Burstein’s study (289) revealed that approximately 62% of megakaryocytes were positive 
after retroviral transduction. The reason of the low percentage of cell transduction may be 
caused from the doubling time which is 36-48 hours in MEG-01 cells. This long doubling 
time might affect the virus transduction leading to low expression of DNMTs. Although the 
exogenous expression of each DNMT in MEG-01 cells was detected, the protein expressions 
of each DNMT were very low or could not be detected even if the input of amount of total 
protein was increased. Therefore, for further work, I focussed on the DNMT-overexpressing 
79 
 
HEK293T cells and used these cell lines for investigation of 1) DNA methylation patterns and 
2) interactions between selected food constituents and DNMTs, on DNA methylation at target 
CpG sites and on activity of the DNMT enzyme. 
 
3.7.3 Overexpression of DNMT isoforms in HEK293T cells 
This study is the first to generate the stable single clones of 13 DNMT isoforms in HEK293T 
cells using an easily handled system with high transduction efficiency. This approach 
diminishes cell line heterogeneity and improves product yield of gene expression (290). The 
expression of GFP was detected in all single clone cells and this confirmed that the 
transferring of exogenous genes was successful in HEK293T cells using lentiviral system. All 
target cells grown and GFP signal was re-measured after cell expanding by fluorescent 
microscopy and image-based cytometer. Also, the expression of the exogenous DNMTs in 
HEK293T cells was detected using Myc primer to capture the exogenous sequences. 
However, it is important to note that the basal endogenous expression of each DNMT isoform 
had different levels in Myc control cell (Figure 3.19). For DNMT3A2, exogenous DNMT3A2 
was detected in cells overexpressing DNMT3A2 but the basal expression of endogenous 
DNMT3A2 was higher. As shown in the Figure 3.19, the expression of DNMT3A2, also highly 
expressed in Myc control cell compared to other DNMT isoforms.  
 
 
Figure 3.19 The basal endogenous expression of DNMTs. The gene expression of DNMT3A1, 
DNMT3A2, DNMT3B1-DNMT3B5, DNMT∆3B1-DNMT∆3B2, DNMT∆3B3-DNMT∆3B4, 







































Due to random integration within the HEK293T genome following the use of the 
lentivirus system, the protein products of exogenous DNMTs were expressed at different 
levels. This finding was in concordance with results from Torres R. et al. (291) indicating that 
random and site-specific integration showed a difference GFP copy number. It was noted that 
the mRNA expression of DNMT3A2 was lower than endogenous level in HEK293T cells, but 
the protein of this isoform was highly expressed. Also, the mRNA expression of DNMT∆3B3 
was higher than endogenous level but the protein expression could not be detected. It is likely 
that the correlation of these proteins and mRNA was poor, possibly reflecting differential 
stabilities of protein. Also, posttranslational modification delayed protein synthesis leading to 
reduction of the correlation between RNA and protein expressions (292). The concordance 
between RNA and protein levels was found to have a correlation coefficient of approximately 
0.3 (293). This correlation was in the line with Edfors F. et al. (294) showing correlation 
coefficient of 0.39 in HEK293 cells.  
Furthermore, a false positive GFP clone cell was found after sorting by FACS as GFP 
expression could not be detected in this cell by qPCR. Accurate sorting of mixed cell 
populations is challenging due to noise from the overlapping target and background signals. 
This problem can be overcome by re-sorting. However, this study sorted single clones of 
positive GFP cells in 96 well plates and selected five clones to check the GFP in both mRNA 
and protein expression. By doing this, only positive GFP cells were selected and further 
expanded for DNA methylation measurement. 
 
3.8 Conclusion 
Cell lines that over-expressed each of 13 DNMT isoforms were successfully generated from 
both MEG-01 (generated mix cell population) and HEK293T cells (generated single cell 
clone) using lentiviral system. These cell models can be expanded and grown normally with 
stable DNMT expression. However, DNMT-overexpressing HEK293T cells were further 
investigated instead of MEG-01 cells due to low exogenous expression of both mRNA and 








Epigenome-wide association studies (EWAS) assess DNA methylation and such studies have 
become a powerful approach to elucidate association between epigenetic variations and 
biological traits. With the rapid development of high-throughput microarray, the Illumina 
HumanMethylation450 BeadChip (450K) is the high-throughput method for characterisation 
of DNA methylation and this chip measures DNA methylation of more than 450,000 CpG 
sites throughout the human genome. However, it was replaced with the Illumina 
HumanMethylationEPIC BeadChip (EPIC), which measures DNA methylation at more than 
850,000 CpG sites and covers 90% of the CpG sites of the 450K chip (295). This new chip is 
non-bias whole epigenome-wide approach and this chip contains new probes targeting gene, 
intergenetic and non-CpG island regions, covering distal regulatory elements (271). 
Therefore, this EPIC array can be used to screen the DNA methylation on CpG target sites of 
DNMTs. Additionally, this new chip requires a low quantity of DNA and it is cost effective. 
Mammals express five different families of DNMTs with a number of subfamilies 
with each protein sharing similar structural features (see introductory section 1.4). Although 
the catalytic sites of each DNMT are similar, the amino acid residues in these areas are 
different and this may determine the preferential target CpG sites of each DNMT. Also, the 
way of entering the DNA major groove for CpG recognition of DNMT1 and DNMT3A was 
different, despite the conformation similarity in their catalytic loop (296). Moreover, the 
catalytic activity of DNMT3B was not required for the induced methylation in DNMT3B-
deficient cell lines (277). 
Choi SH. et.al (87) showed the preferential CpG target of each DNMT subfamily. The 
de novo DNA methylation target sites of DNMTs were identified using the Illumina 
GoldenGate Methylation Cancer Panel I, which contains 1,505 CpG sites from 808 cancer-
related genes (87). The clustering analysis of 514 CpGs induced by any DNMT isoforms 
showed that the DNA methylation patterns induced by DNMTs were clustered according to 
the structural similarity of the DNMT variants, for example, DNMT3A1 and DNMT3A2, 
DNMT3B1 and DNMT3B2, DNMTΔ3B1 and DNMTΔ3B2, and DNMTΔ3B3 and 
DNMTΔ3B4 (87). In another study from Duymich C.E. et al., the target sites of DNMT3B 
isoforms on a genome-wide level and their function in DNMT3B-deficient cells (3BKO and 
DKO8 derivatives of the HCT116 colon cancer cell line), were identified using the 450K chip 
(277). They found DNMT3L restored DNA methylation patterns in DNMT3B-deficient cells 
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and DNMT3L showed the strongest overall induction of DNA methylation compared with the 
DNMT3Bs (277). However, none of these studies mentioned the specific DMPs of each 
DNMT isoform. Moreover, the partners of DNMTs were studied to reveal the factor of 
DNMT recruitment on DNA, but no study describing the underlying mechanism for any 
specific isoforms has yet been published. For example, SP1 complex recruits DNMT1 to 
target on the promoter of Slit Guidance Ligand 2 to maintain DNA methylation inheritance 
(297). DNMT3A and DNMT3B cooperate with oncoprotein EV1 to methylate the miRNA-
124-3 promoter leading to the repression of this gene (298). Preferable sequences for 
DNMT1, DNMT3A, and DNMT3B were predicted respectively (A/G/T)(T/G/A)(T/A/C) 
CG(T/G/A)(C/A/T)(A/T/C), (T/A/C)(A/T)(T/G/A)CG(T/G/C)G(G/C/A), and 
(A/C)(C/G/A)(A/G)CGT(C/G)(A/G) (123). 
Therefore, this study focused on the DNA methylation patterns and de novo target 
DMPs of the DNMTs individually by EPIC array to allow the interrogation of methylation 
patterns at genome-wide and site-specific methylation from the stable transduced single-cell 
derived clonal lines. 
  
4.2 Hypotheses 
The hypotheses for this study were; 
1. The pattern of DNA methylation in cells that overexpress individual DNMT isoforms 
is altered by the structure of each DNMT isoform. 
2. Despite the conformational similarity in the catalytic site of DNMTs, each DNMT 
isoform targets different CpG sites across the human genome. 
3. The DNA methylation changes in cells that overexpress each DNMT are involved in 
biological pathway associated with diseases. 
 
4.3 Aims 
The aims of this study were: 
• To test the above hypotheses by quantifying 1) the DNA methylation patterns of each 
DNMT, 2) the DMPs of the preferential target sites of each DNMT using EPIC array 
and 3) the implication of target DMPs of each DNMT isoform to determine a possible 
mechanism pathway involved in diseases by pathway analysis. 
 
4.4 Objectives 
The objectives of this study were: 
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1. Using EPIC arrays, to determine the DNA methylation patterns of cell lines that 
overexpress each of the DNMTs individually. 
2. To quantify the methylation levels of each DMP and to select the DMPs that are 
specific for each DNMT isoform. 
3. To analyse the implication of differential methylation of the target DMPs of each 
individual DNMT isoform using pathway analysis to investigate potential associations 
with disease. 
 
4.5 Overview of the methods 
A detailed description of the experimental procedures and methods for quantifying DNA 
methylation levels of cell lines that overexpress each of the DNMTs individually can be found 
in the Methods chapters (2.2 DNA methylation microarray with DNMT overexpressing cells, 
page 43). 
In brief, DNA was extracted from cell lines that overexpress each of the DNMTs 
individually (see section 2.2.1 in Methods section, page 43). After DNA was extracted, all 
DNA samples were measured for the concentration and purity using Nanodrop and all 
samples were sent to Eurofins Genomics, Germany, to perform EPIC array. Statistical 
analysis and data analysis for EPIC data were performed using R studio (R version 3.6.0) with 
the Bioconductor package (see section 2.2.2 in Methods section, page 43). The ∆β values 
were set the cut-offs at Δβ ≤ -0.2 and Δβ ≥ 0.2, Δβ ≤ -0.3 and Δβ ≥ 0.3, and Δβ ≤ -0.4 and Δβ 
≥ 0.4 with FDR adjusted p-value ≤ 0.05. DNMT over expressing dataset was explored in 
order to determine the DNA methylation patterns and CpG target sites of DNMTs. Moreover, 




4.6.1 Selection of duplicate cell clones for each overexpressing DNMT cell 
To select biological duplicates of each overexpressing DNMT cell for EPIC array analysis, 
five cell clones of each overexpressing DNMT cell were measured the levels of exogenous 
DNMTs by qPCR. Two clones were selected with the similar levels of exogenous DNMT, 
individually (Figure 4.1): clone 2 and 5 for DNMT3A1, clone 2 and 5 for DNMT3A2, clone 
number 1 and 5 for DNMT3B1, clone number 2 and 3 for DNMT3B2, clone number 1 and 5 
for DNMT3B3, clone number 3 and 4 for DNMT3B4, clone number 4 and 5 for DNMT3B5, 
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clone number 4 and 5 for DNMTΔ3B1, clone number 4 and 5 for DNMTΔ3B2, clone number 
1 and 3 for DNMTΔ3B3, clone number 2 and 5 for DNMTΔ3B4, clone number 1 and 2 for 
DNMT3L, and clone number 2 and 5 for DNMT1. 
 
 
Figure 4.1 Exogenous expression of individual DNMTs in overexpressing DNMT cells. 
 
4.6.2 Data quality checking and preprocessing 
To normalise data and check the quality of EPIC datasets, all datasets from cell lines 
overexpressing individual DNMT isoforms were analysed in R studio using the Bioconductor 
package. After normalisation using the ssNoob method, β values of Infinitum I and II probes 
were adjusted and the probe biases were removed (Figure 4.2). The β values expressed the 





Figure 4.2 β density of all 14 datasets. The distributions of β value from the Infinium I 
(yellow lines) and II (purple lines) probes were showed before (left graph) and after (right 
graph) applying the ssNoob normalisation method. 
 
After filtering a high detected p-value (p-value ≤ 0.05), normalising, adjusting probe-
type bias, and removing rs probes, 814,341 probes remained. Bland Altman analysis was 
performed to illustrate the similarity, and differences, between duplicate biological samples 
and the 95% limits of agreement (mean ± 1.96SD) were calculated (Figure 4.3). Probes that 
had a difference value greater than 95% limits of agreement, were filtered out (approximately 
6.8% of 814,341 probes) (Table 4.1). Therefore, only high correlation probes were selected 
from duplicates of each DNMT cell and Myc cell to get reliable results. Among these probes, 
those of each over-expressed DNMT cell that were found in common with Myc cell were 




Figure 4.3 Bland Altman plots of each DNMT cell. The scatter plots showed the distribution 
of mean β values and the difference of DNA methylation levels from each biological 






Table 4.1 The number of remaining probes after filtering. The probes were selected by mean 
± 1.96SD and then those of each over-expressed DNMT cell that were found in common with 
Myc cell were selected. 
DNMT isoforms 
The number of the 
remaining probes after 
selecting by mean ± 1.96SD 
The number of the remaining 
probes that were found in 
common with Myc cell 
DNMT3A1 755,841 719,204 
DNMT3A2 759,760 721,122 
DNMT3B1 759,105 722,459 
DNMT3B2 758,044 721,013 
DNMT3B3 759,484 721,685 
DNMT3B4 758,196 721,175 
DNMT3B5 758,100 720,891 
DNMTΔ3B1 756,788 719,958 
DNMTΔ3B2 761,685 723,441 
DNMTΔ3B3 758,191 720,896 
DNMTΔ3B4 760,585 722,149 
DNMT3L 763,014 725,148 
DNMT1 761,073 723,090 
 
DNA methylation changes were analysed by subtracting the β value for each CpG in 
the Myc control from the β value for the corresponding CpG site in each individual DNMT 
dataset. The methylation changes of each DNMT isoform were indicated in the volcano plots 








Figure 4.4 Volcano plots of each DNMT isoform. Volcano plots demonstrated the distribution 
of the DNA methylation changes (Δβ; DNMTs - Myc control) with -log10 (p-value) of 




Three different cut-offs: Δβ ≤ -0.2 and Δβ ≥ 0.2, Δβ ≤ -0.3 and Δβ ≥ 0.3, and Δβ ≤ -0.4 
and Δβ ≥ 0.4 with FDR adjusted p-value ≤ 0.05, were set to observe the significant loci of 
each DNMT (Table 4.2). Narrowing the cut-offs did not significantly change the ranking of 
DNMTs by number of loci; DNMT3A2 and DNMTΔ3B4. Also, the distribution of significant 
loci by genomic region was not significantly different among the cut-offs (Figure 4.5-4.7). 
The significant probes were significantly annotated at the gene body and TSS1500 (p-value ≤ 
0.05) in DNMT cells; the significant probes in DNMT3L and DNMTΔ3B2 were annotated at 
the gene body (p-value ≤ 0.05), and the significant probes in DNMT3A1, DNMT3A2, 
DNMT3B1, DNMT3B4, DNMT3B5, DNMTΔ3B1, DNMTΔ3B3, DNMTΔ3B4, and DNMT1 
were annotated at TSS1500 (p-value ≤ 0.05). 
 
Table 4.2 The number of significant loci of each DNMT after using three different cut-offs: 
Δβ ≤ -0.2 and Δβ ≥ 0.2, Δβ ≤ -0.3 and Δβ ≥ 0.3, and Δβ ≤ -0.4 and Δβ ≥ 0.4 with FDR 
adjusted p-value ≤ 0.05. 
DNMT isoforms Δβ ≤ -0.2 and 
Δβ ≥ 0.2 
Δβ ≤ -0.3 and 
Δβ ≥ 0.3 
Δβ ≤ -0.4 and 
Δβ ≥ 0.4 
DNMT1 2,576 896 272 
DNMT3L 4,433 1,517 404 
DNMT3A1 2,149 702 199 
DNMT3A2 6,612 2,874 983 
DNMT3B1 2,564 825 226 
DNMT3B2 2,380 722 189 
DNMT3B3 2,211 700 178 
DNMT3B4 4,430 1,625 495 
DNMT3B5 2,251 783 202 
DNMTΔ3B1 2,682 909 247 
DNMTΔ3B2 4,459 1,913 719 
DNMTΔ3B3 4,775 1,749 536 






Figure 4.5 Mean Δβ DNA methylation pattern (setting cut-of at Δβ ≤ -0.2 and Δβ ≥ 0.2) by 
genomic location of cells overexpressing DNMTs: 3’UTR: 3’ untranslated region, TSS1500: 
transcription start site 1500, TSS200: transcription start site 200, 1stExon: the first exon, 





Figure 4.6 Mean Δβ DNA methylation pattern (setting cut-of at Δβ ≤ -0.3 and Δβ ≥ 0.3) by 
genomic location of cells overexpressing DNMTs: 3’UTR: 3’ untranslated region, TSS1500: 
transcription start site 1500, TSS200: transcription start site 200, 1stExon: the first exon, 





Figure 4.7 Mean Δβ DNA methylation pattern (setting cut-of at Δβ ≤ -0.4 and Δβ ≥ 0.4) by 
genomic location of cells overexpressing DNMTs: 3’UTR: 3’ untranslated region, TSS1500: 
transcription start site 1500, TSS200: transcription start site 200, 1stExon: the first exon, 




CpG sites that showed Δβ ≤ -0.4 and Δβ ≥ 0.4 were retained for further analysis and 
the distribution of those CpGs is shown as volcano plots with the number of hyper- and hypo- 
methylated loci (Figure 4.5). The expected methylation increase was observed for the 
majority of DNMT isoforms, where hypermethylated probes were in higher number than 
hypomethylated ones. However, DNMT3A1, DNMT3B3, and DNMT3B5 showed lower 







Figure 4.8 Volcano plots of each DNMT isoform. Volcano plots demonstrated the distribution 
of the methylation change (Δβ ≤ -0.4 and Δβ ≥ 0.4) with -log10 (p-value) of significant loci 
(p-value ≤ 0.05) in cell lines over-expressing individual DNMT isoforms. The number of 




4.6.3 The effect of over-expressed DNMTs on the DNA methylation pattern 
PCA was performed using β values for all probes to visualise methylation pattern differences 
by DNMT isoforms (Figure 4.9). PC1 explained 16.04% of the variance between samples 
while 9.8% of the variance was explained by PC2. There was no noticeable clustering pattern 
by DNMT isoforms (Figure 4.9A) but the β values of duplicate samples were not significantly 






Figure 4.9 Principal component analysis (PCA). PCA was performed using β values from all 
probes passed the quality control for all overexpressing DNMT cells. A) colour dots indicate 
individual DNMT isoforms B) multicolour dots indicate individual DNMT isoforms with 




To explore the DNA methylation patterns in cell lines that overexpress each of the 
DNMTs individually, a two-dimensional unsupervised hierarchical cluster analysis of all 
hyper/hypo-methylated loci (after selecting from cut-offs, Δβ ≤ -0.4 and Δβ ≥ 0.4), compared 
with Myc control, was conducted. The majority of DNA methylation patterns of DNMTs did 
not depended on the structurally similar DNMTs, but there were two clustering induced by 
structurally similar DNMTs: 1) DNMTΔ3B4 and DNMTΔ3B2, 2) DNMT3B2 and 
DNMT3B3 (Figure 4.5). The DNA methylation patterns of DNMT3A2, DNMTΔ3B4 and 
DNMTΔ3B2, presented more hypermethylated patterns than other isoforms. The DNA 
methylation patterns of DNMT3B3 appeared to be hypomethylated pattern. The smallest 
isoform missing catalytic domains on C terminus, DNMT3L, shown a unique pattern and it 





Figure 4.10 Heatmap of DNA methylation data with 3,544 CpG sites (after selecting from 
cut-offs, Δβ ≤ -0.4 and Δβ ≥ 0.4 in cell lines over-expressing individual DNMT isoforms). 
CpGs were selected as they were targeted by at least one DNMT isoform. Myc was a control. 





To observe a clear hypermethylation patterns by DNMTs, a two-dimensional 
unsupervised hierarchical cluster analysis using only hypermethylated probes (2,833 loci) of 
each isoform was computed. The DNA methylation patterns of DNMT3B5, DNMT3A1, 
DNMT3B2, and DNMT3B3 were correlated with Myc control (Figure 4.6). DNMT3A2, 
DNMTΔ3B4 and DNMTΔ3B2 showed the hypermethylation patterns as the same as in Figure 
4.5. DNMT1 and DNMTΔ3B3 were grouped together and were clustered with DNMT3L. 
 
 
Figure 4.11 Heatmap of DNA methylation data with 2,833 CpG sites (Δβ ≥ 0.4). CpGs were 
selected as they were targeted by at least one DNMT isoform. Myc was a control. Red colour 
represents high methylation β values and blue indicates low methylation β values. 
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4.6.4 De novo target CpG sites of each DNMT isoform 
Significant (FDR-adjusted p-value ≤ 0.05) CpG sites with ∆β ≥ 0.4 were identified in each 
DNMT isoform. Although there is a similarity of catalytic sites among DNMT isoforms, 
unique target CpGs of each isoform were identified (Figure 4.7). 23.2% of the 
hypermethylated probes of DNMT3A1 overlapped with the hypermethylated probes of 
DNMT3A2: this was 2.5% when it was calculated from the total of hypermethylated probes 
of DNMT3A2. 27% of the hypermethylated probes of DNM3B1, 30.5% of the 
hypermethylated probes of DNM3B2, 41.7% of the hypermethylated probes of DNM3B3, 
25% of the hypermethylated probes of DNM3B4, and 27.8% of the hypermethylated probes 
of DNM3B5 were overlapped with other DNMT3Bs. The percentage of the hypermethylated 
probes of DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4 overlapping among 
DNMTΔ3Bs was 42%, 25.5%, 37.5%, and 31.7%, respectively. Top five of de novo 
hypermethylated probes with gene name of each DNMT isoform were showed in the Table 






Figure 4.12 Venn diagrams of specific and overlapping target CpG sites of cell lines over-expressing individual DNMT isoforms. The number of 
target hypermethylated probes for each DNMT family; DNMT3A, DNMT3B, and DNMTΔ3B, overlapping with target CpG sites within those 
DNMT families is depicted.
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Table 4.3 Top five hypermethylated loci of each DNMT isoform. 
DNMT 
isoforms  
CpG  Chromosome  
Relation to 
CpG island  
β DNA methylation  ∆β  
Gene name 





cg21534766 chr21 OpenSea 0.64 0.24 0.41 NCAM2 
cg06041732 chr18 OpenSea 0.78 0.13 0.65 LINC00907 
cg17001806 chr8 OpenSea 0.82 0.40 0.42 - 
cg08969304 chr10 CpG Island 0.67 0.24 0.43 - 





cg02732111 chr4 OpenSea 0.77 0.21 0.56 - 
cg15930380 chr1 South Shelf 0.63 0.16 0.47 MIER1 
cg16204524 chr2 North Shelf 0.61 0.20 0.42 GPR113 
cg07018561 chr3 South Shore 0.65 0.12 0.52 ENTPD3-
AS1 





cg09102332 chr7 OpenSea 0.62 0.22 0.40 - 
cg01529359 chr8 OpenSea 0.52 0.08 0.44 - 
cg23967739 chr12 OpenSea 0.61 0.19 0.43 A2ML1 
cg23491841 chr2 North Shelf 0.55 0.10 0.44 C2orf85 





cg18425254 chr13 CpG Island 0.67 0.15 0.52 - 
cg01986486 chr3 OpenSea 0.55 0.07 0.47 C3orf67 
cg02286819 chr1 OpenSea 0.52 0.09 0.43 - 
cg17764572 chr10 CpG Island 0.68 0.27 0.41 - 




cg06580033 chr17 South Shore 0.64 0.10 0.54 ZNF830; 
CCT6B 
cg12173487 chr16 OpenSea 0.63 0.20 0.43 CPNE2 
cg22354874 chr5 OpenSea 0.87 0.45 0.42 - 





cg26286826 chr18 OpenSea 0.54 0.12 0.42 - 
cg08954783 chr2 OpenSea 0.60 0.13 0.47 - 
cg24424219 chr15 OpenSea 0.57 0.14 0.43 - 
cg10483660 chr13 South Shelf 0.66 0.11 0.55 - 


































cg15923359 chr8 OpenSea 0.79 0.27 0.52 CSGALCT1 
cg11439662 chr8 OpenSea 0.74 0.32 0.42 - 
cg13081981 chr4 OpenSea 0.62 0.12 0.50 - 
cg20268758 chr15 North Shelf 0.68 0.25 0.43 FAM189A1 






cg26763380 chr8 OpenSea 0.73 0.30 0.43 EIF3E 
cg16318688 chr1 OpenSea 0.64 0.19 0.45 EPHX4 
cg13054800 chr4 OpenSea 0.50 0.07 0.44 - 
cg03894789 chr5 OpenSea 0.71 0.27 0.44 
MIR874; 
KLHL3 





cg01910804 chr14 North Shore 0.48 0.08 0.40 TTC6 
cg10617796 chr5 OpenSea 0.54 0.12 0.42 EDIL3 
cg21808287 chr2 OpenSea 0.58 0.12 0.45 TNP1 
cg04502126 chr4 OpenSea 0.67 0.21 0.46 LINC01258 





cg08927738 chr20 OpenSea 0.60 0.18 0.42 BCAS1 
cg04751120 chr8 OpenSea 0.68 0.27 0.40 RP1L1 
cg03883300 chr8 OpenSea 0.56 0.15 0.41 - 
cg20364776 chr4 OpenSea 0.80 0.36 0.44 EEF1AL7 





cg26295057 chr5 CpG Island 0.55 0.12 0.43 GDNF 
cg22976313 chr14 North Shore 0.77 0.36 0.41 TMEM179 
cg07504154 chr4 OpenSea 0.53 0.10 0.42 ASB5 
cg04220501 chr14 OpenSea 0.53 0.09 0.44 - 





cg07383415 chr2 OpenSea 0.79 0.34 0.44 FAM49A 
cg12150401 chr7 OpenSea 0.74 0.33 0.41 TAS2R16 
cg20540357 chr5 OpenSea 0.69 0.19 0.50 PPP2R2B 
cg16796997 chr7 OpenSea 0.71 0.17 0.54 - 





cg06877649 chr8 OpenSea 0.71 0.20 0.51 - 
cg20943641 chr12 South Shore 0.47 0.07 0.40 CCDC53 
cg09559735 chr22 OpenSea 0.49 0.05 0.43 - 
cg21298915 chr4 OpenSea 0.64 0.21 0.43 - 
cg26096646 chr12 OpenSea 0.64 0.22 0.42 - 
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 All hypermethylated loci of each DNMT isoform were explored the DNA methylation 
levels by CpG density (Figure 4.8). The majority of the hypermethylated probes was 
annotated at CpG Island and Opensea (p-value ≤ 0.05) in DNMT cells. Also, the 
hypermethylated probes after overexpression of DNMT3A2, DNMT3B4, DNMT∆3B4, and 
DNMT3L were significantly annotated at North shore and South Shore (p-value ≤ 0.05). Only 
the hypermethylated probes after overexpression of DNMT∆3B2 was significantly annotated 





Figure 4.13 Mean Δβ DNA methylation pattern by CpG density of cells overexpressing 
DNMTs. N_shelf: North Shelf, N_shore: North Shore, Island: CpG island, S_shore: South 






4.6.5 The implication of target DMPs of each DNMT isoform using pathway 
analysis 
To investigate possible links with mechanisms underlying human diseases, the target DMPs 
(significantly hyper- and hypomethylated probes) were performed in DAVID (for data after 
setting cut-off at Δβ ≤ -0.2 and Δβ ≥ 0.2) and IPA (for data after setting cut-off at Δβ ≤ -0.4 
and Δβ ≥ 0.4. DAVID was used to highlighted pathway members within the biochemical 
pathways provided by KEGG. The p-value and the Benjamini-Hochberg FDR were used to 
determine significant of enrichment or overrepresentation of terms for each annotation in 
DAVID. Canonical pathway analysis identified the top pathways from IPA knowledge Base 
and Fischer’s exact test was used to calculate a p-value determining the probability of the 
association between the significant loci and canonical pathway. The top enriched categories 
of KEGG pathway and canonical pathways with a p-value ≤ 0.05 were listed in Table 4.4 and 
4.5, respectively.  
 For KEGG pathway in Table 4.3, the significant probes after overexpression of 
DNMT3A1, DNMT3B3, DNMT3B4, DNMTΔ3B1, and DNMTΔ3B3, were associated with 
neuroactive ligand-receptor interaction. The significant loci in DNMT3A2, DNMTΔ3B4, and 
DNMT3L cells were correlated with focal adhesion. Calcium signalling was associated with 
the target DMPs of DNMT3A1, DNMT3B1, and DNMT3B3. PI3K-Akt signalling was 
enriched in DNMT3B3, DNMTΔ3B4, and DNMT3L. Ascorbate and aldarate metabolism 
were correlated with the target DMPs of DNMT3B4 and DNMTΔ3B3. The target DMPs of 
DNMTΔ3B1 and DNMTΔ3B4 were associated with axon guidance. The significant loci in 
DNMT3B3, DNMT3B5, DNMTΔ3B3, and DNMT3L were correlated with glutamatergic 
synapse. Chondroitin sulfate biosynthesis was enriched in the target DMPs of DNMT3A1 and 
DNMT1. 
For canonical pathway in Table 4.5, the significant probes after overexpression of 
DNMT3B2, DNMT3B3, and DNMTΔ3B1, were associated with Synaptogenesis signalling 
pathway. The significant probes in DNMTΔ3B3 and DNMT3B3 cells were correlated with 
CREB signalling in neurons and glutamate receptor signalling. IL-15 production was enriched 
in the target DMPs of DNMT3A2 and DNMT3L. Citrulline-nitric oxide cycle was associated 
with the target DMPs of DNMT3B1 and DNMT3L. GP6 signalling pathway was enriched in 
DNMTΔ3B2 and DNMTΔ3B4. GPCR-mediated integration of enteroendocrine signalling 
exemplified by an L cell was correlated with the target DMPs of DNMT3B2 and DNMT1. 
The target DMPs of DNMTΔ3B1 and DNMT1 involved in Renin-angiotensin signalling. The 
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significantly target probes of DNMT3A2, DNMTΔ3B2, and DNMT3L were associated with 
sperm motility.  
 
Table 4.4  List of top KEGG pathways of each DNMT isoform. 
DNMT 





Cell adhesion molecules 0.016 0.230 
Neuroactive ligand-receptor interaction 0.019 0.140 
Calcium signalling 0.068 0.310 
Chondroitin sulfate biosynthesis 0.077 0.270 
NOD-like receptor signalling 0.690 0.900 
DNMT3A2 
Focal adhesion 0.00000052 0.000096 
Regulation of actin cytoskeleton 0.00000120 0.000110 
Adherens junction 0.00002300 0.001300 
Neurotrophin signalling 0.00012000 0.005300 
Tight junction 0.00013000 0.004800 
DNMT3B1 
Calcium signalling 0.00000700 0.001800 
Insulin secretion 0.00003800 0.005 
Circadian entrainment 0.00004900 0.004300 
Rap1 signalling 0.00015000 0.009500 
Pentose and glucoronate interconversions 0.00028000 0.012 
DNMT3B2 
Protein digestion and absorption 0.00035000 0.088 
Mucin type O-glycan biosynthesis  0.00140000 0.160 
Rap1 signalling 0.00160000 0.130 
Regulation of actin cytoskeleton 0.00340000 0.200 
Ras signalling 0.004 0.190 
DNMT3B3 
Calcium signalling  0.00004600 0.012 
ECM-receptor interaction 0.00014000 0.017 
PI3K-Akt signalling 0.00020000 0.017 
Neuroactive ligand-receptor interaction 0.00050000 0.032 
Glutamatergic synapse 0.00075000 0.038 
DNMT3B4 
Pentose and glucoronate interconversions 0.00000360 0.000930 
Ascorbate and aldarate metabolism 0.00001300 0.003600 
Steroid hormone biosynthesis 0.00014000 0.018 
Drug metabolism-cytochrome P450 0.00015000 0.013 









Table 4.5 (continue) List of top KEGG pathways of each DNMT isoform. 
DNMT 





Focal adhesion 0.0001100 0.029 
Oestrogen signalling 0.0025000 0.280 
Amyotrophic lateral sclerosis 0.0028000 0.220 
Glutamatergic synapse 0.0036000 0.210 
Regulation of actin cytoskeleton 0.0041000 0.200 
DNMT∆3B1 
Neuroactive ligand-receptor interaction 0.0000370 0.00620 
Axon guidance 0.0002800 0.073 
Morphine addiction 0.0003100 0.026 
Hippo signalling 0.0003800 0.050 
Wnt signalling 0.0008200 0.070 
DNMTΔ3B2 
Phosphatidylinositol signalling  0.0000270 0.00640 
Cholinergic synapse 0.0004100 0.048 
Rap1 signalling 0.0004100 0.035 
Retrograde endocannabinoid signalling 0.0004500 0.032 
Salivary secretion  0.0005400 0.130 
DNMT∆3B3 
ECM-receptor interaction  0.0000020 0.00049 
Neuroactive ligand-receptor interaction 0.0001700 0.044 
Ascorbate and aldarate metabolism  0.0002300 0.029 
Glutamatergic synapse 0.0003900 0.032 
Dopaminergic synapse 0.0004500 0.028 
DNMT∆3B4 
Focal adhesion 0.0000050 0.00130 
Ras signalling  0.0000110 0.00150 
Proteoglycans in cancer 0.0000380 0.00960 
Axon guidance  0.0000440 0.00560 
PI3K-Akt signalling 0.0004100 0.051 
DNMT3L 
Focal adhesion 0.0000400 0.010 
ECM-receptor interaction 0.0000540 0.007 
Amoebiasis 0.0007300 0.018 
PI3K-Akt signalling 0.0009500 0.120 
Glutamatergic synapse 0.0015000 0.120 
DNMT1 
MAPK signalling 0.009 0.770 
Dilated cardiomyopathy 0.026 0.880 
Chondroitin sulfate biosynthesis 0.028 0.790 
ECM-receptor interaction 0.036 0.780 
Pancreatic cancer 0.039 0.730 
Genes were categorised to KEGG pathways from gene enrichment analysis was used to 
calculate p-value and Benjamini-Hochberg FDR determining the probability of the association 






Table 4.5 List of top canonical pathways of each DNMT isoform. 
DNMT 
isoforms Top Canonical pathways p-value 
DNMT3A1 
LXR/RXR activation  0.003 
IL-10 signalling 0.005 
RhoGDI signalling 0.011 
Circadian rhythm signalling  0.011 
GABA receptor signalling  0.011 
DNMT3A2 
Sperm motility  0.003 
PTEN signalling 0.006 
Myo-inositol biosynthesis  0.009 
IL-15 production 0.010 
SAPK/JNK signalling 0.012 
DNMT3B1 
Superpathway of citrulline metabolism  0.004 
Lipoate biosynthesis and incorporation II  0.013 
Serotonin and melatonin biosynthesis  0.025 
Citrulline-nitric oxide cycle 0.032 
Urea cycle 0.038 
DNMT3B2 
PFKFB4 signalling pathway 0.001 
GPCR-mediated integration of enteroendocrine 
signalling exemplified by an L cell 0.005 
Trehalose degradation II (Trehalase) 0.015 
Synaptogenesis signalling pathway  0.018 
Adenine and adenosine salvage III 0.025 
DNMT3B3 
Chondroitin sulfate biosynthesis  0.002 
Dermatan sulfate biosynthesis  0.002 
Glutamate receptor signalling 0.002 
CREB signalling in neurons 0.002 
Synaptogenesis signalling pathway  0.003 
DNMT3B4 
GDP-glucose biosynthesis  0.002 
Glucose and glucose-1-phosphate degradation 0.003 
UDP-N-acetyl-D-galactosamine biosynthesis II 0.005 
PFKFB4 signalling pathway 0.020 












Table 4.5 (continue) List of top canonical pathways of each DNMT isoform. 
DNMT 
isoforms Top Canonical pathways p-value 
DNMT3B5 
HER-2 signalling in breast cancer 0.001 
ErbB signalling 0.014 
iCOS-iCOSL signalling in T helper cells 0.017 
Triacylglycerol degradation 0.018 
Chronic myeloid leukaemia signalling 0.019 
DNMT∆3B1 
FGF signalling  0.003 
RANK signalling in osteoclasts 0.004 
Synaptogenesis signalling pathway  0.007 
Endocannabinoid developing neuron pathway 0.010 
Renin-angiotensin signalling 0.010 
DNMTΔ3B2 
T helper cell differentiation <0.001 
Calcium signalling <0.001 
Cellular effects of sildenafil (Viagra) 0.001 
GP6 signalling pathway 0.002 
Sperm motility  0.004 
DNMT∆3B3 
Netrin signalling  <0.001 
Amyotrophic lateral sclerosis signalling  <0.001 
Glutamate receptor signalling  0.009 
CREB signalling in neurons  0.001 
Opioid signalling pathway  0.005 
DNMT∆3B4 
p53 signalling  <0.001 
Amyotrophic lateral sclerosis signalling <0.001 
Human embryonic stem cell pluripotency  0.001 
GP6 signalling pathway 0.001 
Leukocyte extravasation signalling 0.001 
DNMT3L 
Citrulline-nitric oxide cycle 0.001 
Sperm motility  0.004 
Neuroinflammation signalling pathway 0.005 
IL-15 production 0.005 
Dopamine receptor signalling  0.005 
DNMT1 
EGF signalling 0.008 
Rac signalling 0.008 
Renin-angiotensin signalling  0.010 
ERK/MAPK signalling 0.012 
GPCR-mediated integration of enteroendocrine 
Signalling exemplified by an L cell 0.015 
Genes were categorised to canonical pathways from IPA knowledge Base and Fischer’s exact 
test was used to calculate a p-value determining the probability of the association between the 







 DNA methylation of the protocadherin genes was explored as loss of methylation at 
the protocadherin gamma gene cluster particularly affects the A and B class variable genes 
(97). Overexpression of DNMTs increased DNA methylation levels of probes located on 
PCDHG (Figure 4.14). However, there are some probes showed low methylation after 
overexpression of DNMTs, i.e. cg16541259, cg 16626420, cg23347399, cg00118365, 
cg00888801, cg07802710, cg21185686, cg27639030, and cg12145907. 
 
 
Figure 4.14 DNA methylation levels of PCDHG by overexpressing DNMT cells. The 
significant probes of PCDHG were represented in green colour (low methylation compared 








In addition to pathway analysis, differentially methylated loci were also categorised to 
related diseases. Similar as the results from canonical pathway analysis, disease with a p-
value ≤ 0.05 were listed in Table 4.6. Most DNMTs were associated with cancer and 
organismal injury and abnormalities. Hereditary disorder and metabolic disorder were 
associated only with DNMT3B1. Also, only DNMT3B3, DNMT3B4, DNMT3B5, 
DNMTΔ3B1, and DNMTΔ3B4 were associated with CVD, psychological disorders, 
inflammatory response, infectious diseases, and hepatic system disease, respectively. 
However, these markers could not be specifically linked. 
 
Table 4.6 List of top diseases of each DNMT isoform. 
Red boxes represent the significant diseases at p-value ≤ 0.05 and white boxes are not 
analysed. Genes were categorised to related disease from IPA knowledge Base and Fischer’s 
exact test was used to calculate a p-value determining the probability of the association 





Diseases 3A1 3A2 3B1 3B2 3B3 3B4 3B5 ∆3B1 ∆3B2 ∆3B3 ∆3B4 DNMT1 3L 
Cancer                           
Organismal injury and 
abnormalities                           
Reproductive system 
disease                            
Gastrointestinal disease                           
Auditory disease                           
Endocrine system disorders                           
Hereditary disorder                           
Metabolic disease                            
Dermatological disease and 
conditions                           
Respiratory disease                            
Cardiovascular disease                            
Neurological disease                           
Psychological disorders                           
Inflammatory response                           
Immunological disease                           
Connective injury and 
abnormalities                           
Infectious Diseases                            





4.7.1 Main findings 
Investigation of the de novo targets of DNMT isoforms revealed that DNMT isoforms that are 
over-expressed in HEK293T cells can influence DNA methylation with increased methylation 
and decreased methylation at different CpG sites. Although there was some overlap in the 
target DMPs within DNMT families (e.g. DNMT3A, DNMT3B, and DNMTΔ3B), the 
majority of the hypermethylated probes was unique to individual DNMTs. This suggests that 
a splicing variance of DNMTs results in different target sites of each DNMT. 
Hypermethylation level changes were lower than 0.7, indicating this was a limitation of 
increase methylation by DNMTs. Moreover, the profiling of de novo DNA methylation target 
CpG sites for each DNMT isoform was revealed and annotated to potential biological 
pathways and diseases. 
 
4.7.2 De novo DNA methylation target DMPs of DNMT isoforms 
Nowadays, the activity of DNMT1, DNMT3A, and DNMT3B can be measured using a 
commercial kit but it cannot measure specific sub-isoforms of DNMTs due to the close 
similarity of the structure of each DNMT sub-family. In this study, 13 different DNMT cell 
lines were created and these cells were used to explore the DNA methylation patterns 
including identifying the de novo methylation sites. Also, the use of EPIC array can enable 
the identification of de novo DNA methylation target sites of DNMT isoforms. 
This study is the first one to identify the de novo methylation sites using biological 
duplicates from single clonal cells. In contrast, a previous publication investigated the over-
expressed DNMTs from a mixed cell population (87). Over 850,000 CpGs were measured for 
DNA methylation levels in this study and the cut-offs of ∆β value were set at three different 
values: Δβ ≤ -0.2 and Δβ ≥ 0.2, Δβ ≤ -0.3 and Δβ ≥ 0.3, and Δβ ≤ -0.4 and Δβ ≥ 0.4. However, 
there was no significant different of the distribution of significant loci along with genomic 
regions among three cut-offs. Additionally, 1,505 loci from the Illumina GoldenGate 
Methylation Cancer Panel I were explored in this study in order to compare the DNA 
methylation levels with the previous study. However, only 436 probes out of 1,505 probes 
passed the quality check and more than 95% of these probes showed -0.4 < ∆β < 0.4. Also, 
the top loci, which were found in the previous study, did not show significant changes in this 
study. This is due to the fact that the data analysis including normalisation and filtering in this 
study, was more robust with statistic analysis.  
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Generally, DNA was hypermethylated in cells that over-expressed each individual 
DNMT. In this study, hypermethylated probes of each DNMT isoform were significantly 
located on CpG island and Opensea areas where low methylation levels are, suggesting that 
these areas were sensitive to induce DNA methylation. Additionally, the significant loci of 
both hyper and hypomethylated probes were enriched in gene body and TSS1500 areas where 
may block the initiation of transcription (299, 300) and also may be more important for 
controlling gene splicing (300) and control of developmental timing of expression (301).  
Obviously, there is no difference in the DNMT isoforms after PCA analysis from the 
whole loci, which passed the quality control and filtering. However, after selecting only the 
significant loci using cut-offs at Δβ ≤ -0.4 and Δβ ≥ 0.4, the results of clustering analysis 
revealed that DNMT3A2, DNMT∆3B2, and DNMT∆3B4 contributed to DNA 
hypermethylation and were clustered in the same group. This suggests that there is a 
specificity of modulating DNA methylation levels by DNMT isoforms. Not only 
hypermethylation but hypomethylation was observed after DNMT overexpression. After 
setting the cut-offs at Δβ ≤ -0.4 and Δβ ≥ 0.4, the number of hypomethylated probes exceeded 
those of hypermethylated probes in cells that over-expressed DNMT3A1, DNMT3B3, and 
DNMT3B5. The hypotheses of this observation are that 1) trans-regulation of DNMTs can 
control the promoter activity of certain DNMTs leading to inducing hypermethylation or 
hypomethylation at its target CpGs 2) the different structure of each DNMT isoform resulted 
in different function of DNMTs. It suggests that lack of catalytic C-terminal of DNMT3B3 
and DNMT3B5 is associated with DNA hypomethylation. Similarly, the DNA methylation 
activities of purified Dnmt3b1-Dnmt3b3 were determined, and results showed that Dnmt3b3 
has no activity toward the methyl acceptors (302). However, DNMT3B4 also lacks the 
conserved methyltransferase motifs IX and X as well as DNMT3B5 does, but DNMT3B4 
showed more hypermethylated probes than DNMT3B5. Furthermore, lacking 200 amino 
acids from the N-terminal area of DNMT3B, DNMTΔ3B1-DNMTΔ3B4 showed higher 
number of hypermethylated probes than DNMT3B families, suggesting that lacking those 
areas enhanced DNA methylation levels. 
DNMT3A2 acts as an active DNMT and displays a localisation pattern suggestive of 
euchromatin association, while DNMT3A1 is a full-length DNMT3A and is concentrated on 
heterochromatin (84). DNMT3A2 is highly expressed in embryonic stem cells and embryonal 
carcinoma cells, while DNMT3A1 is expressed at low levels ubiquitously (84). In this study, 
the basal DNMT3A2 was highly expressed in HEK293T cell. This might lead to increase a 
number of DNMT3A2 protein after overexpression and DNMT3A2 increased DNA 
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methylation of several CpG targets. Another reason is that DNMT3A2 shares binding regions 
with DNMT3A1 and DNMT3B1, while DNMT3A1 has distinct binding targets (303).  
DNMTΔ3B2 showed the highest number of hypermethylated probes and 25% of these 
probes overlapped with the target probes of other DNMTΔ3Bs. Although, the structure of 
DNMTΔ3B2 is similar to DNMTΔ3B1, the number of overlapped hypermethylated probes 
was 5%. Only DNMTΔ3B2 and DNMTΔ3B4 showed low number of hypomethylated probes 
compared to other DNMT3Bs. It suggests that lacking 200 amino acid N-terminal and exon 6 
of DNMT3B in both isoforms induces hypermethylation within 103 shared target CpG sites. 
DNMT1 and DNMT3L induced hypermethylation and this result was concomitant with 
previous publication (87). Although DNMT3L is an inactive form, DNMT3L plays an 
important role in modulating DNA methylation through activating or recruiting de novo 
DNMTs (111-113). In this study, DNMT3L showed an activity to increase DNA methylation. 
This is concordant with Duymich C.E.’s study, which showed that DNMT3L demonstrated 
the ability to restore DNA methylation in DNMT3B deficient cells (277). Additionally, 
DNMT3L enhanced DNMT activity of DNMT3A2 and increased SAM binding by binding to 
DNMT3A2 promoters resulting in reorganisation of DNMT3A2 subunits (304).   
 
4.7.3 Implication of de novo DNA methylation targets of DNMTs to biological 
pathways and diseases 
In the introduction chapter (see section 1.4.2, page 14), I reviewed evidence that DNMTs play 
an important role in human diseases and especially in cancers. Increased hypermethylation of 
tumour suppressor genes in cancer cells is attributable to the aberrant expression or activity of 
DNMT1, DNMT3A, or DNMT3B (283, 305-307). The de novo target DMPs of each DNMT 
were located in the genes enriched in cancer and in cancer-related pathways such as IL-10 
signalling (308), RhoGDI signalling (309), PTEN signalling (310), HER-2 signalling (311, 
312), focal adhesion (313), PI3K-Akt (314), calcium signalling (315), and ERK/MAPK 
signalling (316). To my knowledge no previous publication has investigated the prediction or 
association of specific DNMTs to other diseases apart from cancers. These pathways 
identified in this study, that were predicted from the de novo DNA methylation target of 
individual DNMT isoforms, showed the potential for associations between individual DNMTs 
and a number of other diseases. The target CpGs of DNMT3B1 was associated with 
hereditary disorder and metabolic disease, while CVD, psychological disorders, and 
inflammatory were associated with DNMT3B3, DNMT3B4, and DNMT3B5, respectively. 
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Infectious diseases, hepatic system disease, and connective injury and abnormalities were 
specific associated with DNMT∆3B1, DNMT∆3B4, and DNMT3L, respectively.  
 The identified target CpGs would be a good marker to measure DNA methylation 
changes by specific DNMT isoforms in order to identify specific health conditions. For 
example, the dysregulation of DNMT3B contributes to ICF syndrome and the depletion of 
DNMT3B was associated with hypomethylation of PCDHG (97, 317). In this study, the 
overexpression of DNMT isoforms especially DNMTΔ3B can increase DNA methylation 
levels of PCDHG. However, further studies need to investigate and research the function of 
those targets on specific health conditions using the different cohort studies. 
 
4.8 Conclusion 
Using an unbiased genome-wide technique, this study examined the de novo target DMPs of 
13 DNMT isoforms from stably transduced single‐cell‐derived clonal lines. The DNA 
methylation patterns of each DNMT were not dependant on the structure of DNMT variants.  
Although some DNMT isoforms showed similar catalytic sites, they modulated DNA 
methylation levels in different CpG sites. Also, some DNMT isoforms might show a trans-
regulated activity on other DNMTs leading to hypomethylation. The majority of the 
preferential target sites of DNMTs were located on CpG island and Opensea where there is a 
space for increased DNA methylation. Not only the similarity of cancer-associated genes was 
identified from target DNMTs, but there were some unique genes associated with specific 
health condition. Therefore, there is a possible way for future mechanistic research to predict 





5. Chapter 5: The effect of dietary constituents (polyphenols and vitamin C) 




As reviewed in the introduction section (see section 1.6.2, page 22), nutrition modulates the 
DNA methylation patterns either at the global scale or at locus specific CpG sites. Specific 
nutrients can alter DNA methylation in two possible ways: 1) through the provision of 
substrates or cofactors required for one-carbon metabolism (Figure 1.10), which generates 
SAM; and 2) through inhibition the activity of DNMT. The methyl donor (SAM) for DNMT 
is synthesised via one-carbon metabolism using nutrients such as folate, choline, betaine, 
vitamin B12 and B6 (198). Diets that are deficient in methyl donors such as folate cause 
reduced concentration of SAM and increased concentration of SAH (318, 319), which have 
been correlated with global DNA hypomethylation (251). In older people (age 65-75 years), 
supplementation with folic acid (400 µg) and vitamin B12 (500 µg) for two years increased 
DNA methylation at hypomethylated areas in the genome including North Shore, South 
Shore, and CpG islands (320). In addition, these supplementations increased methylation of 
locus-specific loci related pre-symptomatic dementia (one of the papers I published as the 
first-author during my PhD training). Altering the enzyme activity of DNMTs is the second 
possible mechanism by which nutrients may modulate patterns of DNA methylation.  
The potential of specific nutrients and other food constituents to inhibit DNMT 
activity has been evaluated (see introduction section 1.5.2, page 17). For example, tea 
polyphenols and bioflavonoids (quercetin, fisetin, and myricetin) have been found to be 
DNMT1 inhibitors and the structural model of DNMT1 catalytic domain revealed a 
substantial interaction with polyphenols (166, 167). In studies with cell lines, treatment with 
EGCG reduced mRNA levels and protein expression of DNMTs resulting in decreased DNA 
methylation and increased histone acetylation (168, 169). Genistein inhibits the effects of 
DNMT1 activity in a dose-dependent manner, but has no effect on expression of DNMTs at 
the mRNA level (227). CA and chlorogenic acid, common coffee polyphenols, increased 
SAH and inhibited of CpG methyltransferase (M.SssI)-mediated DNA methylation (173). 
Analysis of molecular docking showed that curcumin blocked the catalytic domain of 
DNMT1 and it also inhibited the activity of M.SssI (174). However, there have been few 
investigations of the effects of nutrients and other food constituents on the activity of specific 
DNMT isoforms. In this study, the sensitivity and specificity of DNMT inhibitors were 
investigated with polyphenols and vitamin C in various concentrations in order to understand 
118 
 
the effect of these compounds on DNMT sub-isoforms. EGCG, curcumin, theaflavin, CA, and 
vitamin C were investigated in this study as these compounds were found the inhibitory effect 
on DNMTs (see the Table 1.2 in Introduction section 1.5.2, page 17). DNA methylation of the 
target DNMTs (hypermethylated probes from EPIC array analysis described in Chapter 4) 
was quantified with/without exposure to each of polyphenols and vitamin C separately in cell 
lines that over-expressed each of the individual DNMT isoforms compared with control cells. 
From EPIC data analysis, DNMT3A2, DNMT3B4, DNMTΔ3B2, DNMTΔ3B4, and DNMT1 
showed more than 300 hypermethylated probes, and they were selected for dietary treatment. 
Although DNMT1 showed less than 300 hypermethylated probes, DNMT1 was selected as it 
is the full length isoform. Furthermore, for CA only, DNMT activity was measured to confirm 
the inhibitory effect of the food derived-polyphenol on target DNMTs. This research aims to 
find the specific effects of food constituents on activity of individual DNMTs as a first step 
towards being able to target, and inhibit, the activities of these DNMT isoforms. 
 
5.2 Hypotheses 
The hypotheses for this study were: 
1. The global DNA methylation is reduced in treated cells with food-derived polyphenols 
(theaflavin, EGCG, CA, curcumin) and vitamin C, compared with untreated cells. 
2. DNMT inhibitors attenuate DNA methylation with specificity to target CpG of 
DNMTs.  
3. DNMT activity is decreased by DNMT inhibitor including food-derived polyphenols 
(theaflavin, EGCG, CA, curcumin) and vitamin C.  
 
5.3 Aim 
• To test the above hypotheses, the sensitivity and specificity of the effects of food-
derived polyphenols (theaflavin, EGCG, CA, and curcumin) and vitamin C on 




The objectives of this study were: 
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1. To perform pyrosequencing to confirm the DNA methylation level results from EPIC 
array (in chapter 4) in the overexpressing DNMT isoform. 
2. To optimise the concentration of dietary constituents and time for treatment into the cell 
lines that overexpress each of the DNMTs individually. 
3. To use pyrosequencing to provide DNA methylation levels of global and specific CpGs 
in treated cells with DNMTi (food-derived compounds) compared with untreated cells. 
 
5.5 Overview of methods 
A detailed description of the experimental procedure and methods for measuring cell 
viability, DNA methylation, and DNMT activity can be found in the Method chapter sections 
2.3 and 2.4, pages 45 and 50, respectively. 
 In brief, seven cell lines that overexpress each of the DNMTs individually 
(DNMT3A2, DNMT3B4, DNMT∆3B2, DNMT∆3B3, DNMT∆3B4, DNMT1, and 
DNMT3L) were treated with several concentrations of food-derived polyphenols (theaflavin, 
EGCG, CA, curcumin) and vitamin C (see section 2.3.1 in Methods section, page 45) to find 
the optimum concentrations of each of these compounds for use in the cell culture 
experiments. After that, cells overexpressing each individual DNMT isoform were cultured 
with the specific concentration of each compound for 48 hours (see section 2.3.2 in Methods 
section, page 46). Global DNA methylation and methylation at specific CpG sites was 
quantified using pyrosequencing (see section 2.3.3 in Methods section, page 46). Finally, 
DNMTΔ3B4 was extracted from the cell line that over-expressed this DNMT isoform (see 
section 2.4.1 in Methods section, page 50), precipitated using IP/Co-IP (see section 2.4.2 in 
Methods section, page 50) and its activity was determined using a DNMT inhibition assay 




5.6.1 Viability of cells overexpressing DNMTΔ3B2 and Myc after treatment with 
theaflavin, EGCG, CA, curcumin, and vitamin C 
Cells overexpressing DNMTΔ3B2 and Myc control cell were selected as the experimental 
sample in order to determine the cell viability after treatment with a range of concentrations 
of theaflavin, EGCG, CA, curcumin, and vitamin C. This choice was made because cells 
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overexpressing DNMTΔ3B2 showed the highest number of hypermethylated CpG sites (using 
data from the EPIC array – see Chapter 4, section 4.6.1, page 84) and the cell-line 
overexpressing Myc was used as the control. Cell viability was assessed with theaflavin 
concentrations of 0, 8.1, 20.1, 40.3, 80.5, 161.0 µM and with concentrations of 0, 10, 25, 50, 
100, 200 µM of vitamin C, EGCG, CA, and curcumin (Figure 5.1). 
 Since the average doubling time of HEK293T cells is 24 hours, cell viability was 
assessed after treatment with food constituents for up to 72 hours to select the optimum of 
incubation time. The viability of cells overexpressing DNMTΔ3B2 and of Myc cells after 
treatment with various concentrations of food constituents showed similar trends in both cell 
lines (Figure 5.1). The proportion of viable cells declined linearly with increasing dose of 
theaflavin, EGCG, CA and, especially, curcumin, but there was no evidence of any effect of 
vitamin C on viability of either cell line at any of the doses tested (Figure 5.1). In addition, for 
curcumin, but not for any of the other food constituents, there was a strong effect of time with 
greater loss of cell viability with increasing duration of exposure (Figure 5.1). The 
concentrations of food constituents to be used in further experiments were selected so that the 
percentage of cell viability was higher than 50%. These were: EGCG at 0, 50, 100 µM, 
curcumin at 0, 10, 25 µM, CA at 0, 100, 200 µM, theaflavin at 0, 80.5, 161 µM and vitamin C 







Figure 5.1 Viability of the cell lines overexpressing DNMTΔ3B2 and Myc after treatment 
with selected dietary constituents. The concentrations of selected dietary constituents were 
theaflavin at 0, 8.1, 20.1, 40.3, 80.5, 161.0 µM and vitamin C, EGCG, CA, curcumin, at 0, 10, 
25, 50, 100, 200 µM. Cells were treated for 12, 24, 48, and 72 hours. Error bars represent 




5.6.2 Effects of treatment with food constituents on global DNA methylation  
To understand global DNA methylation level, LINE-1 assay was measured in Myc (control) 
and cells overexpressing DNMT3A2, DNMT3B4, DNMT∆3B2, DNMT∆3B3, DNMT∆3B4, 
DNMT1 and DNMT3L. It was found for these cells that global DNA methylation was 
significantly (p-value ≤ 0.05) increased compared with the control Myc cell (Figure 5.2).  
 
 
Figure 5.2 The level of LINE-1 methylation in DNMT cells. Global DNA methylation level 
(using LINE-1 assay) was measured in the selected cell lines (DNMT3A2, DNMT3B4, 
DNMT∆3B2, DNMT∆3B3, DNMT∆3B4, DNMT1, and DNMT3L) compared with that in the 
control Myc cell line. Error bars represent standard deviation from triplicates and * represents 
p-value ≤ 0.05. 
 
 Global DNA methylation (assessed used the LINE-1 assay) was quantified in cells 
overexpressing DNMT3A2, DNMT3B4, DNMT∆3B2, DNMT∆3B3, DNMT∆3B4, DNMT1, 
and DNMT3L after treatment with theaflavin, vitamin C, EGCG, CA, and curcumin. After the 
48-hour treatment with CA, global DNA methylation of cells overexpressing DNMT∆3B4 
decreased significantly from 66.2% to 63.2% (p-value ≤ 0.05) at 100 µM CA and to 60.6% 
(p-value ≤ 0.05) at 200 µM CA (Figure 5.3) but there were no significant changes global 





Figure 5.3 Global DNA methylation changes after treatment with CA. The global DNA 
methylation levels (using LINE-1 assay) were measured after treatment with CA at 100 and 
200 µM for 48 hours in cells overexpressing DNMT3A2, DNMT3B4, DNMTΔ3B2, 
DNMTΔ3B3, DNMTΔ3B4, DNMT1, and DNMT3L. Error bars represent standard deviation 
from triplicates and * represents p-value ≤ 0.05 compared with untreated condition. 
  
As for EGCG, the concentration at 100 µM reduced significantly of the global DNA 




Figure 5.4 Global DNA methylation changes after treatment with EGCG. The global DNA 
methylation levels (using LINE-1 assay) were measured after treatment with EGCG at 50 and 
100 µM for 48 hours in cells overexpressing DNMT3A2, DNMT3B4, DNMTΔ3B2, 
DNMTΔ3B3, DNMTΔ3B4, DNMT1, and DNMT3L. Error bars represent standard deviation 




For curcumin and vitamin C, there were no significant changes after treatment (Figure 
5.5 and 5.6). Global DNA methylation level in cells overexpressing DNMT1 was decreased 
significantly from 53.7% to 48.0% (p-value ≤ 0.05) after treatment with theaflavin at 80.5 µM 
for 48 hours (Figure 5.7). I cannot detect the global methylation from DNA of cells 
overexpressing DNMT3L treated with curcumin at 25 µM and of cells overexpressing 
DNMTΔ3B3, DNMTΔ3B4, DNMT1, and DNMT3L treated with theaflavin at 161 µM for 48 
hours (data not available). 
 
 
Figure 5.5 Global DNA methylation changes after treatment with curcumin. The global DNA 
methylation levels (using LINE-1 assay) were measured after treatment with curcumin at 10 
and 25 µM for 48 hours in cells overexpressing DNMT3A2, DNMT3B4, DNMTΔ3B2, 
DNMTΔ3B3, DNMTΔ3B4, DNMT1, and DNMT3L. Error bars represent standard deviation 






Figure 5.6 Global DNA methylation changes after treatment with vitamin C. The global DNA 
methylation levels (using LINE-1 assay) were measured after treatment with vitamin C at 100 
and 200 µM for 48 hours in cells overexpressing DNMT3A2, DNMT3B4, DNMTΔ3B2, 
DNMTΔ3B3, DNMTΔ3B4, DNMT1, and DNMT3L. Error bars represent standard deviation 
from triplicates and * represents p-value ≤ 0.05 compared with untreated condition. 
 
 
Figure 5.7 Global DNA methylation changes after treatment with theaflavin. The global DNA 
methylation levels (using LINE-1 assay) were measured after treatment with theaflavin at 
80.5 and 161 µM for 48 hours in cells overexpressing DNMT3A2, DNMT3B4, DNMTΔ3B2, 
DNMTΔ3B3, DNMTΔ3B4, DNMT1, and DNMT3L. Error bars represent standard deviation 
from triplicates and * represents p-value ≤ 0.05 compared with untreated condition. 
   
5.6.3 Screening of the effect of selected food constituents on DNA methylation 
changes of target CpGs for across DNMT isoforms 
To identify the specificity of inhibitory effects from theaflavin, EGCG, CA, curcumin, and 
vitamin C on any of the five DNMT isoforms (DNMT3A2, DNMT3B4, DNMTΔ3B2, 
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DNMTΔ3B3, and DNMTΔ3B4), DNMT-specific hypermethylated CpG sites were selected 
from EPIC array analysis. Methylation at cg25843713 (Figure 5.8A) and cg04458645 (Figure 
5.8B) in five selected cells was higher than in Myc control cell and cells overexpressing 
DNMT3L (non-target cell). Therefore, cg25843713 and cg04458645 were selected to 
quantify the methylation in across cells overexpressing DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4, including cells overexpressing DNMT3L as 
non-target cell, after treatment with selected food constituents.  
 
 
Figure 5.8 DNA methylation levels (data from EPIC array) of target CpGs for across DNMT 
isoforms. A) cg25843713 and B) cg04458645 were specific across 5 DNMTs (DNMT3A2, 
DNMT3B4, DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4) compared with cells overexpressing 
DNMT3L and Myc control cell. Error bars represent standard deviation from duplicates. 
After 48 hours of CA treatment, CA at 100 and 200 µM exhibited a significant 
inhibitory effect on cg25843713 (p-value ≤ 0.05) in cells overexpressing DNMT∆3B2 (from 
59.1% to 56.3% at 100 µM and 56.1% at 200 µM) and cells overexpressing DNMT∆3B4 
(from 72.5% to 66.6% at 100 µM and 64.5% at 200 µM) (Figure 5.9A) and cg04458645 in 
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cells overexpressing DNMTΔ3B4 (from 77.2% to 71.2% at 100 µM and 68.5% at 200 µM) 
(Figure 5.9B).  
 
 
Figure 5.9 Effect of CA at 100 and 200 µM on specific CpG sites for 48 hours. A) 
cg25843713 and B) cg04458645 were specific to across 5 DNMTs (DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4). Cells overexpressing DNMT3L was a non-
target cell of these CpGs. Error bars represent standard deviation from triplicates and * 
represents p-value ≤ 0.05 compared with untreated condition. 
 
 
EGCG at 50 µM showed a significant increase of DNA methylation (p-value ≤ 0.05) 
at cg25843713 in cells overexpressing DNMTΔ3B4 (from 69.0% to 73.1%) and DNMT3L 
(from 12.5% to 17.2%) (Figure 5.10A) and also at cg04458645 in cells overexpressing 
DNMTΔ3B3 (from 58.5% to 63.2%), while this concentration exhibited a significant decrease 
(p-value ≤ 0.05) of DNA methylation at cg04458645 in cells overexpressing DNMTΔ3B2 
(from 64.4% to 59%) (Figure 5.10B). Moreover, EGCG at 100 µM increased significantly 
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DNMT methylation (p-value ≤ 0.05) at cg25843713 in cells overexpressing DNMT3L (from 
12.5% to 16.5%) (Figure 5.10A) and cg04458645 in cells overexpressing DNMTΔ3B4 (from 
72.5% to 77.8%), but this concentration decreased DNA methylation at this loci in cells 




Figure 5.10 Effect of EGCG at 50 and 100 µM on specific CpG sites for 48 hours. A) 
cg25843713 and B) cg04458645 were specific to across 5 DNMTs (DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4). Cells overexpressing DNMT3L was a non-
target cell of these CpGs. Error bars represent standard deviation from triplicates and * 
represents p-value ≤ 0.05 compared with untreated condition. 
Curcumin at 10 µM showed a significant increase of DNA methylation (p-value ≤ 
0.05) at cg25843713 in cells overexpressing DNMT3B4 (from 45.6% to 60.0%) (Figure 
5.11A). Additionally, at 25 µM of curcumin, it significantly enhanced DNA methylation 
levels (p-value ≤ 0.05) at cg25843713 in cells overexpressing DNMT3A2 (from 34.44% to 
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36.35%) and DNMT3B4 (from 45.6% to 64.4%) (Figure 5.11A). This concentration also 
significantly increased of DNA methylation levels at cg04458645 in cells overexpressing 
DNMTΔ3B2 (from 60.3% to 64.0%) (Figure 5.11B). However, curcumin at 25 µM exhibited 
a significant inhibitory effect on cg04458645 (p-value ≤ 0.05) in cells overexpressing 
DNMTΔ3B3 (from 60.4% to 55.1%) (Figure 5.11B). Data is not available from cg25843713 
and cg04458645 in cells overexpressing DNMT3L treated with curcumin at 25 µM for 48 




Figure 5.11 Effect of curcumin at 10 and 25 µM on specific CpG sites for 48 hours. A) 
cg25843713 and B) cg04458645 were specific to across 5 DNMTs (DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4). Cells overexpressing DNMT3L was a non-
target cell of these CpGs. Error bars represent standard deviation from triplicates and * 




At 100 and 200 µM of vitamin C, it decreased significantly DNA methylation levels at 
cg25843713 in cells overexpressing DNMT3A2 (from 35.8% to 33.4% and 32.8%), 
DNMT3B4 (from 63.7% to 51.2% and 53.3%), DNMTΔ3B2 (from 58.4% to 52.7% and 
53.5%), DNMTΔ3B3 (from 69.3% to 63.8% and 64.9%), and DNMTΔ3B4 (from 69.0% to 
48.5% to 61.5%) but these concentrations also decreased significantly DNA methylation 
levels at this loci in cells overexpressing DNMT3L (from 12.5% to 9.7% to 9.2%, 
respectively) (Figure 5.12A). Also, at a concentration of 100 µM, it significantly reduced 
DNA methylation levels at cg04458645 (p-value ≤ 0.05) in cells overexpressing DNMTΔ3B2 
(from 64.4% to 59.2%) (Figure 5.12B). 
 
Figure 5.12 Effect of vitamin C at 100 and 200 µM on specific CpG sites for 48 hours. A) 
cg25843713 and B) cg04458645 were specific to across 5 DNMTs (DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4). Cells overexpressing DNMT3L was a non-
target cell of these CpGs. Error bars represent standard deviation from triplicates and * 




As for theaflavin, its concentration at 161 µM increased significantly DNA 
methylation levels at cg25843713 in cells overexpressing DNMT3A2 (from 35.8% to 38.1%) 
and DNMTΔ3B2 (from 58.4% to 61.9%) (p-value ≤ 0.05) (Figure 5.13A). At 80.5 µM of 
theaflavin, the DNA methylation of cg25843713 also increased significantly in cells 
overexpressing DNMT3L (from 12.5% to 16.0%) (p-value ≤ 0.05), but it was significantly 
decreased in cells overexpressing DNMT3B4 (from 60.0% to 54.1%) (p-value ≤ 0.05) (Figure 
5.13A). This nutrient at 161 µM enhanced DNA methylation level of cg04458645 in cells 
overexpressing DNMT3A2 (from 70.7% to 74.8%) but this concentration decreased DNA 
methylation at cg04458645 in cells overexpressing DNMT3B4 (from 60.79 to 60.08) (p-value 
≤ 0.05) (Figure 5.13B). However, DNA methylation level of this loci was significantly 
decreased (p-value ≤ 0.05) in cells overexpressing DNMT3L (from 20.2% to 17.8%) after 
treatment with theaflavin at 80.5 µM (Figure 5.13B). Moreover, I cannot detect the 
percentage of DNA methylation on both cg25843713 and cg04458645 in cells overexpressing 
DNMTΔ3B3, DNMTΔ3B4, and DNMT3L treated with theaflavin at 161 µM for 48 hours 





Figure 5.13 Effect of theaflavin at 80.5 and 161 µM on specific CpG sites for 48 hours. A) 
cg25843713 and B) cg04458645 were specific to across 5 DNMTs (DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4). Cells overexpressing DNMT3L was a non-
target cell of these CpGs. Error bars represent standard deviation from triplicates and * 




5.6.4 The specificity and sensitivity of DNMT isoforms on selected food 
constituents 
To identify the specificity and sensitivity of each DNMT isoform to each of the food 
constituents (CA, EGCG, curcumin, vitamin C, and theaflavin), methylation at one or two 
target CpG sites from top 10 DMPs for each DNMT isoform was quantified by 
pyrosequencing after treatment with selected food constituents. cg02372111 and cg16204524 
were specific targets of DNMT3A2, cg02788195 for DNMT3B4, cg21808287 and cg 
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25533247 for DNMTΔ3B2, cg08927738 and cg20364776 for DNMTΔ3B3, cg22976313 and 
cg07504154 for DNMTΔ3B4, cg01065960 for DNMT1, cg12150401 and cg20540357 for 
DNMT3L (see Chapter 4, 4.6.3, Table 4.2). Most of these specific loci for each individual 
DNMT showed no differences of the DNA methylation levels measured by EPIC array and 
pyrosequencing (Figure 5.14) but the DNA methylation levels, measured by pyrosequencing, 
of cg02788195, cg16204524, cg21808287, cg25533247, cg08927738, cg07504154, 
cg12150401, and cg20540357 were lower than measuring by EPIC array. In each case, the 
cell lines were treated, separately, with 100 and 200 µM of CA and vitamin C, 50 and 100 of 





Figure 5.14 The DNA methylation levels of each target loci for each DNMT between EPIC 




DNA methylation at cg02372111 in cells overexpressing DNMT3A2 was increased 
significantly (p-value ≤ 0.05) after treatment with EGCG at 200 µM (from 83.8% to 86.1%), 
curcumin at 10 and 25 µM (from 84.2% to 85.2% and 87.5%, respectively), and theaflavin at 
80.5 and 161 µM (from 83.8% to 86.6% and 87.1%, respectively) (Figure 5.15A). However, 
methylation at this locus was increased significantly (from 84.2% to 85.2%) after treatment 
with 10 µM curcumin (p-value ≤ 0.05). Methylation at cg16204524 increased significantly 
after treatment with EGCG at 200 µM (from 46.6% to 51.3%) (Figure 5.15B). In contrast, 
methylation at this locus in the DNMT3A2 overexpressing cell line decreased substantially, 
and significantly, after treatment with 25 µM curcumin (from 56.4% to 32.8%), 100 and 200 
µM vitamin C (from 46.6% to 38.5% and 39.4%, respectively), and 161 µM theaflavin (from 





Figure 5.15 DNA methylation changes in specific CpG sites of cells overexpressing DNMT3A2 after treatment with selected food constituents 
for 48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 and 161 µM 
theaflavin, on A) cg02732111, B) cg16204524 were measured by pyrosequencing. Error bars represent standard deviation from triplicates and * 




 Methylation at cg02788195 in cells overexpressing DNMT3B4 was decreased 
significantly from 35.5% to 33.3% after treatment with 100 µM CA (p-value ≤ 0.05) (Figure 
5.16) with a similar fall in methylation at this CpG (from 35.2% to 32.8%) after treatment 
with 100 µM EGCG (p-value ≤ 0.05) (Figure 5.16). However, methylation at cg02788195 in 
cells overexpressing DNMT3A2 was increased from 12.4% to 15.7% (p-value ≤ 0.05) after 
treatment with 25 µM curcumin (Figure 5.16). 
In cells overexpressing DNMTΔ3B2, treatment with 100 µM EGCG and 80.5 µM 
theaflavin, increased methylation at cg21808287 from 47.67% to 52.51% and 47.67% to 
51.44%, respectively (p-value ≤ 0.05) (Figure 5.17A). After treatment with 200 µM CA, 10 
µM curcumin, and 200 µM vitamin C, methylation at this locus decreased significantly (p-
value ≤ 0.05) from 51.2% to 46.6%, 51.3% to 49.3%, and 55.1% to 50.2% respectively 
(Figure 5.17A). Also, cells overexpressing DNMTΔ3B2 showed decrease of methylation at 
cg25533247 after treatment with 100 µM and 200 µM (from 54.5% to 52.6% and 48.5%, 
respectively) (p-value ≤ 0.05) (Figure 5.17B), while methylation at this locus was increased 
from 47.7% to 52.5% after treatment with 200 µM EGCG (Figure 5.17B). Moreover, I cannot 
detect the DNA methylation of both target sites of DNMTΔ3B2 from DNA of cells 
overexpressing DNMT3L treated with curcumin at 25 µM and with theaflavin at 161 µM for 








Figure 5.16 DNA methylation changes in specific CpG site of cells overexpressing DNMT3B4 after treatment with selected food constituents for 
48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 and 161 µM, on 
cg02788195 were measured by pyrosequencing. Error bars represent standard deviation from triplicates and * represents p-value ≤ 0.05 













Figure 5.17 DNA methylation changes in specific CpG sites of cells overexpressing DNMTΔ3B2 after treatment with selected food constituents 
for 48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 and 161 
µM theaflavin, on A) cg21808287 B) cg25533247 were measured by pyrosequencing. Error bars represent standard deviation from triplicates 





 Methylation at cg08927738 in cells overexpressing DNMTΔ3B3 were increased 
significantly after treatment with 25 µM curcumin (from 52.7% to 63.2%) and 80.5 µM 
theaflavin (from 53.2% to 57.1%) (p-value ≤ 0.05) (Figure 5.18A). In contrast, vitamin C 
exhibited an inhibitory effect on cg20364776 in cells overexpressing DNMTΔ3B3 (from 
100% to 85.85% and 85.91% at 100 and 200 µM, respectively) (p-value ≤ 0.05) (Figure 
5.18B). However, I cannot detect the DNA methylation of both target sites of DNMTΔ3B3 
from DNA of cells overexpressing DNMT3L treated with curcumin at 25 µM and with 
theaflavin at 161 µM for 48 hours, and of cells overexpressing DNMTΔ3B3 treated with 






Figure 5.18 DNA methylation changes in specific CpG sites of cells overexpressing DNMTΔ3B3 after treatment with selected food constituents 
for 48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 and 161 µM 
theaflavin, on A) cg08927738 B) cg20364776 were measured by pyrosequencing. Error bars represent standard deviation from triplicates and * 
represents p-value ≤ 0.05 compared with untreated condition.
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 Methylation at cg22976313 in cells overexpressing DNMTΔ3B4 was decreased 
significantly after treatment with 200 µM CA (from 84.9% to 74.9%) (p-value ≤ 0.05) (Figure 
5.19A). Also, CA showed the inhibitory effect on another loci (cg07504154) in cells 
overexpressing DNMTΔ3B4 (from 43.29% to 26.62% and 36.70% at 100 and 200 µM, 
respectively) (p-value ≤ 0.05) (Figure 5.19B). Additionally, methylation at cg07504154 was 
decreased significantly after treatment with 100 and 200 µM vitamin C (from 39.5% to 23.0% 
and 18.9%, respectively) (p-value ≤ 0.05) (Figure 5.19B). In contrast, methylation at 
cg07504154 in the DNMTΔ3B4 overexpressing cell line increased substantially, and 
significantly, after treatment with 100 and 200 µM EGCG (from 39.5% to 42.2% and 42.8%, 
respectively), 10 and 25 µM curcumin (from 41.6% to 46.3% and 45.0%, respectively), and 
80.5 µM theaflavin (from 39.5% to 43.7%) (p-value ≤ 0.05) (Figure 5.19B). Furthermore, 200 
µM curcumin increased methylation at cg22976313 from 85.8% to 89.3% (p-value ≤ 0.05) 
(Figure 5.19A). However, I cannot detect the DNA methylation of both target sites of 
DNMTΔ3B4 from DNA of cells overexpressing DNMT3L treated with curcumin at 25 µM 
and with theaflavin at 161 µM for 48 hours, and of cells overexpressing DNMTΔ3B4 treated 







Figure 5.19 DNA methylation changes in specific CpG sites of cells overexpressing DNMTΔ3B4 after treatment with selected food constituents 
for 48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 and 161 µM 
theaflavin, on A) cg22976313 B) cg07504154 were measured by pyrosequencing. Error bars represent standard deviation from triplicates and * 




 Methylation at cg01065960 in cells overexpressing DNMT1 was decreased 
significantly after treatment with 100 and 200 µM vitamin C (from 60.9% to 52.9% and 
55.2%, respectively) (p-value ≤ 0.05) (Figure 5.20). However, I cannot detect the DNA 
methylation of target site of DNMT1 from DNA of cells overexpressing treated with 
theaflavin at 161 µM for 48 hours (data not available). 
Methylation at cg12150401 in cells overexpressing DNMT3L was increased 
significantly after treatment with 200 µM EGCG (from 67.8% to 74.2%) and 80.5 µM 
theaflavin (from 67.8% to 71.7%) (p-value ≤ 0.05) (Figure 5.21A). Moreover, methylation at 
cg20540357 was increased in cells overexpressing DNMT3L after treatment with 100 µM 
CA (from 40.7% to 46.5%) and 80.5% µM theaflavin (from 40.6% to 46.5%) (p-value ≤ 
0.05) (Figure 5.21B). However, I cannot detect the DNA methylation of both target sites of 
DNMT3L from DNA of cells overexpressing DNMT3L treated with curcumin at 25 µM and 
with theaflavin at 161 µM for 48 hours, and of cells overexpressing DNMTΔ3B3 treated with 








Figure 5.20 DNA methylation changes in specific CpG site (cg01065960) of cells overexpressing DNMT1 after treatment with selected food 
constituents for 48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 
and 161 µM theaflavin, on cg01065960 were measured by pyrosequencing. Error bars represent standard deviation from triplicates and * 







Figure 5.21 DNA methylation changes in specific CpG sites of cells overexpressing DNMT3L after treatment with selected food constituents for 
48 hours. The effects of 100 and 200 µM CA, 50 and 100 µM EGCG, 10 and 25 µM curcumin, 100 and 200 µM vitamin C, 80.5 and 161 µM 
theaflavin, on A) cg12150401 B) cg20540357 were measured by pyrosequencing. Error bars represent standard deviation from triplicates and * 




5.6.5 Effect of CA on DNMT enzymatic activity  
In the previous section, I reported that DNMTΔ3B4 was targeted specifically by CA and that 
this led to reduced methylation levels of its target CpG sites (see section 5.6.4, Figure 5.19). 
To investigate the possible mechanism for this effect, the enzymatic activity of the DNMT 
was quantified after treatment with a range of concentrations of CA. Cells overexpressing 
DNMTΔ3B4 were selected to quantify the inhibitory effect of CA, as these cells showed low 
methylation in both methylation of global and site-specific loci after treatment with CA. 
DNMTΔ3B4 proteins were extracted and purified from cells overexpressing DNMTΔ3B4. 
The method used (described in the Methods chapter, section 2.4) ensured that only DNMT 
proteins tagged with Myc i.e. those derived from the over-expressed DNMTΔ3B4 isoform 
were captured by Myc-antibody. These proteins were eluted and used to perform the DNMT 
activity assay. CA exhibited the inhibitory effect on DNMTΔ3B4 activity at all concentrations 
tested from 25 to 300 µM (p-value ≤ 0.05) (Figure 5.22A). The degree of inhibition decreased 
linearly with increasing CA concentrations (Figure 5.22B).  
 
 
Figure 5.22 DNMT activity (%) of DNMTΔ3B4 after treatment with CA. DNMTΔ3B4 was 
treated with CA at 25, 50, 100, 200, and 300 µM; A) the percentage of DNMTΔ3B4 activity 
after treatment with CA B) linear regression of concentration of CA and DNMTΔ3B4 
activity. Error bars represent standard deviation from triplicates and * represents p-value ≤ 






5.7.1 Main findings 
The primary objectives of this study were to quantify the effects of food-derived polyphenols 
(theaflavin, EGCG, CA, curcumin) and of vitamin C on cell lines over-expressing individual 
DNMT isoforms and to determine whether these effects of these food constituents were 
specific to particular DNMT isoforms. Target CpG sites of each DNMT isoform were 
selected from the EPIC array data (described in Chapter 4) to test the effect of each 
polyphenol and of vitamin C, separately. Table 5.1 shows the summary of finding all 
significant methylation changes after treatment with selected dietary constituents. The results 
show that curcumin at 100 and 200 µM and theaflavin at 80.5 decreased global DNA 
methylation in cells that over-expressed DNMTΔ3B4 and DNMT1, respectively. For 
screening the effect of food constituents on cells overexpressing DNMTs, CA showed the 
inhibitory effect on cells overexpressing DNMTΔ3B2 and DNMTΔ3B4 by decreasing the 
DNA methylation of their target CpGs. Vitamin C also decreased the DNA methylation of 
target CpGs in cells overexpressing DNMT3A2, DNMT3B4, DNMTΔ3B2, DNMTΔ3B3, 
DNMTΔ3B4, and DNMT1. EGCG, curcumin, and theaflavin showed both enhancement and 
reduction of the DNA methylation levels of target CpGs across the DNMT isoforms. After 
investigation of each DNMT isoform to dietary constituents, DNA methylation changes of 
their target CpG sites in DNMT3A2 and DNMT1 were unique to vitamin C treatment, and 
DNMTΔ3B2 and DNMTΔ3B4 were to CA. The confirmation of inhibitory effect on DNMT 
activity revealed that CA decreased DNMTΔ3B4 activity. 
 
 















100 200 50 100 10 25 100 200 80.5 161 
Global DNA methylation  
DNMTΔ3B4           








Table 5.1 (Continue) Summary the significant decrease or increase of methylation after 














100 200 50 100 10 25 100 200 80.5 161 
Screening of the effect of selected food constituents on DNA methylation changes of target 
CpGs for across DNMT isoforms 
cg25843713 
DNMT3A2           
DNMT3B4           
DNMTΔ3B2           
DNMTΔ3B3           
DNMTΔ3B4           
cg04458645 
DNMT3A2           
DNMT3B4           
DNMTΔ3B2           
DNMTΔ3B3           
DNMTΔ3B4           
The effect of selected food constituents on DNA methylation changes of target CpGs for 
each individual DNMT isoform 
DNMT3A2 
cg02732111           
cg16204524           
DNMT3B4 
cg02788195           
DNMTΔ3B2 
cg21808287           
cg25533247           
DNMTΔ3B3 
cg08927738           
DNMTΔ3B4 
cg22976313           
cg07504154           
DNMT1 
cg01065960           
DNMT3L 
cg12150401           
cg20540357           





5.7.2 The effect of selected food constituents on DNMT isoforms through 
modulating DNA methylation in global DNA methylation and site-specific target 
CpGs 
Epigenetic studies have tried to reveal the link between diet and DNA methylation. The 
results from computer models (119) and in vitro studies (165) show that nutrition interferes 
with DNA methylation by changing the cofactors and substrates in one-carbon metabolism 
and food constituents such as polyphenols inhibits DNMT activity (see Introductory section 
1.5.2 and 1.6.2). Hypermethylation of DNA was one of the epigenetic mechanisms for 
silencing the gene expression, including tumour suppressor genes (321, 322). The inhibition 
of DNMTs is a possible therapeutic mechanism that contributes to protection against cancer. 
Although DNMT subfamilies have been identified, most studies focus on the main DNMT 
isoforms (DNMT3L, DNMT1, DNMT3A, and DNMT3B). There is a limitation of the study 
about the sensitivity and specificity of DNMT inhibitors to DNMT subfamilies as there is no 
specific antibody to each DNMT subfamily due to the similarity of the structure. 
 In this study, five dietary constituents: CA, curcumin, EGCG, vitamin C, and 
theaflavin, were selected as these nutrients showed a potential inhibitory effect on DNMT 
activity (see Introduction section 1.5.2, page 17). To my knowledge, apart from the major 
DNMT isoforms (DNMT1, DNMT3A, and DNMT3B), there is no published study that has 
investigated the effects of these particular food constituents on methylation of target CpGs by 
individual DNMT isoforms. This is the first one to investigate the effect of polyphenols and 
vitamin C on DNMT sub-isoforms. Cells overexpressing DNMT3A2, DNMT3B4, 
DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4, and DNMT3L were selected in this study based on 
the number of significant hypermethylation probes, which were more than 300 probes. Also 
DNMT1 was selected as it is a full-length isoform and several studies showed that DNMT1 
was inhibited by polyphenols (166, 223). 
To investigate the effect of selected compounds on DNMT sub-isoforms, the DNA 
methylation levels were measured at the target CpGs of DNMTs before and after treatment 
with polyphenols and vitamin C. Firstly, the specificity of all the target CpG sites (across 
DNMT isoforms across DNMTs and specific DNMT targets) selected from EPIC data 
analysis, was confirmed by pyrosequencing as the baseline of DNA methylation level of 
target CpG sites was higher than the control cell. The global methylation was also 







In this study, DNA methylation of LINE-1 was reduced in the over-expressed DNMTΔ3B4 
cell after treatment with CA at 100 and 200 µM. CA also showed specific inhibitory effect on 
DNMTΔ3B2 and DNMTΔ3B4 at specific CpG target sites and DNMTΔ3B4 activity by dose-
dependence. CA was found as DNMTi through inhibiting the activity of M.SssI and DNMT1 
(173). Dibutyltin (IV) complex of CA decrease global DNA methylation using imprint DNA 
methylation kit (323). However, no previous study has explored inhibition of DNMTΔ3B4 by 
CA. It was interesting that the catalytic sites of DNMTΔ3B2, DNMTΔ3B3, and DNMTΔ3B4 
are identical (see introduction section, Figure 1.7), but only DNMTΔ3B2 and DNMTΔ3B4 
can be inhibited by CA. This finding indicates that lacking 200 amino acids at the N-terminal 
and exon 6 of DNMT3B in DNMTΔ3B2 and DNMTΔ3B4 was important for interaction with 
CA.   
 
EGCG 
Molecular modelling studies demonstrate that EGCG is well accommodated in a hydrophilic 
pocket of DNMT1 by at least four hydrogen bonds (167). In this study, EGCG at 100 μM 
showed the inhibitory effect on global DNA methylation in the over-expressed DNMT1 cell 
and this concentration decreased the methylation of the target CpG of DNMT3B4. 
Concomitantly, this dose of EGCG showed the potent anti-proliferative effects on HCT-116 
cells (324). However, Fang MZ. et al. found that 20 and 50 µM EGCG are the effective 
concentration to re-activate of methylation-silenced genes (Retinoic acid receptor beta and 
p16INK4a genes) (167).  
EGCG has demonstrated beneficial effects in cancer prevention through the inhibition 
of DNMT (167). In addition, expression of DNMT1, DNMT3a, and DNMT3b at both RNA 
and protein levels in human skin cancer cells was inhibited after EGCG treatment (168). 
Further, EGCG inhibit DNMT activity in human cervical HeLa cells (325). Also, EGCG 
treatment did not affect the mRNA expression of DNMT3A, DNMT3B, and DNMT1 (167, 
326). There is no study showing an enhancing effect of EGCG on locus-specific CpGs. 
However, the results from this study showed the enhancing effect of EGCG on the target 
DMPs of DNMTΔ3B4 and DNMT3L. This effect is hypothesised that the endogenous 
expression of DNMT3B4, which was inhibited specifically by EGCG, might be inhibited in 
cells overexpressing DNMTΔ3B4 and DNMT3L after treatment. This effect leads to 







Vitamin C is a co-factor or the catalytic activity of Tet enzymes that are involved in 
demethylation of DNA (327). Vitamin C does not change Tet expression (328) but it enhances 
the activity of Fe (II)-2-oxoglutarate dioxygenases, including TETs, as a critical step in DNA 
demethylation (329). Vitamin C also was demonstrated to prevent hypermethylation and 
prevent loss of DlK1-Dio3 imprinting gene in iPS cell (330). Vitamin C accumulated in 
haematopoietic stem cells promotes Tet function and suppressing leukaemogenesis (331).  
According to the formulations of DMEM and serum used in this study, the culture 
media does not contain a detectable amount of vitamin C (332). This study exhibits that 
vitamin C decreased DNA methylation of some CpG target sites of DNMT3A2, DNMTΔ3B2, 
DNMTΔ3B4, and DNMT1. However, other over-expressed DNMT cells (DNMT3B4, 
DNMTΔ3B3, and DNMT3L) did not change the levels of DNA methylation at the specific 
CpG sites after treatment with vitamin C. For the concentration of vitamin C in this study, the 
highest concentration was 200 µM and this concentration does not harm cell viability. Also, 
this concentration can inhibit the methylation of both target sites of DNMT3A2. 
Concomitantly, the high concentration (8 mM) of vitamin C inhibited the DNMT activity in 
nuclear extracts of melanoma cells (176). However, it is important to note that the 
concentration of vitamin C in plasma for supplementation, following oral administration of 
high doses of vitamin C (>500 mg/day), does not exceed 150 µM, because of the intestinal 
absorption (333).  
 
Curcumin 
Curcumin has beneficial activities such as antioxidant and anti-cancer properties (334). Liu Z. 
et al. (174) showed the molecular docking analysis between catalytic pocket of DNMT1 and 
curcumin. In this study, curcumin increased DNA methylation of the target CpGs of 
DNMT3A2 and also decreased DNA methylation at cg16204524, which was another target 
site of DNMT3A2, suggesting that modulating activity on DNA methylation by curcumin is 
independent of its direct effect on DNMTs. Concomitantly with previous publication, 
DNMT1 expression and activity analyses following treatment with curcumin failed to observe 
any significantly changes (335). Also, curcumin can restore the DNMT activity and DNMT1 
expression in the retinal pigment epithelial cell of diabetes mice (336). Its effects also 
downregulated the oxidative stress-induced expression of miR-302, which is an inhibitor of 
DNMT1 (337). The antioxidative effect of curcumin might therefore be a potential factor in 






Theaflavin and its galloyl esters are the main red pigment in black tea. From in vitro study, 
the theaflavin has been found to reduce the viability of ovarian cancer cells and it appears to 
mediate apoptosis pathway via both intrinsic and extrinsic pathways. In this study, theaflavin 
increased DNA methylation of target CpG sites of DNMTΔ3B2 and DNMT3L. It is possible 
that theaflavin might modulate the SAM and SAH intracellular ratio, thus this ratio should be 
further measured after treatment with theaflavin in cells overexpressing DNMTΔ3B2 and 
DNMT3L. From in vitro study, theaflavin found to be an inhibitor of Dnmt3a (175). In this 
study, theaflavin showed both hypermethylation and hypomethylation on the CpG targets of 
DNMT3A2, suggesting that theaflavin might inhibit other DNMTs in cells overexpressing 
DNMT3A2 leading to hypermethylation at DNMT3A2’s target CpG. 
 
5.8 Conclusion 
Here, for the first time, the target CpG sites of each DNMT were used to explore the 
sensitivity and specificity of polyphenols and vitamin C to DNMTs. This study also shows 
that CA inhibits DNMTΔ3B2 and DNMTΔ3B4 through decreased DNA methylation of the 
target CpGs of DNMTΔ3B2 and DNMTΔ3B4, and decreased DNMTΔ3B4 enzyme activity. 
Vitamin C also decreased DNA methylation levels of the target CpGs of DNMT3A2, 
DNMTΔ3B2, DNMTΔ3B4, and DNMT1. However, EGCG, curcumin, and theaflavin 
showed both increased and decreased DNA methylation, suggesting that these compounds act 
independently or inhibit endogenous DNMT targets resulting in hypermethylation at some 















6. Chapter 6: General discussion 
 
 
The objectives of my PhD project were  
1) to generate the cell lines that over-expressed 13 individual DNMT isoforms (DNMT3A1, 
DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMTΔ3B1, 
DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4, DNMT3L, and DNMT1) and to identify the de 
novo DNA methylation target sites of each specific DNMT isoform,  
2) to undertake genome-wide DNA methylation analysis using the Illumina Infinium 
Methylation EPIC BeadChip, 
3) to assess CpG specific DNMTs in relation to biological mechanism by pathway analysis 
according to enrichment statistics of the difference of gene and 
4) to investigate interactions between selected food constituents, i.e. theaflavin, EGCG, CA, 
curcumin, and vitamin C, and specific DNMT isoforms in modulating DNA methylation 
patterns.  
 
6.1 Generating the over-expressed DNMT cells 
There are three enzymatically active DNMTs i.e. DNMT3A, DNMT3B, and DNMT1, and an 
enzymatically inactive regulatory factor, DNMT3L (338). In addition, multiple subfamilies of 
DNMT3A and DNMT3B have also been identified (106). In this study, 13 isoforms were 
investigated. Of these isoforms, nine contained the catalytically active region (see 
Introduction section 1.4, page 9), whilst the other four i.e. DNMT3B3, DNMT3B4, 
DNMT3B5, and DNMT3L did not. However, DNMT3B3 and DNMT3B4 are over-expressed 
in many tumour cell lines where they bind to, and regulate the activity of DNMT3A or 
DNMT3B (85). In addition, DNMT3B4 and DNMT3B5 are over-expressed in gastric 
carcinoma (278). DNMT1 acts primarily as a maintenance methyltransferase and it can 
maintain DNA methylation even when uncoupled from the DNA replication machinery (339). 
All DNMTs facilitate a similar catalytic mechanism in which a covalent reaction intermediate 
is formed between the substrate and its catalytic pocket. The identity matrix of the catalytic 
sites of the previously mentioned 13 DNMT isoforms plus DNMT2 was analysed by 
Fernanda I. et al. (119) (see Introduction section 1.4.1, page 11). Nonetheless, DNMT 




study used an earlier version of the Illumina DNA methylation assay which contained probes 
for only 1,505 CpG sites from 808 cancer-related genes to identify the CpG sites that were the 
targets of each of the DNMTs (87). To enable my investigation of de novo target CpG sites of 
each DNMT isoform, I generated cell lines that over-expressed each of 13 individual DNMT 
isoforms (DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, 
DNMT3B5, DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4, DNMT3L, and DNMT1) in 
a separate cell line. These cell lines were generated successfully by integrating the mRNA of 
each DNMT isoform into HEK293T genome using a lentiviral system. 
Use of the lentiviral system was an effective approach for incorporating the exogenous 
DNMTs into both the HEK293T genome and the MEG-01 genome. However, the amount of 
positive GFP cells was higher in HEK293T cells compared with MEG-01 cells because of 
their reliable growth and propensity for incorporating exogenous DNA. Another factor is that 
the doubling time of HEK293T (24 hours) (340) is shorter than MEG-01 cells (36-48 hours) 
(341). The reduced cell population after a governed time point in MEG-01 populations is 
likely to impact the number of transgene-expressing cells. mRNA expression of exogenous 
DNMTs in HEK239T cells was detected by qPCR using a pair of primers that bound to the 
Myc-tag sequence and to the relevant DNMT isoform.  
Exogenous DNMT expression was clearly observed in GFP positive cells compared 
with Myc control cell. However, the mRNA expression of DNMT3A2 in Myc control cell was 
higher than in cells overexpressing DNMT3A2, possibly due to high expression of 
endogenous DNMT3A2 in HEK293T cells. The expression of exogenous DNMTs was not 
correlated with protein expression levels, especially DNMT3ΔB3 (see Discussion section 3.7.3 
in the Chapter 3, page 79). This observation was consistent with a previous publication (87). 
Additionally, Duymich, C.E. et al. (277) reported that the different mRNA expression of 
DNMT3Bs was seen for each of DNMT3B, but the protein levels showed a large variation, 
indicating the different stabilities of the DNMT variants. Also, Fredrik E. et al. found the 
correlation between total RNA expression (assessed using transcriptomics) and protein 
expression (assessed using proteomics) of the selected 55 genes (DNMT was not included) in 
HEK293 cells to be 0.39 (294). However, cell lines that over-expressed DNMT showed a 
significant increase in global methylation (Figure 5.2, page 122), suggesting that the extent of 





6.2 Identifying de novo DNA methylation target sites of each specific DNMT isoform 
After generating single cell clone of individually overexpressing DNMTs, the target 
CpG sites of each DNMT isoform were explored using the Illumina EPIC array, which has 
probes for more than 850,000 CpG sites. As mentioned earlier, due to the structural 
similarities between each DNMT, a limitation is to targeting individual isoforms is the lack of 
specific antibodies to the sub-families of DNMT isoforms. There are a small selection of 
specific antibodies on the market available for DNMT1, DNMT3A, DNMT3B and 
DNMT3A2. Also, the specificity of each splice variant of DNMT isoforms using specific 
primers to discriminate their mRNA levels has not been fully investigated. Therefore, it 
remains unclear over which sub-family of DNMTs would be a specific marker in disease 
conditions as well as which DNMTs are inhibited by a given DNMTi. Over-expressed DNMT 
cells can fill in this gap and provide epigenetic information about their target CpGs. The 
results from the current cannot be compared with the previous work from Choi SH. et.al (87) 
because I used a different method for generating the cells overexpressing DNMTs and a 
different parameter for statistical analysis. In this study, the cut-offs for Δβ values were set at 
different values: ≥ 0.2 and ≤ -0.2, ≥ 0.3 and ≤ -0.3, ≥ 0.4 and ≤ -0.4 relative to the β values of 
the Myc control cell. However, the results from different cut-offs showed the same proportion 
of significant loci along the genomic location and these results strengthen the analysis of the 
sites showing ≥ 0.4 difference in β values. These stringent criteria were selected due to the 
limitation of only running biological duplicates and the variation this may introduce, but also 
to considerably reduce the incidence of false results, i.e. readings that cannot be reaffirmed by 
pyrosequencing. The number of significantly hypermethylated probes was distributed from 
36-915 probes across the cells overexpressing DNMTs. The lowest numbers of 
hypermethylated probes (36 and 79 probes respectively) were observed in cells lines that 
over-expressed the catalytically inactive DNMT3B3 and DNMT3B5. Also, the numbers of 
hypomethylated probes in both DNMT3B3 and DNMT3B5 (142 and 123, respectively) were 
higher than the numbers of hypermethylated probes, suggesting that these isoforms might 
inhibit, or compete for binding to, the same CpG positions as other DNMT3 isoforms. 
Another explanation might be the possibility of DNMT3B3 and DNMT3B5 as trans-
regulatory elements, leading to hypermethylation of target promoters to other DNMTs. This 
could result in hypomethylation of the target CpG sites of those DNMTs (illustrated 






Figure 6.1 The diagrammatic overview of trans-regulation by DNMTy on the promoter of 
DNMTx leading to hypomethylation on the target CpG of DNMTx. 
 
DNMT3B4, shortest isoform compared with DNMT3B1-DNMT3B5, showed 320 
hypermethylated probes. This corresponded to the mRNA levels of DNMT3B4, which showed 
the highest expression among DNMT3B cells. However, in a previous study, the over-
expression of DNMT3B4 using transient transfection in HEK293 cells led to DNA 
hypomethylation in pericentromeric satellite regions analysed by Southern blotting, 
depending on the expression level of DNMT3B4 (285). From pathway analysis (see Table 4.3, 
page 109), the target CpGs of DNMT3B4 involved in cell growth and cell proliferation 
through DP-glucose Biosynthesis, Glucose and Glucose-1-phosphate Degradation, and 
PFKFB4 Signalling Pathway. This observation is supported by finding Shao G. et al. who 
observed that DNMT3B4 inhibited cell proliferation in HEK293A cell line through inducing 
p21, a cyclin-dependent kinase inhibitor (342).  
Moreover, in my study, in cell lines that over-expressed DNMT3L and DNMT1, they 
showed identified 394 and 197 hypermethylated probes, respectively (see Figure 4.4, page 
94). Since there were approximately twice as many hypermethylated probes with DNMT3L 
than with DNMT1, this suggests that DNMT3L might play a regulatory role in DNA 
methylation at certain CpG sites via interaction with endogenous DNMT3A and DNMT3B 
(116). This finding supports the activity of DNMT3L to restore DNA methylation in 
DNMT3B-deficient cells (3BKO and DKO8 derivatives of the HCT116 colon cancer cell 
line) (277). 
Furthermore, in this study, the cell line that over-expressed DNMT3A2 cells showed 
the highest number of hypermethylated probes (915 probes). With this finding, it is plausible 
to postulate that high endogenous DNMT3A2 might cause aberrant DNA methylation in over-
expressed DNMT3A2 cells. Also, DNMT3A2 shares binding targets with DNMT3A1 and 
DNMT3B1 (303) and this sharing caused an increase of hypermethylated loci. Furthermore, 
the majority of Δβ levels in the over-expressed DNMT cell lines showed hypermethylation 
below 0.7. These results are consistent with those observed in a previous publication (87), 




6.3 Determining the sensitivity and specificity of theaflavin, EGCG, CA, curcumin, and 
vitamin C in interactions with specific DNMT isoforms 
Natural products known as DNMTi or demethylating agents have been extensively 
investigated (119, 343) because there is a great need for the development of nontoxic and 
effective inhibitors of DNMTs. Natural DNMTi products have distinct chemical scaffolds, 
providing a starting point in determining their mechanism to inhibit DNMT activity. Although 
the specificity of these DNMTi products to DNMT sub-isoforms is poor understood, the 
structural variation amongst DNMTs supports the concept of each natural DNMTi specifically 
targeting a DNMT isoform(s) as opposed to all isoforms. The chemical structures of these 
natural products and food chemicals have been computerised in search of their inhibitory 
mechanism on DNMTs. However, the lack of appropriate cell models and antibodies specific 
to each DNMT sub-family isoform have hindered the progression in efforts towards 
identifying the mechanistic effect of DNMTi. Therefore, over-expressed DNMT cells, as 
created for this study, are important tools to boost the research in this field. 
 In this study, theaflavin, EGCG, CA, curcumin, and vitamin C were selected to test 
the sensitivity and specificity to each DNMT isoform. These dietary constituents have shown 
the modulating effects on DNMT activity or expression (see Introduction section, 1.5.2, page 
17). Based on previous publications, these compounds affect DNMTs in a concentration-
dependent manner, and with cell availability greater than 50%. However, there is no study to 
specify the activity of those compounds on DNMT subfamilies. There is evidence of 
differential expression of some DNMT variants in diseases and in distinctive cell types. For 
example, DNMT∆3B4 was highly expressed in non-small cell lung cancer (104). DNMT3L is 
expressed in only embryonic stem cells and germ cells (111, 112). DNMT1 and DNMT3A1 
are expressed more abundantly than DNMT3B and DNMT3A2 (84, 344, 345). Therefore, the 
study of DNMTi on each DNMT isoform will bring closer the understanding of the specific 
targets of each DNMTi and to which DNMT isoform they act upon. CA was found to be a 
specific DNMTi to DNMTΔ3B2 and DNMTΔ3B4 but not specific to DNMTΔ3B3. This 
implies that, despite these isoforms exhibiting a similar catalytic structure, the interaction 
between CA with affected DNMTs may be different. It suggests that lacking 200 amino acid 
N-terminal and exon 6 of DNMT3B in DNMTΔ3B2 and DNMTΔ3B4 isoforms are sensitive 
and specific to CA. Vitamin C showed inhibitory effects to DNMT3A2, DNMTΔ3B2, 
DNMTΔ3B4, and DNMT1. This finding supports the DNMT inhibitory activity of vitamin C, 
but the doses of this vitamin performed in this study were lower than in the Venturelli’s study 




expressed DNMT3L, DNMTΔ3B3, and DNMTΔ3B4 cells, suggesting that this compound 
increases DNA methylation levels in the over-expressed inactive-DNMT cells. EGCG and 
curcumin showed both types of methylation marks in over-expressed DNMT cells; 
hypermethylation and hypomethylation. This can be explained by trans-regulation effects of 
DNMTs. In the illustration (Figure 6.2), EGCG or curcumin might inhibit DNMTy, leading to 
hypomethylation in the promoter area of DNMTx, and in turn, increased DNMTx expression 
and methylation of its target CpG sties. 
 
 
Figure 6.2 The diagrammatic overview of the effect of DNMTi (EGCG and curcumin) on 
trans-regulation of DNMTy on the promoter of DNMTx. This effect led to increase DNMTx 
and hypermethylation on the target CpG of DNMTx. 
 
6.4 Strengths and limitations of the overall project 
The main strength of this study was the ability to generate novel stable cell lines that over-
expressed each of the DNMT isoforms, individually. In addition, the use of single cell clones 
provided a homogeneous population of cells and avoid the likely variation that would have 
occurred with use of heterogeneous cell lines. Also, this study covered all the major DNMT 
isoforms which allowed the understanding of the different structure on DNA methylation 
patterns. Biological duplicates were used in this study, each from a different single cell clone. 
This approach was taken to reduce sample bias. Additionally, cell lines that overexpress each 
of the DNMTs individually, were generated using a lentivirus system, which is a highly 
efficient method for introducing foreign mRNA into the host genome. This exogenous mRNA 
is inherited to subsequent cell generations. In this study, DNMTs were over-expressed in two 
different cell types to begin with MEG-01 and HEK293T cells. HEK293T was the selected 
cell type for the main study due to its more reliable expression of exogenous DNMTs, 
compared with MEG-01 cells (see section 3.6.4, page 72). The reference genes for making a 
comparative quantification were calculated and selected using eleven house-keeping genes 




over-expressed DNMT cells and the Myc control were selected to obtain a more accurate 
expression. Furthermore, this study measured DNA methylation changes using the EPIC 
array, which interrogates >850,000 CpGs. Pyrosequencing was conducted to confirm the 
DNA methylation levels from EPIC array findings and to measure the DNA methylation of 
CpG sites targeted by DNMTs. Discordant duplicates from the EPIC array data were filtered 
out of the analysis. Additionally, the cut-offs for Δβ were set at Δβ ≤ -0.4 and ≥ 0.4 to capture 
true changes in DNA methylation, which were confirmed by pyrosequencing. All 
measurements of DNA methylation changes and DNMT activity were performed with 
technical triplicates.  
The limitations of this study are that 1) the single cell clone cannot be generated for 
MEG-01 cells because of technical problems including separating live and dead cells, and 2) 
the number of samples replicates carried forward for EPIC array analysis was small (two 
samples represented each cell line that overexpresses each of the DNMTs individually) due to 
the budget of the research grant 3) the bioinformatic tool for pathway analysis was changed 
due to the current inability to access IPA from home during the Covid-19 pandemic. 
However, the vulnerabilities in the study design from point 2 above were somewhat negated 
by the statistical approach to select only for significant or true positive results, through 
employing the cut-offs (Δβ ≤ -0.4 and ≥ 0.4). Difficulties were experienced in achieving 
distinct bands in western blots, due to each DNMT isoform differing in expression level and 
in protein stability. Thus, the western blot was performed across a concentration gradient. 
Although DNMTΔ3B3 was not clearly detected on the blot, the function of this isoform can 
be measured using LINE-1 assay. Global methylation was increased by this isoform (see 
section 5.6.2, page 122).  
 
6.5 Future studies 
The panel of cell lines created in this project is a valuable tool to facilitate in studying of the 
function of individual DNMT isoforms because these cell lines make it possible to observe 
the changes in DNA methylation patterns for each DNMT individually. Over-expression of 
DNMTs is associated with a number of diseases, especially cancer (see Introduction section, 
1.4.2 and Table 1.1). Some leukaemia cases, as well as, pancreatic cancer, colon and lung 
cancers show elevated expression of DNMT1 and DNMT3B (306, 346-348). Furthermore, 




including cancer cell lines, e.g. H69 and U937 (306). Concurrently, Dnmt1 overexpression in 
ES cells showed a significant change of the genomic DNA methylation level (281). 
Studies investigating all potential DNMTi and methyl donors are needed to understand 
the biological link and broader picture of the function of DNMTs under micronutrient 
exposure. Epigenetic traits are cell and tissue specific, thus the study of epigenetics in model 
organisms may provide extrapolative findings. This study provides some clues about the 
concentration and timing of treatment with nutritional compounds. These can be applied in 
the setup of an epigenetics intervention study in disease prevention, since the timing of 
epigenetic modification through exposure to a medicinal compound might be of significance. 
Conducting further investigation of downstream analyses will give a deeper understanding of 
the underlying epigenetic modifying mechanism of each nutrient. It would be beneficial to 
carry out gene expression profiles and protein quantitation of DNMT target genes and then, 
predict potential pathways which may form as potential targets for therapy. In future work, 
methylation profiles could be recorded prior to, and after, treatments with the nutritional 
compounds, where correlation may be drawn with the data obtained from this study. This type 
of dataset would provide detail on the epigenetic profiles in other CpG sites rather than target 
CpG sites of DNMTs. Furthermore, the relationship between DNA methylation and histone 
modification can be explored as both mechanisms influence transcription. Yang C. et al. 
found that epigenetically methylated CpG sites of Cellular Retinoic Acid Binding Protein 2 
might affect histone binding and associated this with gene silencing (349).  
 Given the opposite DNA methylation patterns measured at the CpGs targeted by 
DNMTs in dietary constituents treated HEK293T cells (e.g. from methylated to 
unmethylated), it is worth examining the effects of these compounds in a broader range of cell 
types to enhance our understanding on the effects of nutrition by cell type. The interaction of 
DNMTs and CA or vitamin C should be investigated by ICM assay described by Kui L. et al. 
(350) to track DNMT’s binding to genomic DNA. Moreover, the computerisation analysis 
should be performed to see how CA and vitamin C binds to DNMTs to confirm the inhibitory 
effects observed in this study. Another proposal for future examination is the research of the 
reversible epigenetic modifications through diet or specific nutrients, which could also help 
health maintenance and disease prevention. Moreover, the outcomes of this study can form 
the basis of finding a suitable balance of DNA methylation levels from dietary DNMTi and 
methyl donors. Tailoring nutriepigenomics will bring us steps closer to the ultimate goal of 






Figure 6.3 Personalised nutriepigenomics. In a typical interaction between environment and 
genome, diet is fed into the body (referred to as a light-dispersing from prism). The individual 
genome and epigenome, including the difference of either the expression or the activity of 
DNMT isoforms, response to diet in a multiway (referred to as individual dispersed light). 
The nutriepigenomic response is a function of the characteristics of the individual reaction to 
nutrient or food bioactive compounds. When taken through a personal nutrition regime, the 
balance diet between methyl donor and DNMT inhibitor diets will be ultimately be controlled 
by the personalised diet intervention (referred to as the last converging lens), leading to an 
optimal health status taking individual characteristics into consideration. 
 
6.6 Conclusion 
This study was successful to generate the novel single stable cell lines with 13 individually 
over-expressed DNMTs from HEK293T cells. The data derived from the EPIC data analysis 
supports my hypothesis that the pattern of DNA methylation in cells that overexpress 
individual DNMT isoforms is altered by the structure of each DNMT isoform. Also, the 
outcome from EPIC analysis allows to identify the de novo target CpG sites of each 
individual DNMT isoform. Results obtained from the outcome measure on DNA methylation 
in over-expressed DNMT cells after treatment with polyphenols and vitamin C support my 
hypothesis that global DNA methylation and locus-specific DMPs were modulated by these 
dietary constituents. Additionally, the activity of DNMT∆3B4 and DNMT3A2 can be 
specifically modulated by CA and AA, respectively, in a dose-response manner. These 
observations further understanding of nutrition-epigenetic mechanisms, especially interactions 
with enzymatic activity and these understanding provides novel evidence on the effect of 
DNMTi diet on DNMT sub-isoforms. These findings highlight the further need to investigate 
the intervention study using CA and vitamin C supplementation to manipulate epigenome, 
especially the DNMT activity. This understanding could be applied to modulate DNA 
methylation profiles using food-derived bioactive compounds in PA. This application of this 
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Figure A1 Alignment result between DNMT3B1 and DNMT3B2. Majority is a method to 
sum the weights of a base in DNA sequences, yellow highlights represent 100% similar 











Figure A2 Alignment result among DNMT3B2, DNMT3B3, DNMT3B4 and DNMT3B5. 
Majority is a method to sum the weights of a base in DNA sequences, yellow highlights 













Figure A3 Alignment result between DNMT3A1 and DNMT3A2. Majority is a method to 
sum the weights of a base in DNA sequences, yellow highlights represent 100% similar 



















Figure A4 Alignment result among DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, and 
DNMTΔ3B4. Majority is a method to sum the weights of a base in DNA sequences, yellow 










Figure A5 Alignment result between DNMT3L and pcDNA-MycDNMT3L (commercial 
plasmid). Majority is a method to sum the weights of a base in DNA sequences, yellow 


















Figure A6 Alignment result between DNMT1 and pcDNA-MycDNMT1 (commercial 
plasmid). Majority is a method to sum the weights of a base in DNA sequences, yellow 








Homo sapiens DNA methyltransferase 3 alpha (DNMT3A), transcript variant 3, mRNA 
Sequence ID: NM_022552.5 Length: 9421Number of Matches: 1 
 
Score Expect Identities 
1317 bits(713) 0.0 713/713(100%) 
Query  1    ATGCCCGCCATGCCCTCCAGCGGCCCCGGGGACACCAGCAGCTCTGCTGCggagcgggag  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  278  ATGCCCGCCATGCCCTCCAGCGGCCCCGGGGACACCAGCAGCTCTGCTGCGGAGCGGGAG  337 
 
Query  61   gaggaccgaaaggacggagaggagcaggaggagccgcgtggcaaggaggagcgccaagag  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  338  GAGGACCGAAAGGACGGAGAGGAGCAGGAGGAGCCGCGTGGCAAGGAGGAGCGCCAAGAG  397 
 
Query  121  cCCAGCACCACGGCACGGAAGGTGGGGCGGCCTGGGAGGAAGCGCAAGCACCCCCCGGTG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  398  CCCAGCACCACGGCACGGAAGGTGGGGCGGCCTGGGAGGAAGCGCAAGCACCCCCCGGTG  457 
 
Query  181  GAAAGCGGTGACACGCCAAAGGACCCTGCGGTGATCTCCAAGTCCCCATCCATGGCCCAG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  458  GAAAGCGGTGACACGCCAAAGGACCCTGCGGTGATCTCCAAGTCCCCATCCATGGCCCAG  517 
 
Query  241  GACTCAGGCGCCTCAGAGCTATTACCCAATGGGGACTTGGAGAAGCGGAGTGAGCCCCAG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  518  GACTCAGGCGCCTCAGAGCTATTACCCAATGGGGACTTGGAGAAGCGGAGTGAGCCCCAG  577 
 
Query  301  CCAGAGGAGGGGAGCCCTGCTGGGGGGCAGAAGGGCGGGGCCCCAGCAGAGGGAGAGGGT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  578  CCAGAGGAGGGGAGCCCTGCTGGGGGGCAGAAGGGCGGGGCCCCAGCAGAGGGAGAGGGT  637 
 
Query  361  GCAGCTGAGACCCTGCCTGAAGCCTCAAGAGCAGTGGAAAATGGCTGCTGCACCCCCAAG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  638  GCAGCTGAGACCCTGCCTGAAGCCTCAAGAGCAGTGGAAAATGGCTGCTGCACCCCCAAG  697 
 
Query  421  GAGGGCCGAGGAGCCCCTGCAGAAGCGGGCAAAGAACAGAAGGAGACCAACATCGAATCC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  698  GAGGGCCGAGGAGCCCCTGCAGAAGCGGGCAAAGAACAGAAGGAGACCAACATCGAATCC  757 
 
Query  481  ATGAAAATGGAGGGCTCCCGGGGCCGGCTGCGGGGTGGCTTGGGCTGGGAGTCCAGCCTC  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541  CGTCAGCGGCCCATGCCGAGGCTCACCTTCCAGGCGGGGGACCCCTACTACATCAGCAAG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  818  CGTCAGCGGCCCATGCCGAGGCTCACCTTCCAGGCGGGGGACCCCTACTACATCAGCAAG  877 
 
Query  601  CGCAAGCGGGACGAGTGGCTGGCACGCTGGAAAAGGGAGGCTGAGAAGAAAGCCAAGGTC  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  878  CGCAAGCGGGACGAGTGGCTGGCACGCTGGAAAAGGGAGGCTGAGAAGAAAGCCAAGGTC  937 
 
Query  661  ATTGCAGGAATGAATGCTGTGGAAGAAAACCAGGGGCCCGGGGAGTCTCAGAA  713 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 alpha (DNMT3A), transcript variant 3, mRNA 
Sequence ID: NM_022552.5Length: 9421Number of Matches: 1 
 
Score Expect Identities 
1491 bits(807) 0.0 807/807(100%) 
Query  1     AATGCTGTGGAAGAAAACCAGGGGCCCGGGGAGTCTCAGAAGGTGGAGGAGGCCAGCCCT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  950   AATGCTGTGGAAGAAAACCAGGGGCCCGGGGAGTCTCAGAAGGTGGAGGAGGCCAGCCCT  1009 
 
Query  61    CCTGCTGTGCAGCAGCCCACTGACCCCGCATCCCCCACTGTGGCTACCACGCCTGAGCCC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1010  CCTGCTGTGCAGCAGCCCACTGACCCCGCATCCCCCACTGTGGCTACCACGCCTGAGCCC  1069 
 
Query  121   GTGGGGTCCGATGCTGGGGACAAGAATGCCACCAAAGCAGGCGATGACGAGCCAGAGTAC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1070  GTGGGGTCCGATGCTGGGGACAAGAATGCCACCAAAGCAGGCGATGACGAGCCAGAGTAC  1129 
 
Query  181   GAGGACGGCCGGGGCTTTGGCATTGGGGAGCTGGTGTGGGGGAAACTGCGGGGCTTCTCC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1130  GAGGACGGCCGGGGCTTTGGCATTGGGGAGCTGGTGTGGGGGAAACTGCGGGGCTTCTCC  1189 
 
Query  241   TGGTGGCCAGGCCGCATTGTGTCTTGGTGGATGACGGGCCGGAGCCGAGCAGCTGAAGGC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1190  TGGTGGCCAGGCCGCATTGTGTCTTGGTGGATGACGGGCCGGAGCCGAGCAGCTGAAGGC  1249 
 
Query  301   ACCCGCTGGGTCATGTGGTTCGGAGACGGCAAATTCTCAGTGGTGTGTGTTGAGAAGCTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1250  ACCCGCTGGGTCATGTGGTTCGGAGACGGCAAATTCTCAGTGGTGTGTGTTGAGAAGCTG  1309 
 
Query  361   ATGCCGCTGAGCTCGTTTTGCAGTGCGTTCCACCAGGCCACGTACAACAAGCAGCCCATG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1310  ATGCCGCTGAGCTCGTTTTGCAGTGCGTTCCACCAGGCCACGTACAACAAGCAGCCCATG  1369 
 
Query  421   TACCGCAAAGCCATCTACGAGGTCCTGCAGGTGGCCAGCAGCCGCGCGGGGAAGCTGTTC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1370  TACCGCAAAGCCATCTACGAGGTCCTGCAGGTGGCCAGCAGCCGCGCGGGGAAGCTGTTC  1429 
 
Query  481   CCGGTGTGCCACGACAGCGATGAGAGTGACACTGCCAAGGCCGTGGAGGTGCAGAACAAG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   CCCATGATTGAATGGGCCCTGGGGGGCTTCCAGCCTTCTGGCCCTAAGGGCCTGGAGCCA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1490  CCCATGATTGAATGGGCCCTGGGGGGCTTCCAGCCTTCTGGCCCTAAGGGCCTGGAGCCA  1549 
 
Query  601   CCAGAAGAAGAGAAGAATCCCTACAAAGAAGTGTACACGGACATGTGGGTGGAACCTGAG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1550  CCAGAAGAAGAGAAGAATCCCTACAAAGAAGTGTACACGGACATGTGGGTGGAACCTGAG  1609 
 
Query  661   GCAGCTGCCTACGCACCACCTCCACCAGCCAAAAAGCCCCGGAAGAGCACAGCGGAGAAG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1610  GCAGCTGCCTACGCACCACCTCCACCAGCCAAAAAGCCCCGGAAGAGCACAGCGGAGAAG  1669 
 
Query  721   CCCAAGGTCAAGGAGATTATTGATGAGCGCACAAGAGAGCGGCTGGTGTACGAGGTGCGG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1670  CCCAAGGTCAAGGAGATTATTGATGAGCGCACAAGAGAGCGGCTGGTGTACGAGGTGCGG  1729 
 
Query  781   CAGAAGTGCCGGAACATTGAGGACATC  807 
             ||||||||||||||||||||||||||| 








Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 1 
 
Score Expect Identities    
1803 bits(976) 0.0 984/987(99%)    
Query  1     AAGGGAGACACCAGGCATCTCAATGGAGAGGAGGACGCCGGCGGGAGGGAAGACTCGATC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  325   AAGGGAGACACCAGGCATCTCAATGGAGAGGAGGACGCCGGCGGGAGGGAAGACTCGATC  384 
 
Query  61    CTCGTCAACGGGGCCTGCAGCGACCAGTCCTCCGACTCGCCCCCAATCCTGGAGGCTATC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  385   CTCGTCAACGGGGCCTGCAGCGACCAGTCCTCCGACTCGCCCCCAATCCTGGAGGCTATC  444 
 
Query  121   CGCACCCCGGAGATCAGAGGCCGAAGATCAAGCTCGCGACTCTCCAAGAGGGAGGTGTCC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  445   CGCACCCCGGAGATCAGAGGCCGAAGATCAAGCTCGCGACTCTCCAAGAGGGAGGTGTCC  504 
 
Query  181   AGTCTGCTAAGCTACACACAGGACTTGACAGGCGATGGCGACGGGGAAGATGGGGATGGC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  505   AGTCTGCTAAGCTACACACAGGACTTGACAGGCGATGGCGACGGGGAAGATGGGGATGGC  564 
 
Query  241   TCTGACACCCCAGTCATGCCAAAGCTCTTCCGGGAAACCAGGACTCGTTCAGAAAGCCCA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  565   TCTGACACCCCAGTCATGCCAAAGCTCTTCCGGGAAACCAGGACTCGTTCAGAAAGCCCA  624 
 
Query  301   GCTGTCCGAACTCGAAATAACAACAGTGTCTCCAGCCGGGAGAGGCACAGGCCTTCCCCA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  625   GCTGTCCGAACTCGAAATAACAACAGTGTCTCCAGCCGGGAGAGGCACAGGCCTTCCCCA  684 
 
Query  361   CGTTCCACCCGAGGCCGGCAGGGCCGCAACCATGTGGACGAGTCCCCCGTGGAGTTCCCG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  685   CGTTCCACCCGAGGCCGGCAGGGCCGCAACCATGTGGACGAGTCCCCCGTGGAGTTCCCG  744 
 
Query  421   GCTACCAGGTCCCTGAGACGGCGGGCAACAGCATCGGCAGGAACGCCATGGCCGTCCCCT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  745   GCTACCAGGTCCCTGAGACGGCGGGCAACAGCATCGGCAGGAACGCCATGGCCGTCCCCT  804 
 
Query  481   CCCAGCTCTTACCTTACCATCGACCTCACAGACGACACAGAGGACACACATGGGACGCCC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   CAGAGCAGCAGTACCCCCTACGCCCGCCTAGCCCAGGACAGCCAGCAGGGGGGCATGGAG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  865   CAGAGCAGCAGTACCCCCTACGCCCGCCTAGCCCAGGACAGCCAGCAGGGGGGCATGGAG  924 
 
Query  601   TCCCCGCAGGTGGAGGCAGACAGTGGAGATGGAGACAGTTCAGAGTATCAGGATGGGAAG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  925   TCCCCGCAGGTGGAGGCAGACAGTGGAGATGGAGACAGTTCAGAGTATCAGGATGGGAAG  984 
 
Query  661   GAGTTTGGAATAGGGGACCTCGTGTGGGGAAAGATCAAGGGCTTCTCCTGGTGGCCCGCC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  985   GAGTTTGGAATAGGGGACCTCGTGTGGGGAAAGATCAAGGGCTTCTCCTGGTGGCCCGCC  1044 
 
Query  721   ATGGTGGTGTCTTGGAAGGCCACCTCCAAGCGACAGGCTATGTCTGGCATGCGGTGGGTC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1045  ATGGTGGTGTCTTGGAAGGCCACCTCCAAGCGACAGGCTATGTCTGGCATGCGGTGGGTC  1104 
 
Query  781   CAGTGGTTTGGCGATGGCAAGTTCTCCGAGGTCTCTGCAGACAAACTGGTGGCACTGGGG  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  1105  CAGTGGTTTGGCGATGGCAAGTTCTCCGAGGTCTCTGCAGACAAACTGGTGGCACT-GGG  1163 
 
Query  841   GCTGTTCAGCCAGCACTTTAATTTGGCCACCTTCAATAAGCTCGTCTCCTATCGAAAAGC  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1164  GCTGTTCAGCCAGCACTTTAATTTGGCCACCTTCAATAAGCTCGTCTCCTATCGAAAAGC  1223 
 
Query  901   CATGTACCATGCTCTGGAGAAAGCTAGGGTGCGAGCTGGCAAGACCTTCCCCAGCAGCCC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1224  CATGTACCATGCTCTGGAGAAAGCTAGGGTGCGAGCTGGCAAGACCTTCCCCAGCAGCCC  1283 
 
Query  961   TGGAAGACTCATTGGAAGGACCAGCTG  987 
             |||| ||||||||||| |||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 1 
 
Score Expect Identities 
1829 bits(990) 0.0 990/990(100%) 
Query  1     AGGCACAGCGGCCGAGGCCAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTCCCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1851  AGGCACAGCGGCCGAGGCCAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTCCCGCA  1910 
 
Query  61    GCGCTGTCATGGCGTCCTGCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCCTTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1911  GCGCTGTCATGGCGTCCTGCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCCTTCTT  1970 
 
Query  121   CACCAGTGACACGGGGCTTGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCCGCAGC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1971  CACCAGTGACACGGGGCTTGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCCGCAGC  2030 
 
Query  181   CCGAAGGCGGCCCATTCGAGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTACCTAGT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2031  CCGAAGGCGGCCCATTCGAGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTACCTAGT  2090 
 
Query  241   CCTCAAAGAGTTGGGCATAAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAGGAGTC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2091  CCTCAAAGAGTTGGGCATAAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAGGAGTC  2150 
 
Query  301   CATTGCTGTTGGAACCGTGAAGCACGAGGGGAATATCAAATACGTGAACGACGTGAGGAA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2151  CATTGCTGTTGGAACCGTGAAGCACGAGGGGAATATCAAATACGTGAACGACGTGAGGAA  2210 
 
Query  361   CATCACAAAGAAAAATATTGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGAAGCCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2211  CATCACAAAGAAAAATATTGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGAAGCCC  2270 
 
Query  421   ATGCAACGATCTCTCAAATGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACAGGCCG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2271  ATGCAACGATCTCTCAAATGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACAGGCCG  2330 
 
Query  481   GCTCTTCTTCGAATTTTACCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGATGACCG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   GCCGTTCTTCTGGATGTTTGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGGGACAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2391  GCCGTTCTTCTGGATGTTTGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGGGACAT  2450 
 
Query  601   CTCACGGTTCCTGGAGTGTAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCTGCTCA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2451  CTCACGGTTCCTGGAGTGTAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCTGCTCA  2510 
 
Query  661   CAGGGCCCGATACTTCTGGGGCAACCTACCCGGGATGAACAGGCCCGTGATAGCATCAAA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2511  CAGGGCCCGATACTTCTGGGGCAACCTACCCGGGATGAACAGGCCCGTGATAGCATCAAA  2570 
 
Query  721   GAATGATAAACTCGAGCTGCAGGACTGCTTGGAATACAATAGGATAGCCAAGTTAAAGAA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2571  GAATGATAAACTCGAGCTGCAGGACTGCTTGGAATACAATAGGATAGCCAAGTTAAAGAA  2630 
 
Query  781   AGTACAGACAATAACCACCAAGTCGAACTCGATCAAACAGGGGAAAAACCAACTTTTCCC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2631  AGTACAGACAATAACCACCAAGTCGAACTCGATCAAACAGGGGAAAAACCAACTTTTCCC  2690 
 
Query  841   TGTTGTCATGAATGGCAAAGAAGATGTTTTGTGGTGCACTGAGCTCGAAAGGATCTTTGG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2691  TGTTGTCATGAATGGCAAAGAAGATGTTTTGTGGTGCACTGAGCTCGAAAGGATCTTTGG  2750 
 
Query  901   CTTTCCTGTGCACTACACAGACGTGTCCAACATGGGCCGTGGTGCCCGCCAGAAGCTGCT  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2751  CTTTCCTGTGCACTACACAGACGTGTCCAACATGGGCCGTGGTGCCCGCCAGAAGCTGCT  2810 
 
Query  961   GGGAAGGTCCTGGAGCGTGCCTGTCATCCG  990 
             |||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 1 
 
Score Expect Identities 
1576 bits(853) 0.0 853/853(100%) 
Query  1     GACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATCAGTC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1689  GACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATCAGTC  1748 
 
Query  61    TTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCAGCAACACGAGCTGCTG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1749  TTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCAGCAACACGAGCTGCTG  1808 
 
Query  121   CCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGTGGGCACAGGCACAGCGGCCGAGGC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1809  CCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGTGGGCACAGGCACAGCGGCCGAGGC  1868 
 
Query  181   CAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTCCCGCAGCGCTGTCATGGCGTCCT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1869  CAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTCCCGCAGCGCTGTCATGGCGTCCT  1928 
 
Query  241   GCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCCTTCTTCACCAGTGACACGGGGCT  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1929  GCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCCTTCTTCACCAGTGACACGGGGCT  1988 
 
Query  301   TGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCCGCAGCCCGAAGGCGGCCCATTCG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1989  TGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCCGCAGCCCGAAGGCGGCCCATTCG  2048 
 
Query  361   AGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTACCTAGTCCTCAAAGAGTTGGGCAT  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2049  AGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTACCTAGTCCTCAAAGAGTTGGGCAT  2108 
 
Query  421   AAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAGGAGTCCATTGCTGTTGGAACCGT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2109  AAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAGGAGTCCATTGCTGTTGGAACCGT  2168 
 
Query  481   GAAGCACGAGGGGAATATCAAATACGTGAACGACGTGAGGAACATCACAAAGAAAAATAT  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   TGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGAAGCCCATGCAACGATCTCTCAAA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2229  TGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGAAGCCCATGCAACGATCTCTCAAA  2288 
 
Query  601   TGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACAGGCCGGCTCTTCTTCGAATTTTA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2289  TGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACAGGCCGGCTCTTCTTCGAATTTTA  2348 
 
Query  661   CCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGATGACCGGCCGTTCTTCTGGATGTT  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2349  CCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGATGACCGGCCGTTCTTCTGGATGTT  2408 
 
Query  721   TGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGGGACATCTCACGGTTCCTGGAGTG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2409  TGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGGGACATCTCACGGTTCCTGGAGTG  2468 
 
Query  781   TAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCTGCTCACAGGGCCCGATACTTCTG  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2469  TAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCTGCTCACAGGGCCCGATACTTCTG  2528 
 
Query  841   GGGCAACCTACCC  853 
             ||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 1 
 
Score Expect Identities 
1838 bits(995) 0.0 995/995(100%) 
Query  1     GACCGAGGGGATGAAGATCAGAGCCGAGAACAAATGGCTTCAGATGTTGCCAACAACAAG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1546  GACCGAGGGGATGAAGATCAGAGCCGAGAACAAATGGCTTCAGATGTTGCCAACAACAAG  1605 
 
Query  61    AGCAGCCTGGAAGATGGCTGTTTGTCTTGTGGCAGGAAAAACCCCGTGTCCTTCCACCCT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1606  AGCAGCCTGGAAGATGGCTGTTTGTCTTGTGGCAGGAAAAACCCCGTGTCCTTCCACCCT  1665 
 
Query  121   CTCTTTGAgggggggCTCTGTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1666  CTCTTTGAGGGGGGGCTCTGTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATG  1725 
 
Query  181   TATGATGACGATGGCTATCAGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1726  TATGATGACGATGGCTATCAGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTG  1785 
 
Query  241   CTTTGCAGCAACACGAGCTGCTGCCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1786  CTTTGCAGCAACACGAGCTGCTGCCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGTG  1845 
 
Query  301   GGCACAGGCACAGCGGCCGAGGCCAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1846  GGCACAGGCACAGCGGCCGAGGCCAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTC  1905 
 
Query  361   CCGCAGCGCTGTCATGGCGTCCTGCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1906  CCGCAGCGCTGTCATGGCGTCCTGCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCC  1965 
 
Query  421   TTCTTCACCAGTGACACGGGGCTTGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1966  TTCTTCACCAGTGACACGGGGCTTGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCC  2025 
 
Query  481   GCAGCCCGAAGGCGGCCCATTCGAGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTAC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   CTAGTCCTCAAAGAGTTGGGCATAAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2086  CTAGTCCTCAAAGAGTTGGGCATAAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAG  2145 
 
Query  601   GAGTCCATTGCTGTTGGAACCGTGAAGCACGAGGGGAATATCAAATACGTGAACGACGTG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2146  GAGTCCATTGCTGTTGGAACCGTGAAGCACGAGGGGAATATCAAATACGTGAACGACGTG  2205 
 
Query  661   AGGAACATCACAAAGAAAAATATTGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2206  AGGAACATCACAAAGAAAAATATTGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGA  2265 
 
Query  721   AGCCCATGCAACGATCTCTCAAATGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2266  AGCCCATGCAACGATCTCTCAAATGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACA  2325 
 
Query  781   GGCCGGCTCTTCTTCGAATTTTACCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGAT  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2326  GGCCGGCTCTTCTTCGAATTTTACCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGAT  2385 
 
Query  841   GACCGGCCGTTCTTCTGGATGTTTGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2386  GACCGGCCGTTCTTCTGGATGTTTGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGG  2445 
 
Query  901   GACATCTCACGGTTCCTGGAGTGTAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCT  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2446  GACATCTCACGGTTCCTGGAGTGTAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCT  2505 
 
Query  961   GCTCACAGGGCCCGATACTTCTGGGGCAACCTACC  995 
             ||||||||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 2 
 
Score Expect Identities 
1733 bits(938) 0.0 938/938(100%) 
Query  1     GTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1685  GTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATC  1744 
 
Query  61    AGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCAGCAACACGAGCT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1745  AGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCAGCAACACGAGCT  1804 
 
Query  121   GCTGCCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGTGGGCACAGGCACAGCGGCCG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1805  GCTGCCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGTGGGCACAGGCACAGCGGCCG  1864 
 
Query  181   AGGCCAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTCCCGCAGCGCTGTCATGGCG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1865  AGGCCAAGCTTCAGGAGCCCTGGAGCTGTTACATGTGTCTCCCGCAGCGCTGTCATGGCG  1924 
 
Query  241   TCCTGCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCCTTCTTCACCAGTGACACGG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1925  TCCTGCGGCGCCGGAAGGACTGGAACGTGCGCCTGCAGGCCTTCTTCACCAGTGACACGG  1984 
 
Query  301   GGCTTGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCCGCAGCCCGAAGGCGGCCCA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1985  GGCTTGAATATGAAGCCCCCAAGCTGTACCCTGCCATTCCCGCAGCCCGAAGGCGGCCCA  2044 
 
Query  361   TTCGAGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTACCTAGTCCTCAAAGAGTTGG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2045  TTCGAGTCCTGTCATTGTTTGATGGCATCGCGACAGGCTACCTAGTCCTCAAAGAGTTGG  2104 
 
Query  421   GCATAAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAGGAGTCCATTGCTGTTGGAA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2105  GCATAAAGGTAGGAAAGTACGTCGCTTCTGAAGTGTGTGAGGAGTCCATTGCTGTTGGAA  2164 
 
Query  481   CCGTGAAGCACGAGGGGAATATCAAATACGTGAACGACGTGAGGAACATCACAAAGAAAA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   ATATTGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGAAGCCCATGCAACGATCTCT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2225  ATATTGAAGAATGGGGCCCATTTGACTTGGTGATTGGCGGAAGCCCATGCAACGATCTCT  2284 
 
Query  601   CAAATGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACAGGCCGGCTCTTCTTCGAAT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2285  CAAATGTGAATCCAGCCAGGAAAGGCCTGTATGAGGGTACAGGCCGGCTCTTCTTCGAAT  2344 
 
Query  661   TTTACCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGATGACCGGCCGTTCTTCTGGA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2345  TTTACCACCTGCTGAATTACTCACGCCCCAAGGAGGGTGATGACCGGCCGTTCTTCTGGA  2404 
 
Query  721   TGTTTGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGGGACATCTCACGGTTCCTGG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2405  TGTTTGAGAATGTTGTAGCCATGAAGGTTGGCGACAAGAGGGACATCTCACGGTTCCTGG  2464 
 
Query  781   AGTGTAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCTGCTCACAGGGCCCGATACT  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2465  AGTGTAATCCAGTGATGATTGATGCCATCAAAGTTTCTGCTGCTCACAGGGCCCGATACT  2524 
 
Query  841   TCTGGGGCAACCTACCCGGGATGAACAGGCCCGTGATAGCATCAAAGAATGATAAACTCG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2525  TCTGGGGCAACCTACCCGGGATGAACAGGCCCGTGATAGCATCAAAGAATGATAAACTCG  2584 
 
Query  901   AGCTGCAGGACTGCTTGGAATACAATAGGATAGCCAAG  938 
             |||||||||||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 1 
 
Score Expect Identities 
1600 bits(866) 0.0 869/870(99%) 
Query  1     GAGTCCCCGCAGGTGGAGGCAGACAGTGGAGATGGAGACAGTTCAGAGTATCAGGATGGG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  922   GAGTCCCCGCAGGTGGAGGCAGACAGTGGAGATGGAGACAGTTCAGAGTATCAGGATGGG  981 
 
Query  61    AAGGAGTTTGGAATAGGGGACCTCGTGTGGGGAAAGATCAAGGGCTTCTCCTGGTGGCCC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  982   AAGGAGTTTGGAATAGGGGACCTCGTGTGGGGAAAGATCAAGGGCTTCTCCTGGTGGCCC  1041 
 
Query  121   GCCATGGTGGTGTCTTGGAAGGCCACCTCCAAGCGACAGGCTATGTCTGGCATGCGGTGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1042  GCCATGGTGGTGTCTTGGAAGGCCACCTCCAAGCGACAGGCTATGTCTGGCATGCGGTGG  1101 
 
Query  181   GTCCAGTGGTTTGGCGATGGCAAGTTCTCCGAGGTCTCTGCAGACAAACTGGTGGCACTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1102  GTCCAGTGGTTTGGCGATGGCAAGTTCTCCGAGGTCTCTGCAGACAAACTGGTGGCACTG  1161 
 
Query  241   GGGCTGTTCAGCCAGCACTTTAATTTGGCCACCTTCAATAAGCTCGTCTCCTATCGAAAA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1162  GGGCTGTTCAGCCAGCACTTTAATTTGGCCACCTTCAATAAGCTCGTCTCCTATCGAAAA  1221 
 
Query  301   GCCATGTACCATGCTCTGGAGAAAGCTAGGGTGCGAGCTGGCAAGACCTTCCCCAGCAGC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1222  GCCATGTACCATGCTCTGGAGAAAGCTAGGGTGCGAGCTGGCAAGACCTTCCCCAGCAGC  1281 
 
Query  361   CCTGGAGACTCATTGGAGGACCAGCTGAAGCCCATGTTGGAGTGGGCCCACGGGGGCTTC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1282  CCTGGAGACTCATTGGAGGACCAGCTGAAGCCCATGTTGGAGTGGGCCCACGGGGGCTTC  1341 
 
Query  421   AAGCCCACTGGGATCGAGGGCCTCAAACCCAACAACACGCAACCAGTGGTTAATAAGTCG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1342  AAGCCCACTGGGATCGAGGGCCTCAAACCCAACAACACGCAACCAGTGGTTAATAAGTCG  1401 
 
Query  481   AAGGTGCGTCGTGCAGGCAGTAGGAAATTAGAATCAAGGAAATACGAGAACAAGACTCGA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   AGACGCACAGCTGACGACTCAGCCACCTCTGACTACTGCCCCGCACCCAAGCGCCTCAAG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1462  AGACGCACAGCTGACGACTCAGCCACCTCTGACTACTGCCCCGCACCCAAGCGCCTCAAG  1521 
 
Query  601   ACAAATTGCTATAACAACGGCAAAGACCGAGGGGATGAAGATCAGAGCCGAGAACAAATG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1522  ACAAATTGCTATAACAACGGCAAAGACCGAGGGGATGAAGATCAGAGCCGAGAACAAATG  1581 
 
Query  661   GCTTCAGATGTTGCCAACAACAAGAGCAGCCTGGAAGATGGCTGTTTGTCTTGTGGCAGG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1582  GCTTCAGATGTTGCCAACAACAAGAGCAGCCTGGAAGATGGCTGTTTGTCTTGTGGCAGG  1641 
 
Query  721   AAAAACCCCGTGTCCTTCCACCCTCTCTTTGAgggggggCTCTGTCAGACATGCCGGGGA  780 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  1642  AAAAACCCCGTGTCCTTCCACCCTCTCTTTGAGGGGGGGCTCTGTCAGACATGCC-GGGA  1700 
 
Query  781   TCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATCAGTCTTACTGCACTGT  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1701  TCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATCAGTCTTACTGCACTGT  1760 
 
Query  841   GTGCTGCGAGGGCCGAGAGCTGCTGCTTTG  870 
             |||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 2, mRNA 
Sequence ID: NM_175848.2Length: 4276Number of Matches: 1 
 
Score Expect Identities 
1415 bits(766) 0.0 769/770(99%) 
Query  1     GAGTCCCCGCAGGTGGAGGCAGACAGTGGAGATGGAGACAGTTCAGAGTATCAGGATGGG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  922   GAGTCCCCGCAGGTGGAGGCAGACAGTGGAGATGGAGACAGTTCAGAGTATCAGGATGGG  981 
 
Query  61    AAGGAGTTTGGAATAGGGGACCTCGTGTGGGGAAAGATCAAGGGCTTCTCCTGGTGGCCC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  982   AAGGAGTTTGGAATAGGGGACCTCGTGTGGGGAAAGATCAAGGGCTTCTCCTGGTGGCCC  1041 
 
Query  121   GCCATGGTGGTGTCTTGGAAGGCCACCTCCAAGCGACAGGCTATGTCTGGCATGCGGTGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1042  GCCATGGTGGTGTCTTGGAAGGCCACCTCCAAGCGACAGGCTATGTCTGGCATGCGGTGG  1101 
 
Query  181   GTCCAGTGGTTTGGCGATGGCAAGTTCTCCGAGGTCTCTGCAGACAAACTGGTGGCACTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1102  GTCCAGTGGTTTGGCGATGGCAAGTTCTCCGAGGTCTCTGCAGACAAACTGGTGGCACTG  1161 
 
Query  241   GGGCTGTTCAGCCAGCACTTTAATTTGGCCACCTTCAATAAGCTCGTCTCCTATCGAAAA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1162  GGGCTGTTCAGCCAGCACTTTAATTTGGCCACCTTCAATAAGCTCGTCTCCTATCGAAAA  1221 
 
Query  301   GCCATGTACCATGCTCTGGAGAAAGCTAGGGTGCGAGCTGGCAAGACCTTCCCCAGCAGC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1222  GCCATGTACCATGCTCTGGAGAAAGCTAGGGTGCGAGCTGGCAAGACCTTCCCCAGCAGC  1281 
 
Query  361   CCTGGAGACTCATTGGAGGACCAGCTGAAGCCCATGTTGGAGTGGGCCCACGGGGGCTTC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1282  CCTGGAGACTCATTGGAGGACCAGCTGAAGCCCATGTTGGAGTGGGCCCACGGGGGCTTC  1341 
 
Query  421   AAGCCCACTGGGATCGAGGGCCTCAAACCCAACAACACGCAACCAGAGAACAAGACTCGA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1342  AAGCCCACTGGGATCGAGGGCCTCAAACCCAACAACACGCAACCAGAGAACAAGACTCGA  1401 
 
Query  481   AGACGCACAGCTGACGACTCAGCCACCTCTGACTACTGCCCCGCACCCAAGCGCCTCAAG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   ACAAATTGCTATAACAACGGCAAAGACCGAGGGGATGAAGATCAGAGCCGAGAACAAATG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1462  ACAAATTGCTATAACAACGGCAAAGACCGAGGGGATGAAGATCAGAGCCGAGAACAAATG  1521 
 
Query  601   GCTTCAGATGTTGCCAACAACAAGAGCAGCCTGGAAGATGGCTGTTTGTCTTGTGGCAGG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1522  GCTTCAGATGTTGCCAACAACAAGAGCAGCCTGGAAGATGGCTGTTTGTCTTGTGGCAGG  1581 
 
Query  661   AAAAACCCCGTGTCCTTCCACCCTCTCTTTGAgggggggCTCTGTCAGACATGCCGGGGA  720 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  1582  AAAAACCCCGTGTCCTTCCACCCTCTCTTTGAGGGGGGGCTCTGTCAGACATGCC-GGGA  1640 
 
Query  721   TCGCTTCCTTGAGCTGTTTTACATGTATGATGACGATGGCTATCAGTCTT  770 
             |||||||||||||||||||||||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 1, mRNA 
Sequence ID: NM_006892.4Length: 4336Number of Matches: 2 
 
Score Expect Identities 
1380 bits(747) 0.0 751/753(99%) 
Query  53    AGGTCTCTGCAGACAAACTGGTGGCACTGGGGCTGTTCAGCCAGCACTTTAATTTGGCCA  112 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1133  AGGTCTCTGCAGACAAACTGGTGGCACTGGGGCTGTTCAGCCAGCACTTTAATTTGGCCA  1192 
 
Query  113   CCTTCAATAAGCTCGTCTCCTATCGAAAAGCCATGTACCATGCTCTGGAGAAAGCTAGGG  172 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1193  CCTTCAATAAGCTCGTCTCCTATCGAAAAGCCATGTACCATGCTCTGGAGAAAGCTAGGG  1252 
 
Query  173   TGCGAGCTGGCAAGACCTTCCCCAGCAGCCCTGGAGACTCATTGGAGGACCAGCTGAAGC  232 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1253  TGCGAGCTGGCAAGACCTTCCCCAGCAGCCCTGGAGACTCATTGGAGGACCAGCTGAAGC  1312 
 
Query  233   CCATGTTGGAGTGGGCCCACGGGGGCTTCAAGCCCACTGGGATCGAGGGCCTCAAACCCA  292 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1313  CCATGTTGGAGTGGGCCCACGGGGGCTTCAAGCCCACTGGGATCGAGGGCCTCAAACCCA  1372 
 
Query  293   ACAACACGCAACCAGTGGTTAATAAGTCGAAGGTGCGTCGTGCAGGCAGTAGGAAATTAG  352 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1373  ACAACACGCAACCAGTGGTTAATAAGTCGAAGGTGCGTCGTGCAGGCAGTAGGAAATTAG  1432 
 
Query  353   AATCAAGGAAATACGAGAACAAGACTCGAAGACGCACAGCTGACGACTCAGCCACCTCTG  412 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1433  AATCAAGGAAATACGAGAACAAGACTCGAAGACGCACAGCTGACGACTCAGCCACCTCTG  1492 
 
Query  413   ACTACTGCCCCGCACCCAAGCGCCTCAAGACAAATTGCTATAACAACGGCAAAGACCGAG  472 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1493  ACTACTGCCCCGCACCCAAGCGCCTCAAGACAAATTGCTATAACAACGGCAAAGACCGAG  1552 
 
Query  473   GGGATGAAGATCAGAGCCGAGAACAAATGGCTTCAGATGTTGCCAACAACAAGAGCAGCC  532 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1553  GGGATGAAGATCAGAGCCGAGAACAAATGGCTTCAGATGTTGCCAACAACAAGAGCAGCC  1612 
 
Query  533   TGGAAGATGGCTGTTTGTCTTGTGGCAGGAAAAACCCCGTGTCCTTCCACCCTCTCTTTG  592 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  593   AgggggggCTCTGTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATG  652 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1673  AGGGGGGGCTCTGTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATG  1732 
 
Query  653   ACGATGGCTATCAGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCA  712 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1733  ACGATGGCTATCAGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCA  1792 
 
Query  713   GCAACACGAGCTGCTGCCGGTGTTTCTGTGTGGAGTGCCTGNAGGTGCTGGTGGGGCACA  772 
             ||||||||||||||||||||||||||||||||||||||||| |||||||||| ||||||| 
Sbjct  1793  GCAACACGAGCTGCTGCCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGT-GGGCACA  1851 
 
Query  773   GGCACAGCGGCCGAGGCCAAGCTTCAGGAGCCC  805 
             ||||||||||||||||||||||||||||||||| 







Homo sapiens DNA methyltransferase 3 beta (DNMT3B), transcript variant 2, mRNA 
Sequence ID: NM_175848.2Length: 4276Number of Matches: 1 
 
Score Expect Identities 
1199 bits(649) 0.0 651/652(99%) 
Query  53    AGGTCTCTGCATACAAACTGGTGGCACTGGGGCTGTTCAGCCAGCACTTTAATTTGGCCA  112 
             ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1133  AGGTCTCTGCAGACAAACTGGTGGCACTGGGGCTGTTCAGCCAGCACTTTAATTTGGCCA  1192 
 
Query  113   CCTTCAATAAGCTCGTCTCCTATCGAAAAGCCATGTACCATGCTCTGGAGAAAGCTAGGG  172 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1193  CCTTCAATAAGCTCGTCTCCTATCGAAAAGCCATGTACCATGCTCTGGAGAAAGCTAGGG  1252 
 
Query  173   TGCGAGCTGGCAAGACCTTCCCCAGCAGCCCTGGAGACTCATTGGAGGACCAGCTGAAGC  232 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1253  TGCGAGCTGGCAAGACCTTCCCCAGCAGCCCTGGAGACTCATTGGAGGACCAGCTGAAGC  1312 
 
Query  233   CCATGTTGGAGTGGGCCCACGGGGGCTTCAAGCCCACTGGGATCGAGGGCCTCAAACCCA  292 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1313  CCATGTTGGAGTGGGCCCACGGGGGCTTCAAGCCCACTGGGATCGAGGGCCTCAAACCCA  1372 
 
Query  293   ACAACACGCAACCAGAGAACAAGACTCGAAGACGCACAGCTGACGACTCAGCCACCTCTG  352 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1373  ACAACACGCAACCAGAGAACAAGACTCGAAGACGCACAGCTGACGACTCAGCCACCTCTG  1432 
 
Query  353   ACTACTGCCCCGCACCCAAGCGCCTCAAGACAAATTGCTATAACAACGGCAAAGACCGAG  412 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1433  ACTACTGCCCCGCACCCAAGCGCCTCAAGACAAATTGCTATAACAACGGCAAAGACCGAG  1492 
 
Query  413   GGGATGAAGATCAGAGCCGAGAACAAATGGCTTCAGATGTTGCCAACAACAAGAGCAGCC  472 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1493  GGGATGAAGATCAGAGCCGAGAACAAATGGCTTCAGATGTTGCCAACAACAAGAGCAGCC  1552 
 
Query  473   TGGAAGATGGCTGTTTGTCTTGTGGCAGGAAAAACCCCGTGTCCTTCCACCCTCTCTTTG  532 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1553  TGGAAGATGGCTGTTTGTCTTGTGGCAGGAAAAACCCCGTGTCCTTCCACCCTCTCTTTG  1612 
 
Query  533   AgggggggCTCTGTCAGACATGCCGGGATCGCTTCCTTGAGCTGTTTTACATGTATGATG  592 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  593   ACGATGGCTATCAGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCA  652 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1673  ACGATGGCTATCAGTCTTACTGCACTGTGTGCTGCGAGGGCCGAGAGCTGCTGCTTTGCA  1732 
 
Query  653   GCAACACGAGCTGCTGCCGGTGTTTCTGTGTGGAGTGCCTGGAGGTGCTGGT  704 
             |||||||||||||||||||||||||||||||||||||||||||||||||||| 








Homo sapiens DNA methyltransferase 1 (DNMT1), transcript variant 2, mRNA 
Sequence ID: NM_001379.4Length: 5226Number of Matches: 1 
 
Score Expect Identities 
1664 bits(901) 0.0 901/901(100%) 
Query  1    CCGGCGCGTACCGCCCCAGCCCGGGTGCCCACACTGGCCGTCCCGGCCATCTCGCTGCCC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  58   CCGGCGCGTACCGCCCCAGCCCGGGTGCCCACACTGGCCGTCCCGGCCATCTCGCTGCCC  117 
 
Query  61   GACGATGTCCGCAGGCGGCTCAAAGATTTGGAAAGAGACAGCTTAACAGAAAAGGAATGT  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  118  GACGATGTCCGCAGGCGGCTCAAAGATTTGGAAAGAGACAGCTTAACAGAAAAGGAATGT  177 
 
Query  121  GTGAAGGAGAAATTGAATCTCTTGCACGAATTTCTGCAAACAGAAATAAAGAATCAGTTA  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  178  GTGAAGGAGAAATTGAATCTCTTGCACGAATTTCTGCAAACAGAAATAAAGAATCAGTTA  237 
 
Query  181  TGTGACTTGGAAACCAAATTACGTAAAGAAGAATTATCCGAGGAGGGCTACCTGGCTAAA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  238  TGTGACTTGGAAACCAAATTACGTAAAGAAGAATTATCCGAGGAGGGCTACCTGGCTAAA  297 
 
Query  241  GTCAAATCCCTTTTAAATAAAGATTTGTCCTTGGAGAACGGTGCTCATGCTTACAACCGG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  298  GTCAAATCCCTTTTAAATAAAGATTTGTCCTTGGAGAACGGTGCTCATGCTTACAACCGG  357 
 
Query  301  GAAGTGAATGGACGTCTAGAAAACGGGAACCAAGCAAGAAGTGAAGCCCGTAGAGTGGGA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  358  GAAGTGAATGGACGTCTAGAAAACGGGAACCAAGCAAGAAGTGAAGCCCGTAGAGTGGGA  417 
 
Query  361  ATGGCAGATGCCAACAGcccccccAAACCCCTTTCCAAACCTCGCACGCCCAGGAGGAGC  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  418  ATGGCAGATGCCAACAGCCCCCCCAAACCCCTTTCCAAACCTCGCACGCCCAGGAGGAGC  477 
 
Query  421  AAGTCCGATGGAGAGGCTAAGCCTGAACCTTCACCTAGCCCCAGGATTACAAGGAAAAGC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  478  AAGTCCGATGGAGAGGCTAAGCCTGAACCTTCACCTAGCCCCAGGATTACAAGGAAAAGC  537 
 
Query  481  ACCAGGCAAACCACCATCACATCTCATTTTGCAAAGGGCCCTGCCAAACGGAAACCTCAG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541  GAAGAGTCTGAAAGAGCCAAATCGGATGAGTCCATCAAGGAAGAAGACAAAGACCAGGAT  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  598  GAAGAGTCTGAAAGAGCCAAATCGGATGAGTCCATCAAGGAAGAAGACAAAGACCAGGAT  657 
 
Query  601  GAGAAGAGACGTAGAGTTACATCCAGAGAACGAGTTGCTAGACCGCTTCCTGCAGAAGAA  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  658  GAGAAGAGACGTAGAGTTACATCCAGAGAACGAGTTGCTAGACCGCTTCCTGCAGAAGAA  717 
 
Query  661  CCTGAAAGAGCAAAATCAGGAACGCGCACTgaaaaggaagaagaaagagatgaaaaagaa  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  718  CCTGAAAGAGCAAAATCAGGAACGCGCACTGAAAAGGAAGAAGAAAGAGATGAAAAAGAA  777 
 
Query  721  gaaaagagaCTCCGAAGTCAAACCAAAGAACCAACACCCAAACAGAAACTGAAGGAGGAG  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  778  GAAAAGAGACTCCGAAGTCAAACCAAAGAACCAACACCCAAACAGAAACTGAAGGAGGAG  837 
 
Query  781  CCGGACAGAGAAGCCAGGGCAGGCGTGCAGGCTGACGAGGACGAAGATGGAGACGAGAAA  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  838  CCGGACAGAGAAGCCAGGGCAGGCGTGCAGGCTGACGAGGACGAAGATGGAGACGAGAAA  897 
 
Query  841  GATGAGAAGAAGCACAGAAGTCAACCCAAAGATCTAGCTGCCAAACGGAGGCCCGAAGAA  900 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  898  GATGAGAAGAAGCACAGAAGTCAACCCAAAGATCTAGCTGCCAAACGGAGGCCCGAAGAA  957 
 
Query  901  A  901 
            | 







Homo sapiens DNA methyltransferase 3 like (DNMT3L), transcript variant 1, mRNA 
Sequence ID: NM_013369.4Length: 1387Number of Matches: 1 
 
Score Expect Identities 
1650 bits(893) 0.0 898/900(99%) 
Query  1     GCGGCCATCCCAGCCCTGGACCCAGAGGCCGAGCCCAGCATGGACGTGATTTTGGTGGGA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  169   GCGGCCATCCCAGCCCTGGACCCAGAGGCCGAGCCCAGCATGGACGTGATTTTGGTGGGA  228 
 
Query  61    TCCAGTGAGCTCTCAAGCTCCGTTTCACCCGGGACAGGCAGAGATCTTATTGCATATGAA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  229   TCCAGTGAGCTCTCAAGCTCCGTTTCACCCGGGACAGGCAGAGATCTTATTGCATATGAA  288 
 
Query  121   GTCAAGGCTAACCAGCGAAATATAGAAGACATCTGCATCTGCTGCGGAAGTCTCCAGGTT  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  289   GTCAAGGCTAACCAGCGAAATATAGAAGACATCTGCATCTGCTGCGGAAGTCTCCAGGTT  348 
 
Query  181   CACACACAGCACCCTCTGTTTGAGGGAGGGATCTGCGCCCCATGTAAGGACAAGTTCCTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  349   CACACACAGCACCCTCTGTTTGAGGGAGGGATCTGCGCCCCATGTAAGGACAAGTTCCTG  408 
 
Query  241   GATGCCCTCTTCCTGTACGACGATGACGGGTACCAATCCTACTGCTCCATCTGCTGCTCC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  409   GATGCCCTCTTCCTGTACGACGATGACGGGTACCAATCCTACTGCTCCATCTGCTGCTCC  468 
 
Query  301   GGAGAGACGCTGCTCATCTGCGGAAACCCTGATTGCACCCGATGCTACTGCTTCGAGTGT  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  469   GGAGAGACGCTGCTCATCTGCGGAAACCCTGATTGCACCCGATGCTACTGCTTCGAGTGT  528 
 
Query  361   GTGGATAGCCTGGTCGGCCCCGGGACCTCGGGGAAGGTGCACGCCATGAGCAACTGGGTG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  529   GTGGATAGCCTGGTCGGCCCCGGGACCTCGGGGAAGGTGCACGCCATGAGCAACTGGGTG  588 
 
Query  421   TGCTACCTGTGCCTGCCGTCCTCCCGAAGCGGGCTGCTGCAGCGTCGGAGGAAGTGGCGC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  589   TGCTACCTGTGCCTGCCGTCCTCCCGAAGCGGGCTGCTGCAGCGTCGGAGGAAGTGGCGC  648 
 
Query  481   AGCCAGCTCAAGGCCTTCTACGACCGAGAGTCGGAGAATCCCCTTGAGATGTTCGAAACC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  541   GTGCCTGTGTGGAGGAGACAGCCAGTCCGGGTGCTGTCCCTTTTTGAAGACATCAAGAAA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  709   GTGCCTGTGTGGAGGAGACAGCCAGTCCGGGTGCTGTCCCTTTTTGAAGACATCAAGAAA  768 
 
Query  601   GAGCTGACGAGTTTGGGCTTTTTGGAAAGTGGTTCTGACCCGGGACAACTGAAGCATGTG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  769   GAGCTGACGAGTTTGGGCTTTTTGGAAAGTGGTTCTGACCCGGGACAACTGAAGCATGTG  828 
 
Query  661   GTTGATGTCACAGACACAGTGAGGAAGGATGTGGAGGAGTGGGGACCCTTCGATCTTGTG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  829   GTTGATGTCACAGACACAGTGAGGAAGGATGTGGAGGAGTGGGGACCCTTCGATCTTGTG  888 
 
Query  721   TACGGCGCCACACCTCCCCTGGGCCACACCTGTGACCGTCCTCCCAGCTGGTACCTGTTC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  889   TACGGCGCCACACCTCCCCTGGGCCACACCTGTGACCGTCCTCCCAGCTGGTACCTGTTC  948 
 
Query  781   CAGTTCCACCGGCTCCTGCAGTACGCACGGCCCAAGCCAGGCAGCCCCAGGCCCTTCTTC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  949   CAGTTCCACCGGCTCCTGCAGTACGCACGGCCCAAGCCAGGCAGCCCCAGGCCCTTCTTC  1008 
 
Query  841   TGGATGTTCGTGGACAATCTGGTGCTGAAACAAGGAAGACCTGGAACGTCGCATCTCGCT  900 
             ||||||||||||||||||||||||||| |||||||||||||||| ||||||||||||||| 

































































































































































































































































































































































































































Figure B1 Alignment result between DNMT1 and pcDNA-MycDNMT1 (commercial 
plasmid). Majority is a method to sum the weights of a base in DNA sequences, yellow 


















Figure B2 Alignment result between DNMT3A1 and pIRESpuro3-DNMT3A1. Majority is a 
method to sum the weights of a base in DNA sequences, yellow highlights represent 100% 













Figure B3 Alignment result between DNMT3A2 and pcDNA3-DNMT3A2. Majority is a 
method to sum the weights of a base in DNA sequences, yellow highlights represent 100% 















Figure B4 Alignment result among DNMT3B2, pIRESpuro3-DNMT3B2, DNMT3B3, and 
pIRESpuro3-DNMT3B3. Majority is a method to sum the weights of a base in DNA 
sequences, yellow highlights represent 100% similar sequences with majority, number 












Figure B5 Alignment result among DNMT3B2, DNMT3B3, DNMT3B4, and DNMT3B5. 
Majority is a method to sum the weights of a base in DNA sequences, yellow highlights 













Figure B6 Alignment result between DNMT3B1 and pIRESpuro3-DNMT3B1. Majority is a 
method to sum the weights of a base in DNA sequences, yellow highlights represent 100% 













Figure B7 Alignment result among DNMTΔ3B1, DNMTΔ3B2, DNMTΔ3B3, and 
DNMTΔ3B4. Majority is a method to sum the weights of a base in DNA sequences, yellow 







Figure B8 Alignment result between DNMT3L and pcDNA-MycDNMT3L (commercial 
plasmid). Majority is a method to sum the weights of a base in DNA sequences, yellow 
highlights represent 100% similar sequences with majority, number indicates the number of 
base pair. 
 
Figure B9 Alignment result between Myc and pIRESpuro3-Myc. Majority is a method to sum 
the weights of a base in DNA sequences, yellow highlights represent 100% similar sequences 





10. Appendix C: Target genes for each DNMT isoform  
 
Table C1 Target genes of DNMT1 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg19245525 ACACB cg08387944 LINC00964 
cg18295758 ADAMTS16 cg27636676 LMX1A 
cg24985738 ADAMTS2 cg15671466 
LOC100506457 
cg26983228 ARHGAP15 cg23676348 
cg05927763 ATXN10 cg10171489 LY86 
cg24859648 BANF2 cg23094728 MAP3K1 
cg20943641 CCDC53 cg23220346 MIR128-2 
cg14085446 CDX1 cg07284339 OSBPL5 
cg13851989 CER1 cg25711003 PHLDB2 
cg23013853 CHGA cg10207469 PLX4 
cg20348618 CMKLR1 cg07461239 PTPRM 
cg10985909 CNST cg13173924 SCN1A 
cg09185643 CRMP1 cg16968681 SHC2 
cg26942892 DLGAP2 cg09868003 SHC4 
cg07611000 EHBP1L1 cg18886071 SLAMF1 
cg01065960 ERAL1 cg04914221 TLN2 
cg15865055 FAM55A cg15646382 TMCO6 
cg24636477 GDF10 cg16933440 VEPH1 








Table C2 Target genes of DNMT3L 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg08344180 AADACL4 cg03853861 EDA2R 
cg21211413 ACAN cg14435469 EHHADH-AS1 
cg06904000 ACSM5 cg17313986 EPHB1 
cg24893551 ACVR1C cg12665345 EVC2 
cg16754015 ADARB2 cg06551520 FAM170B-AS1 
cg10533744 ADARB2 cg09543693 FAM19A5 
cg22069688 ADGRE1 cg07383415 FAM49A 
cg11425164 AGPAT9 cg16967830 GABRA5 
cg08624915 AHSP cg18172281 GFRA2 
cg03459928 AK7 cg04096150 GPR176 
cg04188756 AKAP6 cg25041439 HYLS1 
cg04304338 ANKRD33B cg07164224 IL1R1 
cg03501666 ANKS1B cg05903710 IL4R 
cg11984673 APBB1IP cg02238012 IRX4 
cg20118431 B3GAT1 cg06828335 KCNMA1 
cg05355436 C10orf107 cg16324958 KCNQ1 
cg27153327 C16orf73 cg08947191 KDR 
cg26090020 C17orf102 cg17031773 KLK9 
cg03343128 C1orf150 cg10334948 L3MBTL4 
cg01311470 C9 cg20840054 LIMS2 
cg23550589 CCDC149 cg18597321 LINC01091 
cg14455169 CCDC162P cg02419849 LINC01107 
cg07125635 CHRM5 cg12958892 LOC101927285 
cg24838240 CLEC17A cg05888741 LOC101928651 
cg15965233 COBLL1 cg19283824 LOC101928940 
cg15784618 CPM cg16653838 LOC101929450 
cg02763813 CRTAM cg23522965 LOC101929608 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg07855920 MACF1 cg02399826 SPOCK1 
cg06150437 MEG8 cg14940332 SQRDL 
cg04251661 MIR4280 cg09365942 SUGCT 
cg00269670 MIR548F5 cg15260465 SUN3 
cg14241523 MKLN1 cg12150401 TAS2R16 
cg00817995 MOV10L1 cg02606650 TENM2 
cg04434896 NKX2-6 cg17153727 TFAP2B 
cg07990664 NOS1 cg09982570 TRPM1 



















































Table C4 Target genes of DNMT3A2 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg14426428 AIM1 cg20593471 BCL2 
cg17095685 ALADL2 cg15729649 BICC1 
cg16074390 ALDH1A2 cg18849256 BICD1 
cg17778221 ALG9 cg01848236 BIRC6 
cg13526659 AMPH cg12328330 BLOC1S4 
cg19159985 ANKHD1 cg02238928 BMP7 
cg09033641 ANKRD11 cg03291755 BNC2 
cg27079614 ANKRD13A cg10649841 BRD8 
cg11672099 ANKRD35 cg25223634 C10orf26 
cg13355704 ANXA4 cg04532551 C19orf47 
cg23267831 AOAH cg04932658 C19orf81 
cg17727159 ARHGAP31 cg21268653 C1orf203 
cg12150041 ARHGAP32 cg18729148 C21orf62-AS1 
cg13376104 ARHGDIB cg17903782 C4orf22 
cg06967020 ARHGEF10L cg09681278 C4orf37 
cg20092396 ARHGEF37 cg07204005 C6orf106 
cg04606397 ARID1B cg09503608 C6orf26 
cg16677621 ARID1B cg19965099 C6orf48 
cg01087456 ARIH1 cg24612707 C7orf68 
cg20452714 ARTN cg03029255 C8orf31 
cg25570306 ASPH cg06758746 C9orf3 
cg05342446 ATAD1 cg21256342 CACUL1 
cg18165237 ATE1 cg22828602 CADPS2 
cg27629145 ATF6B cg09367967 CALR 
cg05433448 ATP2C1 cg18093691 CCNI2 
cg12097550 ATP5G2 cg12824456 CCNY 
cg03034900 ATP5I cg17862993 CDH18 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg18090634 CELF1 cg07587451 DPYSL2 
cg27638662 CEP170 cg10258107 DYNC1I1 
cg10169382 CGREF1 cg16893968 DYNC1I2 
cg00239870 CH25H cg25329325 E2F6 
cg27018185 CH25H cg21978593 EBF1 
cg03542374 CHD2 cg23029193 EGFLAM 
cg03212674 CLK2 cg15052505 EIF2AK1 
cg13630493 CLTA cg09241638 ELMO1 
cg09006659 CLU cg15810415 ENPEP 
cg11662760 COG3 cg07018561 ENTPD3-AS1 
cg23211065 COPB2 cg06129726 EPB41L3 
cg10325507 COQ5 cg16411256 EPHX2 
cg18179075 CPA2 cg12413918 ERBB2 
cg15095213 CRACR2A cg11492274 ERICH1-AS1 
cg07492937 CREM cg10426370 ESM1 
cg15029935 CRTC3 cg08079330 ESRRB 
cg27082285 CTN3 cg16934235 EXPH5 
cg13180058 CTNNBL1 cg01297479 FAM108C1 
cg07115822 CXADR cg10833066 FAM109A 
cg06817368 DCP2 cg14140515 FAM159B 
cg10706802 DDX6 cg00184203 FAM171B 
cg03263272 DENND3 cg15133477 FAM205BP 
cg27037802 DEPDC5 cg26062455 FAM71F1 
cg14240608 DESI2 cg15357165 FANCC 
cg14735313 DH14 cg15828427 FBXW9 
cg07134608 DHDH cg00723017 FER1L6 
cg13880379 DLC1 cg16794471 FMNL2 
cg21678614 DLGAP1 cg18174678 FOXJ3 





CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg12152765 FOXK2 cg20696451 HSPA14 
cg10551484 GATB cg10400423 HSPA5 
cg17430362 GBA2 cg07310984 IFIT3 
cg13808803 GHR cg01396302 IGF2BP2 
cg06245658 GLI2 cg16181505 IGF2BP2 
cg26875524 GLIS1 cg19230532 IGF2BP2 
cg17753877 GLIS3 cg09202145 IGFBP7 
cg07038690 GLTSCR1 cg09729065 IKZF3 
cg11267359 GMDS cg04100971 IL18 
cg02948693 GNB1 cg08978665 IL32 
cg08038054 GNG11 cg01806261 IMMP2L 
cg09726355 GPATCH8 cg23806656 IMMP2L 
cg01987047 GPCPD1 cg06779086 INPP5F 
cg16204524 GPR113 cg25238640 IP 
cg04685975 GRB2;GRB2 cg02835421 IPO13 
cg10020309 GTF2E1 cg02802590 ITPRIPL1 
cg02749560 GTPBP2 cg03474430 KANK1 
cg19475988 GULP1 cg04852685 KCNMB2 
cg24238527 H2AFV cg13329032 KDM2A 
cg22277567 HDAC4 cg26671851 KDM6A 
cg14973347 HDAC9 cg04458670 KIAA0947 
cg09624120 HEATR6 cg01885559 KIDINS220 
cg11677533 HHLA3 cg15819739 KIFC1 
cg21461470 HIST2H2AA4 cg06326971 KIFC3 
cg24245397 HK1 cg19823803 KIT 
cg18348836 HOOK1 cg16167943 KLB 
cg07797397 HOXD1 cg01260308 KLHDC2 
cg13044985 HOXD1 cg05241571 KRTDAP 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg17190362 LAMA4 cg11346282 MAP4K3 
cg01895696 LATS2 cg09331409 MAP6 
cg18708502 LATS2 cg01837497 MAPK14 
cg05527869 LHX1 cg14455887 MAST4 
cg23966569 LIMS2 cg12688268 MBP 
cg23345395 LINC00343 cg25737410 MCF2L2 
cg03647393 LINC01069 cg21444749 MDN1 
cg25043996 LINC01307 cg07593915 MED13L 
cg26734132 LINC01330 cg08581446 MED13L 
cg21817764 LINC01489 cg21265996 MED21 
cg13572309 LMO3 cg09221431 METTL24 
cg20017295 LOC100506844 cg13302154 MGP 
cg21231068 LOC101926975 cg15930380 MIER1 
cg00524136 LOC101927780 cg01069675 MIP 
cg02254041 LOC101928103 cg04933317 MIR1273H 
cg03288924 LOC101929123 cg25970929 MIR155HG 
cg14132585 LOC101929710 cg03794238 MITD1 
cg13696490 LOC201651 cg07113570 MITF 
cg26759486 LOC645434 cg02296932 MMD2 
cg10445599 LOH12CR1 cg09637723 MON1A 
cg07263235 LPL cg19753469 MORF4L1 
cg22985146 LRRFIP2 cg06470279 MRC2 
cg06171633 LTK cg15709536 MRPS31 
cg09879137 LUC7L3 cg12935350 MRPS9 
cg08443014 LYPD6 cg14679803 MTFMT 
cg06473548 MACF1 cg13628726 MTMR3 
cg09866472 MACF1 cg23423181 MTRNR2L4 
cg10946938 MACROD1 cg18121434 MYO18A 





CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg24581547 MYO5B cg25064395 PDGFRA 
cg25551043 MYOF cg10206741 PHC1 
cg14125537 NBPF8 cg01428071 PHIP 
cg00813334 NCOA6 cg02304767 PHLPP1 
cg20537764 NEK11 cg05018608 PIP5K1B 
cg06703222 NFAT5 cg17047829 PLCE1 
cg03449946 NFIA cg16222616 POC1B 
cg15484811 NGRN cg22956231 PPP2R2C 
cg08546514 NINL cg07182343 PPP6R3 
cg26739807 NME2 cg14217558 PRDM16 
cg26954135 NOCT cg06135990 PRR5-ARHGAP8 
cg03446508 NOVA1 cg27441872 PSME1 
cg01432046 NR5A2 cg10589408 PTP4A2 
cg17530754 NRIP1 cg01369817 PTPN23 
cg01654560 NTM cg18122501 PTPRN2 
cg12682110 NTM cg17698886 PTPRS 
cg17619803 NUMBL cg00632811 PWP1 
cg12582028 OAZ3 cg12130067 RAB11FIP1 
cg03727842 OPHN1 cg15415783 RAB40C 
cg00516867 OPN1SW cg26734848 RALB 
cg13212525 OTOL1 cg09202322 RBM18 
cg17466151 PACS1 cg14615491 RBM33 
cg24934408 PADI1 cg02698507 RFX2 
cg16684992 PAFAH1B1 cg03191504 RNF149 
cg02187196 PANK2 cg17796813 RNF168 
cg06903211 PBX1 cg15672877 RNF43 
cg16155772 PCCA cg19083634 RNFT2 
cg15770136 PCDH9 cg05572461 RPA3 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg05651511 RPTOR cg16911115 SRP72 
cg14640066 RTN4 cg05465104 ST7L 
cg17401362 RWDD4 cg04828068 STAM2 
cg24089111 SARM1 cg27328824 STAMBPL1 
cg24196318 SCAF4 cg20716209 STAT3 
cg05463545 SCAPER cg05692128 STIM2 
cg04274830 SCARB2 cg06075946 STPG1 
cg02390614 SCMH1 cg14994183 SYN2 
cg13001838 SEC61G cg21958743 SYT1 
cg03855973 SENP6 cg13449839 TAF4B 
cg14423617 SERPI5 cg00274587 TAPBP 
cg00049545 SERPINB13 cg00555420 TAPT1 
cg14677615 SEZ6 cg06218079 TBCD 
cg07126559 SGCG cg05555876 TCEA1 
cg04297507 SGMS2 cg07321291 TCEB1 
cg13667782 SH3GLB2 cg19261940 THRA1/BTR 
cg00961640 SLC16A4 cg18953822 TIAM1 
cg05487207 SLC39A14 cg24262469 TIPARP 
cg20392013 SLC39A9 cg11454957 TMEFF2 
cg00029150 SLC51A cg25565793 TMEM260 
cg04799948 SMAD5-AS1 cg19490180 TMPRSS6 
cg05730460 SMARCA2 cg26745222 TOX2 
cg19927678 SMG6 cg13059495 TPRG1L 
cg20188739 SNORD87 cg12825509 TRA2B 
cg13074203 SNTB1 cg02854396 TRHDE 
cg05614305 SNX10 cg20792582 TRIM24 
cg03594550 SOX11 cg13628022 TTLL11 
cg16920608 SPATA16 cg03487391 TTLL4 





CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg20249071 UBASH3B cg18978297 ZBTB10 
cg02020772 UBE2D2 cg16958493 ZCCHC7 
cg22455082 UBE2K cg17692028 ZDHHC17 
cg22212260 UBP1 cg25766774 ZDHHC3 
cg04839974 UGCG cg24857943 ZFAND3 
cg01062424 UHRF1BP1 cg23661268 ZFHX3 
cg24310913 USP3 cg16586418 ZFHX4 
cg26561986 USP44 cg22043381 ZHX2 
cg27257939 VBP1 cg08769844 ZNF233 
cg09954698 VSX2 cg06704974 ZNF438 
cg03268306 WDFY4 cg19866478 ZNF480 
cg01096191 WDR25 cg04085696 ZNF559 
cg03104358 WDTC1 cg17712400 ZNF652 







































































Table C8 Target genes of DNMT3B4 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg26975768 ABLIM1 cg18537730 IZUMO1 
cg03745383 ACCN1 cg03890215 LINC00907 
cg00354572 ACSS3 cg00935967 LOC100133612 
cg04977222 ATP13A5 cg18976321 LOC102546229 
cg27163126 AZIN1-AS1 cg10081994 LONRF2 
cg03380861 B3GLCT cg08643824 LPXN 
cg10687420 C7orf58 cg26179289 LY86 
cg27167221 CAMTA1 cg19995387 MC5R 
cg26636590 COX7B2 cg10350998 MLLT3 
cg07233933 CPEB4 cg02765998 MOB3B 
cg14776738 DENND1C cg06797656 MYO18B 
cg05101674 DOK5 cg14736911 MYOZ2 
cg12269473 EHF cg26657649 NEDD4L 
cg07196212 ESR1 cg05112298 NOD2 
cg09096933 FGD4 cg07494218 OR2C1 
cg25980637 FLJ37453 cg02399892 OTOA 
cg06830784 FRZB cg20836372 OTOA 
cg03345391 GCK cg17637556 PACRGL 
cg26966698 HECW2 cg00354484 PAX8 
cg11451043 HLA-DPA1 cg00586113 PCSK5 
cg00310588 HTR3C cg12381317 PFKM 













































Table C10 Target genes of DNMTΔ3B1 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg22381317 ACVR1B cg01400040 RORA 
cg09302836 ALPK2 cg09001356 RPTOR 
cg15872575 ASB18 cg10821341 SIL1 
cg06650659 ATP13A5 cg19819818 SLC24A4 
cg06717221 ATP8B3 cg02965511 SLC51A 
cg19378216 C20orf114 cg24871226 SSH1 
cg19399653 CEACAM8 cg09044458 ST5 
cg17309085 CNTN5 cg12603229 STK4 
cg01287361 DJC15 cg13693826 SYNE2 
cg26763380 EIF3E cg21918419 TAPT1 
cg16318688 EPHX4 cg06490287 TCTE3 
cg11703750 FAM13C cg14665901 TEAD1 
cg23752752 FOXK1 cg16275707 ZNF10 





















Table C11 Target genes of DNMTΔ3B2 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg23891985 A1CF cg03191962 C9orf98 
cg15769388 A2ML1 cg17108476 CA12 
cg05894322 ABCA10 cg10352688 CAMK4 
cg00747477 ACCN1 cg24521848 CCDC108 
cg21474880 AFAP1 cg10106388 CD244 
cg23434264 AKAP13 cg09781987 CDYL 
cg15930120 AKAP6 cg10375597 CEACAM20 
cg25533247 AKAP8L cg23818780 CECR2 
cg18761400 ALDH8A1 cg24229206 CELF2 
cg25104512 ALS2CL cg00028056 CHPF 
cg22615730 ANXA4 cg17599620 CLASP2 
cg00341504 ARHGAP28 cg10223809 CLEC12A 
cg26988221 ARPC2 cg11937448 CLEC12B 
cg11304664 ATF5 cg10301072 CLGN 
cg05365685 ATP2B2 cg05404912 CLIP3 
cg16847719 ATP8A2 cg13507084 CNTFR 
cg12431207 ATRNL1 cg03122917 COL6A5 
cg03440454 B3GNTL1 cg19985724 CORIN 
cg04628938 BCAS3 cg11270449 CPB2-AS1 
cg09911747 BCL11B cg14806927 CR1 
cg14168713 BICC1 cg05080132 CTBP2 
cg00076072 BPIFB3 cg14665921 DCDC2C 
cg21488132 C11orf31 cg27228578 DH9 
cg16216885 C19orf81 cg03831312 DIRC3 
cg22213391 C1orf106 cg05511924 DIRC3 
cg01450736 C1orf110 cg01697794 DLG4 
cg24731625 C1orf229 cg12017315 DLST 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg22811478 DOCK4 cg01858205 GPR108 
cg05465131 DRD3 cg25244238 GPR108 
cg05292310 DSPP cg09648243 GPR39 
cg01248810 DYDC1 cg05458052 GRHL2 
cg17372920 EDDM3A cg21007931 GSG1L 
cg10617796 EDIL3 cg04836362 GTF2IRD1 
cg17877237 EEF1DP3 cg05309750 GXYLT2 
cg03746008 EIF2B5-AS1 cg06118312 GZMA 
cg04054100 ENTHD1 cg22438640 HCG4 
cg17572324 ESYT2 cg11246805 HDLBP 
cg26404422 ETS1 cg16638857 HKDC1 
cg05643360 FAM110B cg26784412 HLA-DPB2 
cg00205703 FAM131A cg05500783 HLA-DRA 
cg16782425 FAM171B cg02563789 HNRNPC 
cg02536065 FLI1 cg02264990 HOXC4 
cg24022651 FNDC3B cg00377794 HUNK 
cg19418525 FRAS1 cg04412506 ICA1 
cg16531955 FRS2 cg11609995 IL18R 
cg16534289 FSTL1 cg16319517 IL1RAP 
cg00056280 G12 cg02349850 IPO11 
cg04769577 G12 cg16840156 ITGA11 
cg21684809 G12 cg09934565 ITPR1 
cg00019118 GALNT9 cg24323597 KALRN 
cg10356397 GBE1 cg05658173 KCNK15 
cg00416130 GJA4 cg08856529 KCNK9 
cg19720377 GLP2R cg14601981 KCNMA1 
cg13559820 GLT6D1 cg19584551 KIAA1217 
cg18138010 GMDS-AS1 cg27587063 KIAA1751 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg03368758 LDB2 cg21435394 NUDT14 
cg03730738 LINC00351 cg18949521 OR5V1 
cg04502126 LINC01258 cg17473495 OSBPL3 
cg17981966 LMO3 cg02078558 OSBPL6 
cg00684347 LOC100271832 cg21191347 PA2G4 
cg03177464 LOC100288798 cg02644583 PDCD1LG2 
cg14236242 LOC101448202 cg10989138 PDE1C 
cg11035685 LOC101927769 cg02202052 PDE3A 
cg23071261 LOC101928162 cg26062141 PDE4B 
cg09552181 LOC101929596 cg20133730 PDK2 
cg07152607 LOC105616981 cg27355501 PFDN6 
cg02088996 LOC285954 cg25845380 PID1 
cg23275355 LOC392232 cg26723002 PLAG1 
cg01680573 LOC729991-MEF2B cg15034764 POSTN 
cg15790804 LRTM2 cg25464078 PPTC7 
cg03354707 LTBP4 cg26493631 PRDM11 
cg04447756 MATR3 cg09420520 PRMT8 
cg26231094 MBOAT7 cg14044685 PRRG4 
cg21331791 MCF2L cg09267188 PTDSS1 
cg13272357 MIR20B cg03398844 PTK2 
cg06671868 MIR548G cg20006825 PTMS 
cg26374481 MIR548G cg07775266 PTPRM 
cg22877504 MREG cg14129439 PTPRZ1 
cg15344442 MYT1L cg26654286 RARA 
cg07918168 NCAM2 cg08384130 RBFOX3 
cg18402101 NDUFC2 cg09959490 RBM47 
cg02870676 NEDD4L cg00430372 RCAN3 
cg01281210 NRG1 cg19585586 RPL17 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg06621691 SDK1 cg10980788 TMC1 
cg27378216 SETBP1 cg14031220 TMEM178A 
cg05777337 SGK223 cg13740979 TNFRSF10B 
cg04421348 SH2D4B cg21808287 TNP1 
cg15710554 SIL1 cg20243424 TNXB 
cg04095373 SKAP1 cg04639174 TRAF6 
cg19734536 SLAMF1 cg23624321 TRAF6 
cg23642651 SLC13A3 cg01910804 TTC6 
cg06421013 SLC24A3 cg11963464 TTPA 
cg04292976 SLC26A9 cg26161386 TTPA 
cg16923485 SLCO1A2 cg12142328 USP34 
cg26990023 SMOC2 cg07337250 USP43 
cg02077920 SMYD3 cg15405572 V3 
cg16046833 SNX7 cg13084429 VWA2 
cg18544696 SORL1 cg17276624 WBSCR17 
cg17284609 SOX6 cg04372929 WISP2 
cg06728232 SPATA16 cg17167536 XKR6 
cg02405517 SPC2 cg20060356 ZFPM2-AS1 
cg14742361 STAU2 cg11473417 ZNF251 
cg10429523 STL cg05859088 ZNF365 
cg04759244 STX16 cg08370080 ZNF429 
cg10206882 STXBP6 cg00845602 ZNF438 
cg26535273 SYNGAP1 cg15604051 ZNF502 
cg08699646 TEPP cg19819404 ZNF718 









Table C12 Target genes of DNMTΔ3B3 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg07152070 ADGRG4 cg18226835 FSHR 
cg19561181 ANKRD60 cg27154418 GP6 
cg08490364 AP2B1 cg25762753 GPR156 
cg00950473 APCDD1L cg20934765 GRID2 
cg06376392 ARHGAP15 cg12518734 HAP1 
cg18484278 ARHGAP22 cg03965949 HECTD2-AS1 
cg26499611 BAIAP3 cg10759591 HRNBP3 
cg08927738 BCAS1 cg08067312 IGFBPL1 
cg17512348 C9orf171 cg16217885 IL1R1 
cg09756599 CALN1 cg24530225 IL1R1 
cg23388535 CDCP1 cg26810336 IL1RAPL1 
cg22379697 CHD6 cg01849284 KCNMB2 
cg04075184 CLASP1 cg12033029 KIF5C 
cg15501456 CNDP1 cg10637292 KRT74 
cg04066265 CSGALCT1 cg14807428 LARP4B 
cg11822265 CTN3 cg26020743 LINC00299 
cg07089660 DEFA4 cg05191222 LINC00703 
cg19839614 DGKK cg15262365 LINC00929 
cg09055992 DLGAP2 cg04008237 LIPE-AS1 
cg00529424 DMRT1 cg22676735 LOC101929710 
cg15665376 DSCR10 cg02542440 LOC441601 
cg20364776 EEF1AL7 cg14704531 LOXHD1 
cg27494843 EHF cg17838834 MIATNB 
cg14055970 ENG cg21876806 MIR299 
cg26381730 ERICH1-AS1 cg19444866 MIR6854 
cg05949399 ERICH1-AS1 cg10609662 MMP24 
cg27343917 FAM176A cg17964305 MSRA 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg08004620 MYOM2 cg20838631 TRRAP 
cg04717370 MYT1L cg12968088 WDFY4 
cg08635101 NBPF25P cg01317060 XYLT1 

































Table C13 Target genes of DNMTΔ3B4 
CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg17713190 ABLIM3 cg13770691 C19orf6 
cg23976464 ACCN1 cg00588517 C2 
cg20240860 ACCS cg01383890 C2CD4A 
cg03202077 ADAMTS5 cg21490417 CAC1A 
cg16559275 ADAMTSL4 cg25231948 CAMK4 
cg13940693 ADCYAP1 cg01544580 CBX1 
cg22842879 AFAP1 cg25051805 CCDC126 
cg14134368 AGFG1 cg25872744 CCDC83 
cg14667832 ALK cg10042846 CCL13 
cg24603490 AMIGO2 cg13720316 CCND1 
cg16859696 AMMECR1 cg24729983 CCNO 
cg02548132 ANGPT2 cg10185424 CD180 
cg15855924 ANKRD10 cg11874272 CD86 
cg11713658 ARHGAP10 cg03829839 CDK4 
cg10984236 ARID1B cg18094824 CENPE 
cg11090211 ARL5C cg20539142 CHR6 
cg14451560 ARRDC1 cg09449447 CLDN14 
cg07504154 ASB5 cg25272432 CLGN 
cg21068480 ATOH8 cg15862165 CRADD 
cg27450074 ATP9B cg06794775 CREB3L4 
cg26402735 BASP1 cg16596604 CRYM 
cg21500300 BCAT1 cg07752723 CT45A10 
cg04678713 BDH1 cg21921460 CTNND2 
cg14304249 BEST2 cg06643622 CTTNBP2 
cg16965449 BRD7 cg20502337 CXorf36 
cg24671734 BTBD11 cg03142049 CYSTM1 
cg03359067 BTNL3 cg02872476 DBNDD1 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg27369423 DKFZP434H168 cg16415340 INS-IGF2 
cg12954425 DOCK8 cg21912938 JAZF1 
cg07258372 DT cg09244349 KANSL1 
cg05293775 DUSP26 cg18639125 KCNF1 
cg11806102 EHHADH cg04431946 KCNK12 
cg26246486 ELAVL2 cg07685869 KIFC3 
cg02156680 ENPP2 cg15199350 KIRREL3 
cg05075705 ENPP3 cg21807198 KSR2 
cg07482337 EOMES cg19909349 LAMA1 
cg24460563 EPAS1 cg04850395 LINC01470 
cg00157656 ERICH1 cg09413116 LOC101928233 
cg06752040 FAM107B cg23281602 LOC101928489 
cg15904427 FAM122C cg17264609 LOC150568 
cg17114257 FCHSD2 cg03065467 LOC641518 
cg22454769 FHL2 cg03946923 LOC641518 
cg24561572 FMNL1 cg04162032 LOC646627 
cg16509658 GABRB2 cg10222309 LRRC3C 
cg13881405 GADD45G cg10316899 MACF1 
cg25435255 GBF1 cg16896847 MAFA 
cg26295057 GDNF cg06852975 MAGEC1 
cg04714954 GLO1 cg18858249 MAGI2 
cg22702243 GNE cg26328687 MAML2 
cg06460174 GON4L cg07618155 MIR124-2HG 
cg21351852 GPR84 cg24603444 MIR125B1 
cg20947470 GT1 cg10082525 MIR380 
cg12151328 GTPBP8 cg20751048 MIR548W 
cg05380503 HECW1 cg02047319 MIR654 
cg13308279 HECW2 cg24456365 MMP16 




CpG UCSC_RefGene_Name CpG UCSC_RefGene_Name 
cg01157261 MOSPD3 cg13130398 RABGAP1L 
cg25584313 MROH7 cg06705767 RARB 
cg14546394 MSC cg06237092 RBM20 
cg16751754 MX1 cg04448201 RBM28 
cg05512413 MYO1D cg03273615 RBM41 
cg27523882 NDUFA4L2 cg08972081 RBP1 
cg18844118 NFE2L3 cg09566735 RGS6 
cg14260162 OR2S2 cg12765549 RGSL1 
cg22075486 OR6B1 cg10827810 RNF125 
cg21515384 OXCT1 cg23548670 RNLS 
cg20701646 PAX6 cg25892001 RTN1 
cg13229291 PCGEM1 cg18426142 SCN8A 
cg11416338 PDE3A cg24867550 SDC2 
cg22488256 PDE4B cg11772956 SERPINB8 
cg09092093 PDE4D cg26840598 SH2D5 
cg21363050 PDGFRA cg04489366 SMPX 
cg21799736 PDHA1 cg09083139 SMURF2 
cg13846114 PEBP4 cg12167284 SNORA11B 
cg07980164 PHLDB3 cg15989068 SOX11 
cg16797824 PIK3R1 cg27463758 SP110 
cg26827893 PLK1S1 cg02213437 ST18 
cg27022570 POLE2 cg09147776 SV2B 
cg01195861 POP5 cg13919174 SVEP1 
cg06649437 PPP4R1L cg02015876 SYNM 
cg20557183 PRDM11 cg06440519 SYT3 
cg15088491 PRLR cg02829601 SYTL3 
cg03049691 PROCA1 cg02833108 TAF4B 
cg00446900 PTPRE cg15657686 TBC1D1 



























11. Appendix D: Schematic location of the pyrosequencing assay 
locations 
  
Yellow highlight represents a CpG site, Green highlight represents a primer, Blue highlight represents 
a part of EPIC probe. Underline represents a sequence primer. 
 
1. cg01065960: DNMT1 
>hg19_dna range=chr17:27181267-27183516 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 










































Sequencing entry TGGTTTTTGGGTC/TGGTG 
 
2. cg20943641: DNMT1 
>hg19_dna range=chr12:102455342-102456841 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 





























































Sequencing entry C/GGAGTTATTATATA 
 
 
3. cg02732111: DNMT3A2 
 
>hg19_dna range=chr4:71728583-71730082 5'pad=0 3'pad=0 strand=+ repeatMasking=none 
 

























































Sequencing entry TTTATATGAAC/TGGTTT 
 
4. cg16204524: DNMT3A2 
 
>hg19_dna range=chr2:26565034-26566533 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 




























































Sequencing entry C/TGGTAGGTATGGTTAC/TGTGGG 
 
5. cg26286826: DNMT3B4 
 
>hg19_dna range=chr18:65084835-65086334 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 





























































6. cg21808287: DNMTΔ3B2 
 
>hg19_dna range=chr2:217724164-217725663 5'pad=0 3'pad=0 strand=+ repeatMasking=none 
























































Sequencing entry TTTTTTTC/GTGTAGT 
 
7. cg25533247: DNMTΔ3B2 
 
>hg19_dna range=chr19:15529905-15531404 5'pad=0 3'pad=0 strand=+ 
repeatMasking=none 
 


























































cg25533247-BS-F  AGAGATTTTGTAATAGTGTAGT 
cg25533247-BS-R-bio ATACAACTCTATCATCTCTAAA 
cg25533247-BS-SP AGAGATTTTGTAATAGTGTAGT 
Sequencing entry C/TGGGTATTAGTTATGT 
 
8. cg08927738: DNMTΔ3B3 
 
>hg19_dna range=chr20:52686669-52688168 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 



























































Sequencing entry C/GTGTTTTTTTTGTT 
 
9. cg20364776: DNMTΔ3B3 
 
>hg19_dna range=chr4:106405077-106406576 5'pad=0 3'pad=0 strand=+ repeatMasking=none 
 





























































Sequencing entry C/GAGAAAGGAAAAG 
 
10. cg07504154: DNMTΔ3B4 
 
>hg19_dna range=chr4:177158662-177160161 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 
























































Sequencing entry GTTATTAGTTGATC/GTAATG 
 
11. cg22976313: DNMTΔ3B4 
 
>hg19_dna range=chr14:105069615-105071114 5'pad=0 3'pad=0 strand=- repeatMasking=none 
 



























































Sequencing entry C/GAATTGGGGAGTTTTATTC/GGTATTATC/GTT 
 
12. cg12150401: DNMT3L 
 






























































13. cg20540357: DNMT3L 
 











































Sequencing entry TATATTTTGTTGATTAC/GGAA 
 
14. cg04458645: DNMT3A2, DNMT3B4, DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4, DNMT1 
 






























































Sequencing entry GTTAAC/TGGATAAT 
 
15. cg25843713: DNMT3A2, DNMT3B4, DNMTΔ3B2, DNMTΔ3B3, DNMTΔ3B4, DNMT1 
 































































Sequencing entry C/TGTTTTGTTGTTTC/TGGGT 
 
 
 
 
 
 
 
